id	sid	tid	token	lemma	pos
dpc-2824	1	1	dermatology	dermatology	NOUN
dpc-2824	1	2	:	:	PUNCT
dpc-2824	1	3	practical	practical	ADJ
dpc-2824	1	4	and	and	CCONJ
dpc-2824	1	5	conceptual	conceptual	ADJ
dpc-2824	1	6	original	original	ADJ
dpc-2824	1	7	article	article	NOUN
dpc-2824	1	8	|	|	ADV
dpc-2824	1	9	dermatol	dermatol	ADJ
dpc-2824	1	10	pract	pract	NOUN
dpc-2824	1	11	concept	concept	NOUN
dpc-2824	1	12	.	.	PUNCT
dpc-2824	2	1	2023;13(3):e2023127	2023;13(3):e2023127	NUM
dpc-2824	2	2	1	1	NUM
dpc-2824	2	3	characterization	characterization	NOUN
dpc-2824	2	4	and	and	CCONJ
dpc-2824	2	5	prognostic	prognostic	ADJ
dpc-2824	2	6	significance	significance	NOUN
dpc-2824	2	7	of	of	ADP
dpc-2824	2	8	 	 	SPACE
dpc-2824	2	9	cutaneous	cutaneous	ADJ
dpc-2824	2	10	immune	immune	NOUN
dpc-2824	2	11	-	-	PUNCT
dpc-2824	2	12	related	relate	VERB
dpc-2824	2	13	adverse	adverse	ADJ
dpc-2824	2	14	events	event	NOUN
dpc-2824	2	15	in	in	ADP
dpc-2824	2	16	indian	indian	ADJ
dpc-2824	2	17	patients	patient	NOUN
dpc-2824	2	18	on	on	ADP
dpc-2824	2	19	immune	immune	ADJ
dpc-2824	2	20	checkpoint	checkpoint	NOUN
dpc-2824	2	21	inhibitor	inhibitor	NOUN
dpc-2824	2	22	 	 	SPACE
dpc-2824	2	23	therapy	therapy	NOUN
dpc-2824	2	24	prasanna	prasanna	PROPN
dpc-2824	2	25	duraisamy1	duraisamy1	PROPN
dpc-2824	2	26	,	,	PUNCT
dpc-2824	2	27	vinitha	vinitha	PROPN
dpc-2824	2	28	varghese	varghese	PROPN
dpc-2824	2	29	panicker1	panicker1	PROPN
dpc-2824	2	30	,	,	PUNCT
dpc-2824	2	31	wesley	wesley	PROPN
dpc-2824	2	32	mannirathil	mannirathil	PROPN
dpc-2824	2	33	jose2	jose2	PROPN
dpc-2824	2	34	1	1	NUM
dpc-2824	2	35	department	department	NOUN
dpc-2824	2	36	of	of	ADP
dpc-2824	2	37	dermatology	dermatology	NOUN
dpc-2824	2	38	,	,	PUNCT
dpc-2824	2	39	amrita	amrita	PROPN
dpc-2824	2	40	institute	institute	PROPN
dpc-2824	2	41	of	of	ADP
dpc-2824	2	42	medical	medical	PROPN
dpc-2824	2	43	sciences	sciences	PROPN
dpc-2824	2	44	,	,	PUNCT
dpc-2824	2	45	kochi	kochi	PROPN
dpc-2824	2	46	,	,	PUNCT
dpc-2824	2	47	india	india	PROPN
dpc-2824	2	48	2	2	NUM
dpc-2824	2	49	department	department	NOUN
dpc-2824	2	50	of	of	ADP
dpc-2824	2	51	medical	medical	ADJ
dpc-2824	2	52	oncology	oncology	NOUN
dpc-2824	2	53	and	and	CCONJ
dpc-2824	2	54	hematology	hematology	NOUN
dpc-2824	2	55	,	,	PUNCT
dpc-2824	2	56	amrita	amrita	PROPN
dpc-2824	2	57	institute	institute	PROPN
dpc-2824	2	58	of	of	ADP
dpc-2824	2	59	medical	medical	PROPN
dpc-2824	2	60	sciences	sciences	PROPN
dpc-2824	2	61	,	,	PUNCT
dpc-2824	2	62	kochi	kochi	PROPN
dpc-2824	2	63	,	,	PUNCT
dpc-2824	2	64	india	india	PROPN
dpc-2824	2	65	key	key	ADJ
dpc-2824	2	66	words	word	NOUN
dpc-2824	2	67	:	:	PUNCT
dpc-2824	2	68	immune	immune	ADJ
dpc-2824	2	69	checkpoint	checkpoint	NOUN
dpc-2824	2	70	inhibitors	inhibitor	NOUN
dpc-2824	2	71	,	,	PUNCT
dpc-2824	2	72	cutaneous	cutaneous	ADJ
dpc-2824	2	73	immune	immune	ADJ
dpc-2824	2	74	related	relate	VERB
dpc-2824	2	75	adverse	adverse	ADJ
dpc-2824	2	76	events	event	NOUN
dpc-2824	2	77	,	,	PUNCT
dpc-2824	2	78	reactions	reaction	NOUN
dpc-2824	2	79	,	,	PUNCT
dpc-2824	2	80	immunotherapy	immunotherapy	NOUN
dpc-2824	2	81	citation	citation	NOUN
dpc-2824	2	82	:	:	PUNCT
dpc-2824	2	83	duraisamy	duraisamy	NOUN
dpc-2824	2	84	p	p	NOUN
dpc-2824	2	85	,	,	PUNCT
dpc-2824	2	86	panicker	panicker	NOUN
dpc-2824	2	87	vv	vv	PROPN
dpc-2824	2	88	,	,	PUNCT
dpc-2824	2	89	jose	jose	PROPN
dpc-2824	2	90	wm	wm	PROPN
dpc-2824	2	91	.	.	PROPN
dpc-2824	2	92	characterization	characterization	NOUN
dpc-2824	2	93	and	and	CCONJ
dpc-2824	2	94	prognostic	prognostic	ADJ
dpc-2824	2	95	significance	significance	NOUN
dpc-2824	2	96	of	of	ADP
dpc-2824	2	97	cutaneous	cutaneous	ADJ
dpc-2824	2	98	immune	immune	ADJ
dpc-2824	2	99	related	relate	VERB
dpc-2824	2	100	adverse	adverse	ADJ
dpc-2824	2	101	events	event	NOUN
dpc-2824	2	102	in	in	ADP
dpc-2824	2	103	indian	indian	ADJ
dpc-2824	2	104	patients	patient	NOUN
dpc-2824	2	105	on	on	ADP
dpc-2824	2	106	immune	immune	ADJ
dpc-2824	2	107	checkpoint	checkpoint	NOUN
dpc-2824	2	108	inhibitor	inhibitor	NOUN
dpc-2824	2	109	therapy	therapy	NOUN
dpc-2824	2	110	.	.	PUNCT
dpc-2824	3	1	dermatol	dermatol	NOUN
dpc-2824	3	2	pract	pract	PROPN
dpc-2824	3	3	concept	concept	NOUN
dpc-2824	3	4	.	.	PUNCT
dpc-2824	4	1	2023;13(3):e2023127	2023;13(3):e2023127	X
dpc-2824	4	2	.	.	PUNCT
dpc-2824	5	1	doi	doi	NOUN
dpc-2824	5	2	:	:	PUNCT
dpc-2824	5	3	https://doi.org/10.5826/	https://doi.org/10.5826/	PROPN
dpc-2824	5	4	dpc.1303a127	dpc.1303a127	NUM
dpc-2824	5	5	accepted	accept	VERB
dpc-2824	5	6	:	:	PUNCT
dpc-2824	5	7	december	december	PROPN
dpc-2824	5	8	15	15	NUM
dpc-2824	5	9	,	,	PUNCT
dpc-2824	5	10	2022	2022	NUM
dpc-2824	5	11	;	;	PUNCT
dpc-2824	5	12	published	publish	VERB
dpc-2824	5	13	:	:	PUNCT
dpc-2824	6	1	july	july	PROPN
dpc-2824	6	2	2023	2023	NUM
dpc-2824	6	3	copyright	copyright	NOUN
dpc-2824	6	4	:	:	PUNCT
dpc-2824	6	5	©	©	PROPN
dpc-2824	6	6	2023	2023	NUM
dpc-2824	6	7	duraisamy	duraisamy	NOUN
dpc-2824	6	8	et	et	PROPN
dpc-2824	6	9	al	al	PROPN
dpc-2824	6	10	.	.	PUNCT
dpc-2824	7	1	this	this	PRON
dpc-2824	7	2	is	be	AUX
dpc-2824	7	3	an	an	DET
dpc-2824	7	4	open	open	ADJ
dpc-2824	7	5	-	-	PUNCT
dpc-2824	7	6	access	access	NOUN
dpc-2824	7	7	article	article	NOUN
dpc-2824	7	8	distributed	distribute	VERB
dpc-2824	7	9	under	under	ADP
dpc-2824	7	10	the	the	DET
dpc-2824	7	11	terms	term	NOUN
dpc-2824	7	12	of	of	ADP
dpc-2824	7	13	the	the	DET
dpc-2824	7	14	creative	creative	ADJ
dpc-2824	7	15	commons	common	NOUN
dpc-2824	7	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-2824	7	17	license	license	NOUN
dpc-2824	7	18	(	(	PUNCT
dpc-2824	7	19	by	by	ADP
dpc-2824	7	20	-	-	PUNCT
dpc-2824	7	21	nc-4.0	nc-4.0	NOUN
dpc-2824	7	22	)	)	PUNCT
dpc-2824	7	23	,	,	PUNCT
dpc-2824	7	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-2824	7	25	,	,	PUNCT
dpc-2824	7	26	which	which	PRON
dpc-2824	7	27	permits	permit	VERB
dpc-2824	7	28	unrestricted	unrestricted	ADJ
dpc-2824	7	29	noncommercial	noncommercial	ADJ
dpc-2824	7	30	use	use	NOUN
dpc-2824	7	31	,	,	PUNCT
dpc-2824	7	32	distribution	distribution	NOUN
dpc-2824	7	33	,	,	PUNCT
dpc-2824	7	34	and	and	CCONJ
dpc-2824	7	35	reproduction	reproduction	NOUN
dpc-2824	7	36	in	in	ADP
dpc-2824	7	37	any	any	DET
dpc-2824	7	38	medium	medium	NOUN
dpc-2824	7	39	,	,	PUNCT
dpc-2824	7	40	provided	provide	VERB
dpc-2824	7	41	the	the	DET
dpc-2824	7	42	original	original	ADJ
dpc-2824	7	43	authors	author	NOUN
dpc-2824	7	44	and	and	CCONJ
dpc-2824	7	45	source	source	NOUN
dpc-2824	7	46	are	be	AUX
dpc-2824	7	47	credited	credit	VERB
dpc-2824	7	48	.	.	PUNCT
dpc-2824	8	1	funding	funding	NOUN
dpc-2824	8	2	:	:	PUNCT
dpc-2824	8	3	none	none	NOUN
dpc-2824	8	4	.	.	PUNCT
dpc-2824	9	1	competing	compete	VERB
dpc-2824	9	2	interests	interest	NOUN
dpc-2824	9	3	:	:	PUNCT
dpc-2824	9	4	none	none	NOUN
dpc-2824	9	5	.	.	PUNCT
dpc-2824	10	1	authorship	authorship	NOUN
dpc-2824	10	2	:	:	PUNCT
dpc-2824	10	3	all	all	DET
dpc-2824	10	4	authors	author	NOUN
dpc-2824	10	5	have	have	AUX
dpc-2824	10	6	contributed	contribute	VERB
dpc-2824	10	7	significantly	significantly	ADV
dpc-2824	10	8	to	to	ADP
dpc-2824	10	9	this	this	DET
dpc-2824	10	10	publication	publication	NOUN
dpc-2824	10	11	.	.	PUNCT
dpc-2824	11	1	corresponding	correspond	VERB
dpc-2824	11	2	author	author	NOUN
dpc-2824	11	3	:	:	PUNCT
dpc-2824	11	4	vinitha	vinitha	PROPN
dpc-2824	11	5	v	v	PROPN
dpc-2824	11	6	panicker	panicker	PROPN
dpc-2824	11	7	,	,	PUNCT
dpc-2824	11	8	department	department	NOUN
dpc-2824	11	9	of	of	ADP
dpc-2824	11	10	dermatology	dermatology	NOUN
dpc-2824	11	11	,	,	PUNCT
dpc-2824	11	12	amrita	amrita	PROPN
dpc-2824	11	13	institute	institute	PROPN
dpc-2824	11	14	of	of	ADP
dpc-2824	11	15	medical	medical	PROPN
dpc-2824	11	16	sciences	sciences	PROPN
dpc-2824	11	17	,	,	PUNCT
dpc-2824	11	18	ponnekara	ponnekara	NOUN
dpc-2824	11	19	,	,	PUNCT
dpc-2824	11	20	kochi	kochi	PROPN
dpc-2824	11	21	.	.	PUNCT
dpc-2824	12	1	tel	tel	ADP
dpc-2824	12	2	:	:	PUNCT
dpc-2824	12	3	0484	0484	NUM
dpc-2824	12	4	-	-	SYM
dpc-2824	12	5	2858590	2858590	NUM
dpc-2824	12	6	,	,	PUNCT
dpc-2824	12	7	9847179964	9847179964	NUM
dpc-2824	12	8	email	email	NOUN
dpc-2824	12	9	:	:	PUNCT
dpc-2824	12	10	varghesevinitha@yahoo.com	varghesevinitha@yahoo.com	NOUN
dpc-2824	12	11	,	,	PUNCT
dpc-2824	12	12	vinithavpanicker@aims.amrita.edu	vinithavpanicker@aims.amrita.edu	NUM
dpc-2824	12	13	introduction	introduction	NOUN
dpc-2824	12	14	:	:	PUNCT
dpc-2824	12	15	cutaneous	cutaneous	ADJ
dpc-2824	12	16	immune	immune	NOUN
dpc-2824	12	17	-	-	PUNCT
dpc-2824	12	18	related	relate	VERB
dpc-2824	12	19	adverse	adverse	ADJ
dpc-2824	12	20	-	-	PUNCT
dpc-2824	12	21	events	event	NOUN
dpc-2824	12	22	(	(	PUNCT
dpc-2824	12	23	ciraes	ciraes	NOUN
dpc-2824	12	24	)	)	PUNCT
dpc-2824	12	25	,	,	PUNCT
dpc-2824	12	26	commonly	commonly	ADV
dpc-2824	12	27	seen	see	VERB
dpc-2824	12	28	in	in	ADP
dpc-2824	12	29	cancer	cancer	NOUN
dpc-2824	12	30	patients	patient	NOUN
dpc-2824	12	31	receiving	receive	VERB
dpc-2824	12	32	immune	immune	ADJ
dpc-2824	12	33	checkpoint	checkpoint	NOUN
dpc-2824	12	34	inhibitors	inhibitor	NOUN
dpc-2824	12	35	(	(	PUNCT
dpc-2824	12	36	ici	ici	PROPN
dpc-2824	12	37	)	)	PUNCT
dpc-2824	12	38	are	be	AUX
dpc-2824	12	39	reported	report	VERB
dpc-2824	12	40	to	to	PART
dpc-2824	12	41	be	be	AUX
dpc-2824	12	42	associated	associate	VERB
dpc-2824	12	43	with	with	ADP
dpc-2824	12	44	better	well	ADJ
dpc-2824	12	45	patient	patient	ADJ
dpc-2824	12	46	survival	survival	NOUN
dpc-2824	12	47	;	;	PUNCT
dpc-2824	12	48	however	however	ADV
dpc-2824	12	49	,	,	PUNCT
dpc-2824	12	50	they	they	PRON
dpc-2824	12	51	have	have	AUX
dpc-2824	12	52	seldom	seldom	ADV
dpc-2824	12	53	been	be	AUX
dpc-2824	12	54	studied	study	VERB
dpc-2824	12	55	in	in	ADP
dpc-2824	12	56	indian	indian	ADJ
dpc-2824	12	57	population	population	NOUN
dpc-2824	12	58	.	.	PUNCT
dpc-2824	13	1	recent	recent	ADJ
dpc-2824	13	2	reports	report	NOUN
dpc-2824	13	3	suggest	suggest	VERB
dpc-2824	13	4	racial	racial	ADJ
dpc-2824	13	5	differences	difference	NOUN
dpc-2824	13	6	in	in	ADP
dpc-2824	13	7	iraes	iraes	NOUN
dpc-2824	13	8	and	and	CCONJ
dpc-2824	13	9	also	also	ADV
dpc-2824	13	10	in	in	ADP
dpc-2824	13	11	survival	survival	NOUN
dpc-2824	13	12	outcomes	outcome	NOUN
dpc-2824	13	13	.	.	PUNCT
dpc-2824	14	1	objectives	objective	NOUN
dpc-2824	14	2	:	:	PUNCT
dpc-2824	14	3	to	to	PART
dpc-2824	14	4	study	study	VERB
dpc-2824	14	5	the	the	DET
dpc-2824	14	6	various	various	ADJ
dpc-2824	14	7	ciraes	ciraes	NOUN
dpc-2824	14	8	in	in	ADP
dpc-2824	14	9	indian	indian	ADJ
dpc-2824	14	10	patients	patient	NOUN
dpc-2824	14	11	on	on	ADP
dpc-2824	14	12	ici	ici	NOUN
dpc-2824	14	13	therapy	therapy	NOUN
dpc-2824	14	14	and	and	CCONJ
dpc-2824	14	15	to	to	PART
dpc-2824	14	16	analyze	analyze	VERB
dpc-2824	14	17	the	the	DET
dpc-2824	14	18	association	association	NOUN
dpc-2824	14	19	between	between	ADP
dpc-2824	14	20	ciraes	ciraes	NOUN
dpc-2824	14	21	and	and	CCONJ
dpc-2824	14	22	patient	patient	ADJ
dpc-2824	14	23	survival	survival	NOUN
dpc-2824	14	24	outcomes	outcome	NOUN
dpc-2824	14	25	.	.	PUNCT
dpc-2824	15	1	methods	method	NOUN
dpc-2824	15	2	:	:	PUNCT
dpc-2824	15	3	we	we	PRON
dpc-2824	15	4	conducted	conduct	VERB
dpc-2824	15	5	a	a	DET
dpc-2824	15	6	retrospective	retrospective	ADJ
dpc-2824	15	7	cohort	cohort	NOUN
dpc-2824	15	8	study	study	NOUN
dpc-2824	15	9	of	of	ADP
dpc-2824	15	10	86	86	NUM
dpc-2824	15	11	cancer	cancer	NOUN
dpc-2824	15	12	patients	patient	NOUN
dpc-2824	15	13	receiving	receive	VERB
dpc-2824	15	14	immunotherapies	immunotherapy	NOUN
dpc-2824	15	15	in	in	ADP
dpc-2824	15	16	a	a	DET
dpc-2824	15	17	tertiary	tertiary	ADJ
dpc-2824	15	18	care	care	NOUN
dpc-2824	15	19	hospital	hospital	NOUN
dpc-2824	15	20	in	in	ADP
dpc-2824	15	21	india	india	PROPN
dpc-2824	15	22	and	and	CCONJ
dpc-2824	15	23	studied	studied	ADJ
dpc-2824	15	24	incidence	incidence	NOUN
dpc-2824	15	25	,	,	PUNCT
dpc-2824	15	26	nature	nature	NOUN
dpc-2824	15	27	and	and	CCONJ
dpc-2824	15	28	grades	grade	NOUN
dpc-2824	15	29	of	of	ADP
dpc-2824	15	30	cutaneous	cutaneous	ADJ
dpc-2824	15	31	immune	immune	NOUN
dpc-2824	15	32	-	-	PUNCT
dpc-2824	15	33	related	relate	VERB
dpc-2824	15	34	adverse	adverse	ADJ
dpc-2824	15	35	events	event	NOUN
dpc-2824	15	36	and	and	CCONJ
dpc-2824	15	37	the	the	DET
dpc-2824	15	38	association	association	NOUN
dpc-2824	15	39	of	of	ADP
dpc-2824	15	40	ciraes	ciraes	NOUN
dpc-2824	15	41	with	with	ADP
dpc-2824	15	42	the	the	DET
dpc-2824	15	43	patient	patient	ADJ
dpc-2824	15	44	survival	survival	NOUN
dpc-2824	15	45	outcomes	outcome	NOUN
dpc-2824	15	46	.	.	PUNCT
dpc-2824	16	1	results	result	NOUN
dpc-2824	16	2	:	:	PUNCT
dpc-2824	16	3	eighty	eighty	NUM
dpc-2824	16	4	-	-	PUNCT
dpc-2824	16	5	six	six	NUM
dpc-2824	16	6	patients	patient	NOUN
dpc-2824	16	7	were	be	AUX
dpc-2824	16	8	included	include	VERB
dpc-2824	16	9	,	,	PUNCT
dpc-2824	16	10	of	of	ADP
dpc-2824	16	11	whom	whom	PRON
dpc-2824	16	12	16	16	NUM
dpc-2824	16	13	patients	patient	NOUN
dpc-2824	16	14	(	(	PUNCT
dpc-2824	16	15	18.6	18.6	NUM
dpc-2824	16	16	%	%	NOUN
dpc-2824	16	17	)	)	PUNCT
dpc-2824	16	18	developed	develop	VERB
dpc-2824	16	19	ciraes	ciraes	NOUN
dpc-2824	16	20	,	,	PUNCT
dpc-2824	16	21	with	with	ADP
dpc-2824	16	22	pruritus	pruritus	PROPN
dpc-2824	16	23	(	(	PUNCT
dpc-2824	16	24	12.8	12.8	NUM
dpc-2824	16	25	%	%	NOUN
dpc-2824	16	26	)	)	PUNCT
dpc-2824	16	27	and	and	CCONJ
dpc-2824	16	28	maculopapular	maculopapular	ADJ
dpc-2824	16	29	eruption	eruption	NOUN
dpc-2824	16	30	(	(	PUNCT
dpc-2824	16	31	8.1	8.1	NUM
dpc-2824	16	32	%	%	NOUN
dpc-2824	16	33	)	)	PUNCT
dpc-2824	16	34	being	be	AUX
dpc-2824	16	35	the	the	DET
dpc-2824	16	36	most	most	ADV
dpc-2824	16	37	common	common	ADJ
dpc-2824	16	38	.	.	PUNCT
dpc-2824	17	1	kaplan	kaplan	PROPN
dpc-2824	17	2	–	–	PUNCT
dpc-2824	17	3	meier	meier	PROPN
dpc-2824	17	4	plot	plot	NOUN
dpc-2824	17	5	with	with	ADP
dpc-2824	17	6	log	log	NOUN
dpc-2824	17	7	-	-	PUNCT
dpc-2824	17	8	rank	rank	NOUN
dpc-2824	17	9	test	test	NOUN
dpc-2824	17	10	showed	show	VERB
dpc-2824	17	11	that	that	SCONJ
dpc-2824	17	12	patients	patient	NOUN
dpc-2824	17	13	developing	develop	VERB
dpc-2824	17	14	any	any	DET
dpc-2824	17	15	type	type	NOUN
dpc-2824	17	16	of	of	ADP
dpc-2824	17	17	cirae	cirae	NOUN
dpc-2824	17	18	had	have	VERB
dpc-2824	17	19	longer	long	ADJ
dpc-2824	17	20	progression	progression	NOUN
dpc-2824	17	21	-	-	PUNCT
dpc-2824	17	22	free	free	ADJ
dpc-2824	17	23	survival	survival	NOUN
dpc-2824	17	24	than	than	ADP
dpc-2824	17	25	those	those	PRON
dpc-2824	17	26	without	without	ADP
dpc-2824	17	27	(	(	PUNCT
dpc-2824	17	28	p	p	X
dpc-2824	17	29	=	=	NOUN
dpc-2824	17	30	0.023	0.023	NUM
dpc-2824	17	31	)	)	PUNCT
dpc-2824	17	32	and	and	CCONJ
dpc-2824	17	33	a	a	DET
dpc-2824	17	34	better	well	ADJ
dpc-2824	17	35	objective	objective	ADJ
dpc-2824	17	36	-	-	PUNCT
dpc-2824	17	37	response	response	NOUN
dpc-2824	17	38	-	-	PUNCT
dpc-2824	17	39	rate	rate	NOUN
dpc-2824	17	40	(	(	PUNCT
dpc-2824	17	41	50	50	NUM
dpc-2824	17	42	%	%	NOUN
dpc-2824	17	43	versus	versus	ADP
dpc-2824	17	44	18.5	18.5	NUM
dpc-2824	17	45	%	%	NOUN
dpc-2824	17	46	,	,	PUNCT
dpc-2824	17	47	p	p	X
dpc-2824	17	48	=	=	NOUN
dpc-2824	17	49	0.008	0.008	NUM
dpc-2824	17	50	)	)	PUNCT
dpc-2824	17	51	.	.	PUNCT
dpc-2824	18	1	abstract	abstract	ADJ
dpc-2824	18	2	2	2	NUM
dpc-2824	18	3	original	original	ADJ
dpc-2824	18	4	article	article	NOUN
dpc-2824	18	5	|	|	ADV
dpc-2824	18	6	dermatol	dermatol	ADJ
dpc-2824	18	7	pract	pract	NOUN
dpc-2824	18	8	concept	concept	NOUN
dpc-2824	18	9	.	.	PUNCT
dpc-2824	19	1	2023;13(3):e2023127	2023;13(3):e2023127	NUM
dpc-2824	19	2	introduction	introduction	NOUN
dpc-2824	19	3	immune	immune	ADJ
dpc-2824	19	4	checkpoint	checkpoint	NOUN
dpc-2824	19	5	inhibitors	inhibitor	NOUN
dpc-2824	19	6	(	(	PUNCT
dpc-2824	19	7	ici	ici	PROPN
dpc-2824	19	8	)	)	PUNCT
dpc-2824	19	9	are	be	AUX
dpc-2824	19	10	a	a	DET
dpc-2824	19	11	class	class	NOUN
dpc-2824	19	12	of	of	ADP
dpc-2824	19	13	immunotherapeutic	immunotherapeutic	ADJ
dpc-2824	19	14	agents	agent	NOUN
dpc-2824	19	15	which	which	PRON
dpc-2824	19	16	act	act	VERB
dpc-2824	19	17	upon	upon	SCONJ
dpc-2824	19	18	the	the	DET
dpc-2824	19	19	immune	immune	ADJ
dpc-2824	19	20	check	check	NOUN
dpc-2824	19	21	points	point	NOUN
dpc-2824	19	22	programmed	program	VERB
dpc-2824	19	23	cell	cell	NOUN
dpc-2824	19	24	death	death	NOUN
dpc-2824	19	25	1	1	NUM
dpc-2824	19	26	(	(	PUNCT
dpc-2824	19	27	pd-1	pd-1	ADV
dpc-2824	19	28	)	)	PUNCT
dpc-2824	19	29	,	,	PUNCT
dpc-2824	19	30	programmed	program	VERB
dpc-2824	19	31	cell	cell	NOUN
dpc-2824	19	32	death	death	NOUN
dpc-2824	19	33	ligand	ligand	NOUN
dpc-2824	19	34	1	1	NUM
dpc-2824	19	35	(	(	PUNCT
dpc-2824	19	36	pd	pd	NOUN
dpc-2824	19	37	-	-	PUNCT
dpc-2824	19	38	l1	l1	NOUN
dpc-2824	19	39	)	)	PUNCT
dpc-2824	19	40	and	and	CCONJ
dpc-2824	19	41	cytotoxic	cytotoxic	ADJ
dpc-2824	19	42	t	t	NOUN
dpc-2824	19	43	lymphocyte	lymphocyte	NOUN
dpc-2824	19	44	antigen	antigen	ADP
dpc-2824	19	45	4	4	NUM
dpc-2824	19	46	(	(	PUNCT
dpc-2824	19	47	ctla-4	ctla-4	NOUN
dpc-2824	19	48	)	)	PUNCT
dpc-2824	19	49	,	,	PUNCT
dpc-2824	19	50	that	that	PRON
dpc-2824	19	51	regulate	regulate	VERB
dpc-2824	19	52	t	t	NOUN
dpc-2824	19	53	-	-	PUNCT
dpc-2824	19	54	cell	cell	NOUN
dpc-2824	19	55	activity	activity	NOUN
dpc-2824	19	56	[	[	X
dpc-2824	19	57	1	1	NUM
dpc-2824	19	58	]	]	PUNCT
dpc-2824	19	59	.	.	PUNCT
dpc-2824	20	1	under	under	ADP
dpc-2824	20	2	normal	normal	ADJ
dpc-2824	20	3	circumstances	circumstance	NOUN
dpc-2824	20	4	,	,	PUNCT
dpc-2824	20	5	immune	immune	ADJ
dpc-2824	20	6	check	check	NOUN
dpc-2824	20	7	points	point	NOUN
dpc-2824	20	8	protect	protect	VERB
dpc-2824	20	9	the	the	DET
dpc-2824	20	10	host	host	NOUN
dpc-2824	20	11	cells	cell	NOUN
dpc-2824	20	12	from	from	ADP
dpc-2824	20	13	immune	immune	ADJ
dpc-2824	20	14	response	response	NOUN
dpc-2824	20	15	.	.	PUNCT
dpc-2824	21	1	however	however	ADV
dpc-2824	21	2	,	,	PUNCT
dpc-2824	21	3	these	these	DET
dpc-2824	21	4	pathways	pathway	NOUN
dpc-2824	21	5	are	be	AUX
dpc-2824	21	6	also	also	ADV
dpc-2824	21	7	utilized	utilize	VERB
dpc-2824	21	8	by	by	ADP
dpc-2824	21	9	cancers	cancer	NOUN
dpc-2824	21	10	to	to	PART
dpc-2824	21	11	escape	escape	VERB
dpc-2824	21	12	the	the	DET
dpc-2824	21	13	host	host	NOUN
dpc-2824	21	14	immunity	immunity	NOUN
dpc-2824	21	15	and	and	CCONJ
dpc-2824	21	16	their	their	PRON
dpc-2824	21	17	inhibition	inhibition	NOUN
dpc-2824	21	18	results	result	NOUN
dpc-2824	21	19	in	in	ADP
dpc-2824	21	20	enhancement	enhancement	NOUN
dpc-2824	21	21	of	of	ADP
dpc-2824	21	22	immune	immune	ADJ
dpc-2824	21	23	response	response	NOUN
dpc-2824	21	24	and	and	CCONJ
dpc-2824	21	25	prevents	prevent	VERB
dpc-2824	21	26	tumor	tumor	NOUN
dpc-2824	21	27	escape	escape	NOUN
dpc-2824	21	28	causing	cause	VERB
dpc-2824	21	29	tumor	tumor	NOUN
dpc-2824	21	30	destruction	destruction	NOUN
dpc-2824	21	31	.	.	PUNCT
dpc-2824	22	1	this	this	DET
dpc-2824	22	2	enhanced	enhance	VERB
dpc-2824	22	3	immune	immune	ADJ
dpc-2824	22	4	response	response	NOUN
dpc-2824	22	5	is	be	AUX
dpc-2824	22	6	non	non	ADJ
dpc-2824	22	7	-	-	ADJ
dpc-2824	22	8	specific	specific	ADJ
dpc-2824	22	9	and	and	CCONJ
dpc-2824	22	10	can	can	AUX
dpc-2824	22	11	have	have	VERB
dpc-2824	22	12	collateral	collateral	ADJ
dpc-2824	22	13	effects	effect	NOUN
dpc-2824	22	14	on	on	ADP
dpc-2824	22	15	the	the	DET
dpc-2824	22	16	normal	normal	ADJ
dpc-2824	22	17	cells	cell	NOUN
dpc-2824	22	18	leading	lead	VERB
dpc-2824	22	19	to	to	ADP
dpc-2824	22	20	a	a	DET
dpc-2824	22	21	new	new	ADJ
dpc-2824	22	22	spectrum	spectrum	NOUN
dpc-2824	22	23	of	of	ADP
dpc-2824	22	24	adverse	adverse	ADJ
dpc-2824	22	25	events	event	NOUN
dpc-2824	22	26	called	call	VERB
dpc-2824	22	27	immune	immune	NOUN
dpc-2824	22	28	-	-	PUNCT
dpc-2824	22	29	related	relate	VERB
dpc-2824	22	30	adverse	adverse	ADJ
dpc-2824	22	31	events	event	NOUN
dpc-2824	22	32	(	(	PUNCT
dpc-2824	22	33	iraes	iraes	NOUN
dpc-2824	22	34	)	)	PUNCT
dpc-2824	22	35	.	.	PUNCT
dpc-2824	23	1	iraes	iraes	PROPN
dpc-2824	23	2	can	can	AUX
dpc-2824	23	3	potentially	potentially	ADV
dpc-2824	23	4	involve	involve	VERB
dpc-2824	23	5	any	any	DET
dpc-2824	23	6	system	system	NOUN
dpc-2824	23	7	and	and	CCONJ
dpc-2824	23	8	in	in	ADP
dpc-2824	23	9	severe	severe	ADJ
dpc-2824	23	10	cases	case	NOUN
dpc-2824	23	11	can	can	AUX
dpc-2824	23	12	lead	lead	VERB
dpc-2824	23	13	to	to	ADP
dpc-2824	23	14	treatment	treatment	NOUN
dpc-2824	23	15	discontinuation	discontinuation	NOUN
dpc-2824	23	16	or	or	CCONJ
dpc-2824	23	17	even	even	ADV
dpc-2824	23	18	death	death	NOUN
dpc-2824	23	19	.	.	PUNCT
dpc-2824	24	1	cutaneous	cutaneous	ADJ
dpc-2824	24	2	iraes	iraes	NOUN
dpc-2824	24	3	(	(	PUNCT
dpc-2824	24	4	ciraes	ciraes	NOUN
dpc-2824	24	5	)	)	PUNCT
dpc-2824	24	6	are	be	AUX
dpc-2824	24	7	one	one	NUM
dpc-2824	24	8	of	of	ADP
dpc-2824	24	9	the	the	DET
dpc-2824	24	10	most	most	ADV
dpc-2824	24	11	common	common	ADJ
dpc-2824	24	12	iraes	irae	NOUN
dpc-2824	24	13	and	and	CCONJ
dpc-2824	24	14	can	can	AUX
dpc-2824	24	15	have	have	VERB
dpc-2824	24	16	myriad	myriad	ADJ
dpc-2824	24	17	presentations	presentation	NOUN
dpc-2824	25	1	[	[	X
dpc-2824	25	2	2	2	NUM
dpc-2824	25	3	]	]	PUNCT
dpc-2824	25	4	.	.	PUNCT
dpc-2824	26	1	since	since	SCONJ
dpc-2824	26	2	both	both	DET
dpc-2824	26	3	tumor	tumor	NOUN
dpc-2824	26	4	regression	regression	NOUN
dpc-2824	26	5	and	and	CCONJ
dpc-2824	26	6	iraes	irae	NOUN
dpc-2824	26	7	are	be	AUX
dpc-2824	26	8	a	a	DET
dpc-2824	26	9	result	result	NOUN
dpc-2824	26	10	of	of	ADP
dpc-2824	26	11	enhanced	enhanced	ADJ
dpc-2824	26	12	immune	immune	ADJ
dpc-2824	26	13	response	response	NOUN
dpc-2824	26	14	,	,	PUNCT
dpc-2824	26	15	the	the	DET
dpc-2824	26	16	presence	presence	NOUN
dpc-2824	26	17	of	of	ADP
dpc-2824	26	18	iraes	iraes	NOUN
dpc-2824	26	19	may	may	AUX
dpc-2824	26	20	correlate	correlate	VERB
dpc-2824	26	21	with	with	ADP
dpc-2824	26	22	greater	great	ADJ
dpc-2824	26	23	antitumor	antitumor	NOUN
dpc-2824	26	24	response	response	NOUN
dpc-2824	26	25	and	and	CCONJ
dpc-2824	26	26	studies	study	NOUN
dpc-2824	26	27	have	have	AUX
dpc-2824	26	28	shown	show	VERB
dpc-2824	26	29	that	that	SCONJ
dpc-2824	26	30	iraes	irae	NOUN
dpc-2824	26	31	,	,	PUNCT
dpc-2824	26	32	particularly	particularly	ADV
dpc-2824	26	33	ciraes	ciraes	NOUN
dpc-2824	26	34	may	may	AUX
dpc-2824	26	35	be	be	AUX
dpc-2824	26	36	associated	associate	VERB
dpc-2824	26	37	with	with	ADP
dpc-2824	26	38	better	well	ADJ
dpc-2824	26	39	patient	patient	ADJ
dpc-2824	26	40	survival	survival	NOUN
dpc-2824	26	41	outcomes	outcome	NOUN
dpc-2824	27	1	[	[	X
dpc-2824	27	2	3–6	3–6	NUM
dpc-2824	27	3	]	]	X
dpc-2824	27	4	.	.	PUNCT
dpc-2824	28	1	however	however	ADV
dpc-2824	28	2	,	,	PUNCT
dpc-2824	28	3	much	much	ADJ
dpc-2824	28	4	of	of	ADP
dpc-2824	28	5	the	the	DET
dpc-2824	28	6	available	available	ADJ
dpc-2824	28	7	literature	literature	NOUN
dpc-2824	28	8	on	on	ADP
dpc-2824	28	9	immune	immune	ADJ
dpc-2824	28	10	checkpoint	checkpoint	NOUN
dpc-2824	28	11	inhibitors	inhibitor	NOUN
dpc-2824	28	12	and	and	CCONJ
dpc-2824	28	13	their	their	PRON
dpc-2824	28	14	iraes	iraes	NOUN
dpc-2824	28	15	is	be	AUX
dpc-2824	28	16	based	base	VERB
dpc-2824	28	17	on	on	ADP
dpc-2824	28	18	trials	trial	NOUN
dpc-2824	28	19	and	and	CCONJ
dpc-2824	28	20	data	datum	NOUN
dpc-2824	28	21	from	from	ADP
dpc-2824	28	22	western	western	ADJ
dpc-2824	28	23	countries	country	NOUN
dpc-2824	28	24	and	and	CCONJ
dpc-2824	28	25	there	there	PRON
dpc-2824	28	26	is	be	VERB
dpc-2824	28	27	an	an	DET
dpc-2824	28	28	inadequate	inadequate	ADJ
dpc-2824	28	29	representation	representation	NOUN
dpc-2824	28	30	of	of	ADP
dpc-2824	28	31	other	other	ADJ
dpc-2824	28	32	populations	population	NOUN
dpc-2824	28	33	particularly	particularly	ADV
dpc-2824	28	34	the	the	DET
dpc-2824	28	35	indian	indian	ADJ
dpc-2824	28	36	population	population	NOUN
dpc-2824	28	37	.	.	PUNCT
dpc-2824	29	1	reports	report	NOUN
dpc-2824	29	2	suggest	suggest	VERB
dpc-2824	29	3	that	that	SCONJ
dpc-2824	29	4	immune	immune	ADJ
dpc-2824	29	5	checkpoint	checkpoint	NOUN
dpc-2824	29	6	inhibitors	inhibitor	NOUN
dpc-2824	29	7	can	can	AUX
dpc-2824	29	8	variation	variation	VERB
dpc-2824	29	9	in	in	ADP
dpc-2824	29	10	activity	activity	NOUN
dpc-2824	29	11	and	and	CCONJ
dpc-2824	29	12	toxicity	toxicity	NOUN
dpc-2824	29	13	spectrum	spectrum	NOUN
dpc-2824	29	14	among	among	ADP
dpc-2824	29	15	various	various	ADJ
dpc-2824	29	16	ethnicities	ethnicity	NOUN
dpc-2824	29	17	such	such	ADJ
dpc-2824	29	18	as	as	ADP
dpc-2824	29	19	lower	low	ADJ
dpc-2824	29	20	incidence	incidence	NOUN
dpc-2824	29	21	of	of	ADP
dpc-2824	29	22	iraes	irae	NOUN
dpc-2824	29	23	and	and	CCONJ
dpc-2824	29	24	poorer	poor	ADJ
dpc-2824	29	25	survival	survival	NOUN
dpc-2824	29	26	outcomes	outcome	NOUN
dpc-2824	29	27	in	in	ADP
dpc-2824	29	28	hispanics	hispanic	NOUN
dpc-2824	29	29	compared	compare	VERB
dpc-2824	29	30	to	to	ADP
dpc-2824	29	31	caucasian	caucasian	ADJ
dpc-2824	29	32	populations	population	NOUN
dpc-2824	30	1	[	[	X
dpc-2824	30	2	7–10	7–10	X
dpc-2824	30	3	]	]	X
dpc-2824	30	4	.	.	PUNCT
dpc-2824	31	1	thus	thus	ADV
dpc-2824	31	2	,	,	PUNCT
dpc-2824	31	3	there	there	PRON
dpc-2824	31	4	is	be	VERB
dpc-2824	31	5	a	a	DET
dpc-2824	31	6	need	need	NOUN
dpc-2824	31	7	for	for	ADP
dpc-2824	31	8	further	further	ADJ
dpc-2824	31	9	data	datum	NOUN
dpc-2824	31	10	on	on	ADP
dpc-2824	31	11	the	the	DET
dpc-2824	31	12	use	use	NOUN
dpc-2824	31	13	of	of	ADP
dpc-2824	31	14	ici	ici	NOUN
dpc-2824	31	15	and	and	CCONJ
dpc-2824	31	16	various	various	ADJ
dpc-2824	31	17	iraes	irae	NOUN
dpc-2824	31	18	in	in	ADP
dpc-2824	31	19	under	under	ADV
dpc-2824	31	20	-	-	PUNCT
dpc-2824	31	21	represented	represent	VERB
dpc-2824	31	22	population	population	NOUN
dpc-2824	31	23	groups	group	NOUN
dpc-2824	31	24	.	.	PUNCT
dpc-2824	32	1	in	in	ADP
dpc-2824	32	2	our	our	PRON
dpc-2824	32	3	study	study	NOUN
dpc-2824	32	4	,	,	PUNCT
dpc-2824	32	5	we	we	PRON
dpc-2824	32	6	aim	aim	VERB
dpc-2824	32	7	to	to	PART
dpc-2824	32	8	study	study	VERB
dpc-2824	32	9	the	the	DET
dpc-2824	32	10	real	real	ADJ
dpc-2824	32	11	-	-	PUNCT
dpc-2824	32	12	world	world	NOUN
dpc-2824	32	13	incidence	incidence	NOUN
dpc-2824	32	14	and	and	CCONJ
dpc-2824	32	15	manifestations	manifestation	NOUN
dpc-2824	32	16	of	of	ADP
dpc-2824	32	17	ciraes	ciraes	NOUN
dpc-2824	32	18	seen	see	VERB
dpc-2824	32	19	in	in	ADP
dpc-2824	32	20	indian	indian	ADJ
dpc-2824	32	21	patients	patient	NOUN
dpc-2824	32	22	on	on	ADP
dpc-2824	32	23	immune	immune	ADJ
dpc-2824	32	24	checkpoint	checkpoint	NOUN
dpc-2824	32	25	inhibitor	inhibitor	NOUN
dpc-2824	32	26	therapy	therapy	NOUN
dpc-2824	32	27	and	and	CCONJ
dpc-2824	32	28	investigate	investigate	VERB
dpc-2824	32	29	the	the	DET
dpc-2824	32	30	relationship	relationship	NOUN
dpc-2824	32	31	between	between	ADP
dpc-2824	32	32	ciraes	ciraes	NOUN
dpc-2824	32	33	and	and	CCONJ
dpc-2824	32	34	patient	patient	ADJ
dpc-2824	32	35	survival	survival	NOUN
dpc-2824	32	36	.	.	PUNCT
dpc-2824	33	1	objectives	objective	NOUN
dpc-2824	33	2	to	to	PART
dpc-2824	33	3	study	study	VERB
dpc-2824	33	4	the	the	DET
dpc-2824	33	5	various	various	ADJ
dpc-2824	33	6	ciraes	ciraes	NOUN
dpc-2824	33	7	in	in	ADP
dpc-2824	33	8	indian	indian	ADJ
dpc-2824	33	9	patients	patient	NOUN
dpc-2824	33	10	on	on	ADP
dpc-2824	33	11	ici	ici	NOUN
dpc-2824	33	12	therapy	therapy	NOUN
dpc-2824	33	13	and	and	CCONJ
dpc-2824	33	14	to	to	PART
dpc-2824	33	15	analyze	analyze	VERB
dpc-2824	33	16	the	the	DET
dpc-2824	33	17	association	association	NOUN
dpc-2824	33	18	between	between	ADP
dpc-2824	33	19	ciraes	ciraes	NOUN
dpc-2824	33	20	and	and	CCONJ
dpc-2824	33	21	patient	patient	ADJ
dpc-2824	33	22	survival	survival	NOUN
dpc-2824	33	23	outcomes	outcome	NOUN
dpc-2824	33	24	.	.	PUNCT
dpc-2824	34	1	methods	method	NOUN
dpc-2824	34	2	this	this	PRON
dpc-2824	34	3	was	be	AUX
dpc-2824	34	4	a	a	DET
dpc-2824	34	5	single	single	ADJ
dpc-2824	34	6	-	-	PUNCT
dpc-2824	34	7	institution	institution	NOUN
dpc-2824	34	8	retrospective	retrospective	ADJ
dpc-2824	34	9	study	study	NOUN
dpc-2824	34	10	of	of	ADP
dpc-2824	34	11	patients	patient	NOUN
dpc-2824	34	12	receiving	receive	VERB
dpc-2824	34	13	icis	icis	NOUN
dpc-2824	34	14	(	(	PUNCT
dpc-2824	34	15	nivolumab	nivolumab	NOUN
dpc-2824	34	16	,	,	PUNCT
dpc-2824	34	17	pembrolizumab	pembrolizumab	NOUN
dpc-2824	34	18	,	,	PUNCT
dpc-2824	34	19	atezolizumab	atezolizumab	NOUN
dpc-2824	34	20	and	and	CCONJ
dpc-2824	34	21	ipilimumab	ipilimumab	NOUN
dpc-2824	34	22	)	)	PUNCT
dpc-2824	34	23	from	from	ADP
dpc-2824	34	24	january	january	PROPN
dpc-2824	34	25	2017	2017	NUM
dpc-2824	34	26	to	to	ADP
dpc-2824	34	27	september	september	PROPN
dpc-2824	34	28	2021	2021	NUM
dpc-2824	34	29	.	.	PUNCT
dpc-2824	35	1	the	the	DET
dpc-2824	35	2	study	study	NOUN
dpc-2824	35	3	was	be	AUX
dpc-2824	35	4	approved	approve	VERB
dpc-2824	35	5	by	by	ADP
dpc-2824	35	6	the	the	DET
dpc-2824	35	7	hospital	hospital	NOUN
dpc-2824	35	8	institution	institution	NOUN
dpc-2824	35	9	review	review	PROPN
dpc-2824	35	10	board	board	NOUN
dpc-2824	35	11	.	.	PUNCT
dpc-2824	36	1	medical	medical	ADJ
dpc-2824	36	2	records	record	NOUN
dpc-2824	36	3	of	of	ADP
dpc-2824	36	4	all	all	DET
dpc-2824	36	5	patients	patient	NOUN
dpc-2824	36	6	with	with	ADP
dpc-2824	36	7	cancers	cancer	NOUN
dpc-2824	36	8	treated	treat	VERB
dpc-2824	36	9	with	with	ADP
dpc-2824	36	10	at	at	ADV
dpc-2824	36	11	least	least	ADV
dpc-2824	36	12	one	one	NUM
dpc-2824	36	13	dose	dose	NOUN
dpc-2824	36	14	of	of	ADP
dpc-2824	36	15	pd-1	pd-1	ADJ
dpc-2824	36	16	antibodies	antibody	NOUN
dpc-2824	36	17	(	(	PUNCT
dpc-2824	36	18	nivolumab	nivolumab	NOUN
dpc-2824	36	19	or	or	CCONJ
dpc-2824	36	20	pembrolizumab	pembrolizumab	NOUN
dpc-2824	36	21	)	)	PUNCT
dpc-2824	36	22	,	,	PUNCT
dpc-2824	36	23	pd	pd	PROPN
dpc-2824	36	24	-	-	PUNCT
dpc-2824	36	25	l1	l1	PROPN
dpc-2824	36	26	antibodies	antibodie	VERB
dpc-2824	36	27	(	(	PUNCT
dpc-2824	36	28	atezolizumab	atezolizumab	NOUN
dpc-2824	36	29	)	)	PUNCT
dpc-2824	36	30	or	or	CCONJ
dpc-2824	36	31	ctla-4	ctla-4	NOUN
dpc-2824	36	32	antibodies	antibodie	VERB
dpc-2824	36	33	(	(	PUNCT
dpc-2824	36	34	ipilimumab	ipilimumab	NOUN
dpc-2824	36	35	)	)	PUNCT
dpc-2824	36	36	during	during	ADP
dpc-2824	36	37	the	the	DET
dpc-2824	36	38	study	study	NOUN
dpc-2824	36	39	period	period	NOUN
dpc-2824	36	40	were	be	AUX
dpc-2824	36	41	drawn	draw	VERB
dpc-2824	36	42	from	from	ADP
dpc-2824	36	43	the	the	DET
dpc-2824	36	44	hospital	hospital	NOUN
dpc-2824	36	45	medical	medical	ADJ
dpc-2824	36	46	records	record	NOUN
dpc-2824	36	47	database	database	NOUN
dpc-2824	36	48	and	and	CCONJ
dpc-2824	36	49	analyzed	analyze	VERB
dpc-2824	36	50	.	.	PUNCT
dpc-2824	37	1	information	information	NOUN
dpc-2824	37	2	regarding	regard	VERB
dpc-2824	37	3	patient	patient	ADJ
dpc-2824	37	4	demographics	demographic	NOUN
dpc-2824	37	5	and	and	CCONJ
dpc-2824	37	6	characteristics	characteristic	NOUN
dpc-2824	37	7	,	,	PUNCT
dpc-2824	37	8	nature	nature	NOUN
dpc-2824	37	9	of	of	ADP
dpc-2824	37	10	the	the	DET
dpc-2824	37	11	malignancies	malignancy	NOUN
dpc-2824	37	12	,	,	PUNCT
dpc-2824	37	13	ici	ici	PROPN
dpc-2824	37	14	used	use	VERB
dpc-2824	37	15	,	,	PUNCT
dpc-2824	37	16	total	total	ADJ
dpc-2824	37	17	duration	duration	NOUN
dpc-2824	37	18	of	of	ADP
dpc-2824	37	19	treatment	treatment	NOUN
dpc-2824	37	20	,	,	PUNCT
dpc-2824	37	21	any	any	DET
dpc-2824	37	22	adverse	adverse	ADJ
dpc-2824	37	23	events	event	NOUN
dpc-2824	37	24	during	during	ADP
dpc-2824	37	25	ici	ici	NOUN
dpc-2824	37	26	therapy	therapy	NOUN
dpc-2824	37	27	,	,	PUNCT
dpc-2824	37	28	grade	grade	NOUN
dpc-2824	37	29	of	of	ADP
dpc-2824	37	30	the	the	DET
dpc-2824	37	31	adverse	adverse	ADJ
dpc-2824	37	32	events	event	NOUN
dpc-2824	37	33	,	,	PUNCT
dpc-2824	37	34	time	time	NOUN
dpc-2824	37	35	till	till	SCONJ
dpc-2824	37	36	progression	progression	NOUN
dpc-2824	37	37	,	,	PUNCT
dpc-2824	37	38	time	time	NOUN
dpc-2824	37	39	till	till	SCONJ
dpc-2824	37	40	death	death	NOUN
dpc-2824	37	41	were	be	AUX
dpc-2824	37	42	retrieved	retrieve	VERB
dpc-2824	37	43	from	from	ADP
dpc-2824	37	44	medical	medical	ADJ
dpc-2824	37	45	records	record	NOUN
dpc-2824	37	46	.	.	PUNCT
dpc-2824	38	1	treatments	treatment	NOUN
dpc-2824	38	2	given	give	VERB
dpc-2824	38	3	for	for	ADP
dpc-2824	38	4	cutaneous	cutaneous	ADJ
dpc-2824	38	5	adverse	adverse	ADJ
dpc-2824	38	6	events	event	NOUN
dpc-2824	38	7	and	and	CCONJ
dpc-2824	38	8	their	their	PRON
dpc-2824	38	9	outcomes	outcome	NOUN
dpc-2824	38	10	were	be	AUX
dpc-2824	38	11	recorded	record	VERB
dpc-2824	38	12	.	.	PUNCT
dpc-2824	39	1	wherever	wherever	SCONJ
dpc-2824	39	2	possible	possible	ADJ
dpc-2824	39	3	,	,	PUNCT
dpc-2824	39	4	telephonic	telephonic	ADJ
dpc-2824	39	5	follow	follow	NOUN
dpc-2824	39	6	-	-	PUNCT
dpc-2824	39	7	up	up	NOUN
dpc-2824	39	8	was	be	AUX
dpc-2824	39	9	performed	perform	VERB
dpc-2824	39	10	to	to	PART
dpc-2824	39	11	complete	complete	VERB
dpc-2824	39	12	missing	missing	ADJ
dpc-2824	39	13	records	record	NOUN
dpc-2824	39	14	.	.	PUNCT
dpc-2824	40	1	responses	response	NOUN
dpc-2824	40	2	were	be	AUX
dpc-2824	40	3	assessed	assess	VERB
dpc-2824	40	4	clinically	clinically	ADV
dpc-2824	40	5	and	and	CCONJ
dpc-2824	40	6	radiologically	radiologically	ADV
dpc-2824	40	7	and	and	CCONJ
dpc-2824	40	8	classified	classified	ADJ
dpc-2824	40	9	according	accord	VERB
dpc-2824	40	10	to	to	ADP
dpc-2824	40	11	standard	standard	ADJ
dpc-2824	40	12	tumor	tumor	NOUN
dpc-2824	40	13	response	response	NOUN
dpc-2824	40	14	evaluation	evaluation	NOUN
dpc-2824	40	15	criteria	criterion	NOUN
dpc-2824	40	16	the	the	DET
dpc-2824	40	17	response	response	NOUN
dpc-2824	40	18	evaluation	evaluation	NOUN
dpc-2824	40	19	criteria	criterion	NOUN
dpc-2824	40	20	in	in	ADP
dpc-2824	40	21	solid	solid	ADJ
dpc-2824	40	22	tumors	tumor	NOUN
dpc-2824	40	23	(	(	PUNCT
dpc-2824	40	24	recist	recist	NOUN
dpc-2824	40	25	)	)	PUNCT
dpc-2824	40	26	version	version	NOUN
dpc-2824	40	27	1.1	1.1	NUM
dpc-2824	40	28	and	and	CCONJ
dpc-2824	40	29	positron	positron	NOUN
dpc-2824	40	30	emission	emission	NOUN
dpc-2824	40	31	tomography	tomography	NOUN
dpc-2824	40	32	response	response	NOUN
dpc-2824	40	33	evaluation	evaluation	NOUN
dpc-2824	40	34	criteria	criterion	NOUN
dpc-2824	40	35	in	in	ADP
dpc-2824	40	36	solid	solid	ADJ
dpc-2824	40	37	tumors	tumor	NOUN
dpc-2824	40	38	(	(	PUNCT
dpc-2824	40	39	percist	percist	NOUN
dpc-2824	40	40	)	)	PUNCT
dpc-2824	40	41	version	version	NOUN
dpc-2824	40	42	1.0	1.0	NUM
dpc-2824	40	43	.	.	PUNCT
dpc-2824	41	1	adverse	adverse	ADJ
dpc-2824	41	2	events	event	NOUN
dpc-2824	41	3	during	during	ADP
dpc-2824	41	4	immunotherapy	immunotherapy	NOUN
dpc-2824	41	5	were	be	AUX
dpc-2824	41	6	documented	document	VERB
dpc-2824	41	7	and	and	CCONJ
dpc-2824	41	8	graded	grade	VERB
dpc-2824	41	9	using	use	VERB
dpc-2824	41	10	the	the	DET
dpc-2824	41	11	common	common	ADJ
dpc-2824	41	12	terminology	terminology	NOUN
dpc-2824	41	13	criteria	criterion	NOUN
dpc-2824	41	14	for	for	ADP
dpc-2824	41	15	adverse	adverse	ADJ
dpc-2824	41	16	events	event	NOUN
dpc-2824	41	17	(	(	PUNCT
dpc-2824	41	18	ctcae	ctcae	NOUN
dpc-2824	41	19	)	)	PUNCT
dpc-2824	41	20	v	v	ADP
dpc-2824	41	21	5.0	5.0	NUM
dpc-2824	41	22	.	.	PUNCT
dpc-2824	42	1	in	in	ADP
dpc-2824	42	2	the	the	DET
dpc-2824	42	3	patients	patient	NOUN
dpc-2824	42	4	with	with	ADP
dpc-2824	42	5	ciraes	ciraes	NOUN
dpc-2824	42	6	,	,	PUNCT
dpc-2824	42	7	response	response	NOUN
dpc-2824	42	8	of	of	ADP
dpc-2824	42	9	ciraes	ciraes	NOUN
dpc-2824	42	10	to	to	ADP
dpc-2824	42	11	their	their	PRON
dpc-2824	42	12	respective	respective	ADJ
dpc-2824	42	13	dermatological	dermatological	ADJ
dpc-2824	42	14	treatment	treatment	NOUN
dpc-2824	42	15	was	be	AUX
dpc-2824	42	16	graded	grade	VERB
dpc-2824	42	17	as	as	ADP
dpc-2824	42	18	no	no	DET
dpc-2824	42	19	improvement	improvement	NOUN
dpc-2824	42	20	,	,	PUNCT
dpc-2824	42	21	partial	partial	ADJ
dpc-2824	42	22	improvement	improvement	NOUN
dpc-2824	42	23	(	(	PUNCT
dpc-2824	42	24	an	an	DET
dpc-2824	42	25	improvement	improvement	NOUN
dpc-2824	42	26	by	by	ADP
dpc-2824	42	27	one	one	NUM
dpc-2824	42	28	ctcae	ctcae	NOUN
dpc-2824	42	29	grade	grade	NOUN
dpc-2824	42	30	)	)	PUNCT
dpc-2824	42	31	or	or	CCONJ
dpc-2824	42	32	significant	significant	ADJ
dpc-2824	42	33	improvement	improvement	NOUN
dpc-2824	42	34	(	(	PUNCT
dpc-2824	42	35	an	an	DET
dpc-2824	42	36	improvement	improvement	NOUN
dpc-2824	42	37	by	by	ADP
dpc-2824	42	38	two	two	NUM
dpc-2824	42	39	or	or	CCONJ
dpc-2824	42	40	more	more	ADJ
dpc-2824	42	41	ctcae	ctcae	NOUN
dpc-2824	42	42	grades	grade	NOUN
dpc-2824	42	43	or	or	CCONJ
dpc-2824	42	44	improvement	improvement	NOUN
dpc-2824	42	45	to	to	ADP
dpc-2824	42	46	grade	grade	NOUN
dpc-2824	42	47	0	0	NUM
dpc-2824	42	48	)	)	PUNCT
dpc-2824	42	49	.	.	PUNCT
dpc-2824	43	1	data	datum	NOUN
dpc-2824	43	2	censoring	censor	VERB
dpc-2824	43	3	was	be	AUX
dpc-2824	43	4	done	do	VERB
dpc-2824	43	5	in	in	ADP
dpc-2824	43	6	october	october	PROPN
dpc-2824	43	7	2021	2021	NUM
dpc-2824	43	8	.	.	PUNCT
dpc-2824	44	1	overall	overall	ADJ
dpc-2824	44	2	-	-	PUNCT
dpc-2824	44	3	response	response	NOUN
dpc-2824	44	4	-	-	PUNCT
dpc-2824	44	5	rates	rate	NOUN
dpc-2824	44	6	(	(	PUNCT
dpc-2824	44	7	orr	orr	PROPN
dpc-2824	44	8	)	)	PUNCT
dpc-2824	44	9	,	,	PUNCT
dpc-2824	44	10	overall	overall	ADJ
dpc-2824	44	11	survival	survival	NOUN
dpc-2824	44	12	(	(	PUNCT
dpc-2824	44	13	os	os	NOUN
dpc-2824	44	14	)	)	PUNCT
dpc-2824	44	15	and	and	CCONJ
dpc-2824	44	16	progression	progression	NOUN
dpc-2824	44	17	-	-	PUNCT
dpc-2824	44	18	free	free	ADJ
dpc-2824	44	19	-	-	PUNCT
dpc-2824	44	20	survival	survival	NOUN
dpc-2824	44	21	(	(	PUNCT
dpc-2824	44	22	pfs	pfs	PROPN
dpc-2824	44	23	)	)	PUNCT
dpc-2824	44	24	were	be	AUX
dpc-2824	44	25	calculated	calculate	VERB
dpc-2824	44	26	and	and	CCONJ
dpc-2824	44	27	compared	compare	VERB
dpc-2824	44	28	between	between	ADP
dpc-2824	44	29	patients	patient	NOUN
dpc-2824	44	30	having	have	VERB
dpc-2824	44	31	cutaneous	cutaneous	ADJ
dpc-2824	44	32	adverse	adverse	ADJ
dpc-2824	44	33	events	event	NOUN
dpc-2824	44	34	and	and	CCONJ
dpc-2824	44	35	those	those	PRON
dpc-2824	44	36	not	not	PART
dpc-2824	44	37	having	have	VERB
dpc-2824	44	38	cutaneous	cutaneous	ADJ
dpc-2824	44	39	adverse	adverse	ADJ
dpc-2824	44	40	events	event	NOUN
dpc-2824	44	41	.	.	PUNCT
dpc-2824	45	1	tumor	tumor	NOUN
dpc-2824	45	2	response	response	NOUN
dpc-2824	45	3	was	be	AUX
dpc-2824	45	4	graded	grade	VERB
dpc-2824	45	5	as	as	ADP
dpc-2824	45	6	complete	complete	ADJ
dpc-2824	45	7	response	response	NOUN
dpc-2824	45	8	(	(	PUNCT
dpc-2824	45	9	cr	cr	NOUN
dpc-2824	45	10	)	)	PUNCT
dpc-2824	45	11	,	,	PUNCT
dpc-2824	45	12	partial	partial	ADJ
dpc-2824	45	13	response	response	NOUN
dpc-2824	45	14	(	(	PUNCT
dpc-2824	45	15	pr	pr	NOUN
dpc-2824	45	16	)	)	PUNCT
dpc-2824	45	17	,	,	PUNCT
dpc-2824	45	18	progressive	progressive	ADJ
dpc-2824	45	19	disease	disease	NOUN
dpc-2824	45	20	(	(	PUNCT
dpc-2824	45	21	pd	pd	NOUN
dpc-2824	45	22	)	)	PUNCT
dpc-2824	45	23	and	and	CCONJ
dpc-2824	45	24	stable	stable	ADJ
dpc-2824	45	25	disease	disease	NOUN
dpc-2824	45	26	(	(	PUNCT
dpc-2824	45	27	sd	sd	NOUN
dpc-2824	45	28	)	)	PUNCT
dpc-2824	45	29	based	base	VERB
dpc-2824	45	30	on	on	ADP
dpc-2824	45	31	standard	standard	ADJ
dpc-2824	45	32	tumor	tumor	NOUN
dpc-2824	45	33	response	response	NOUN
dpc-2824	45	34	evaluation	evaluation	NOUN
dpc-2824	45	35	criteria	criterion	NOUN
dpc-2824	45	36	–	–	PUNCT
dpc-2824	45	37	recist	recist	NOUN
dpc-2824	45	38	and	and	CCONJ
dpc-2824	45	39	percist	percist	NOUN
dpc-2824	45	40	.	.	PUNCT
dpc-2824	46	1	overall	overall	ADJ
dpc-2824	46	2	response	response	NOUN
dpc-2824	46	3	rate	rate	NOUN
dpc-2824	46	4	(	(	PUNCT
dpc-2824	46	5	orr	orr	PROPN
dpc-2824	46	6	)	)	PUNCT
dpc-2824	46	7	was	be	AUX
dpc-2824	46	8	defined	define	VERB
dpc-2824	46	9	as	as	ADP
dpc-2824	46	10	the	the	DET
dpc-2824	46	11	proportion	proportion	NOUN
dpc-2824	46	12	of	of	ADP
dpc-2824	46	13	patients	patient	NOUN
dpc-2824	46	14	who	who	PRON
dpc-2824	46	15	have	have	VERB
dpc-2824	46	16	a	a	DET
dpc-2824	46	17	partial	partial	ADJ
dpc-2824	46	18	or	or	CCONJ
dpc-2824	46	19	complete	complete	ADJ
dpc-2824	46	20	response	response	NOUN
dpc-2824	46	21	to	to	ADP
dpc-2824	46	22	therapy	therapy	NOUN
dpc-2824	46	23	,	,	PUNCT
dpc-2824	46	24	excluding	exclude	VERB
dpc-2824	46	25	stable	stable	ADJ
dpc-2824	46	26	disease	disease	NOUN
dpc-2824	46	27	.	.	PUNCT
dpc-2824	47	1	progression	progression	NOUN
dpc-2824	47	2	free	free	ADJ
dpc-2824	47	3	survival	survival	NOUN
dpc-2824	47	4	(	(	PUNCT
dpc-2824	47	5	pfs	pfs	PROPN
dpc-2824	47	6	)	)	PUNCT
dpc-2824	47	7	was	be	AUX
dpc-2824	47	8	defined	define	VERB
dpc-2824	47	9	as	as	ADP
dpc-2824	47	10	the	the	DET
dpc-2824	47	11	time	time	NOUN
dpc-2824	47	12	conclusions	conclusion	NOUN
dpc-2824	47	13	:	:	PUNCT
dpc-2824	47	14	most	most	ADV
dpc-2824	47	15	common	common	ADJ
dpc-2824	47	16	ciraes	ciraes	NOUN
dpc-2824	47	17	in	in	ADP
dpc-2824	47	18	our	our	PRON
dpc-2824	47	19	study	study	NOUN
dpc-2824	47	20	were	be	AUX
dpc-2824	47	21	pruritus	pruritus	NOUN
dpc-2824	47	22	and	and	CCONJ
dpc-2824	47	23	maculopapular	maculopapular	ADJ
dpc-2824	47	24	rash	rash	NOUN
dpc-2824	47	25	.	.	PUNCT
dpc-2824	48	1	the	the	DET
dpc-2824	48	2	incidence	incidence	NOUN
dpc-2824	48	3	of	of	ADP
dpc-2824	48	4	ciraes	ciraes	NOUN
dpc-2824	48	5	was	be	AUX
dpc-2824	48	6	lower	low	ADJ
dpc-2824	48	7	in	in	ADP
dpc-2824	48	8	our	our	PRON
dpc-2824	48	9	indian	indian	ADJ
dpc-2824	48	10	cohort	cohort	NOUN
dpc-2824	48	11	compared	compare	VERB
dpc-2824	48	12	to	to	ADP
dpc-2824	48	13	that	that	PRON
dpc-2824	48	14	reported	report	VERB
dpc-2824	48	15	in	in	ADP
dpc-2824	48	16	caucasian	caucasian	ADJ
dpc-2824	48	17	cohorts	cohort	NOUN
dpc-2824	48	18	.	.	PUNCT
dpc-2824	49	1	development	development	NOUN
dpc-2824	49	2	of	of	ADP
dpc-2824	49	3	cutaneous	cutaneous	ADJ
dpc-2824	49	4	immune	immune	NOUN
dpc-2824	49	5	-	-	PUNCT
dpc-2824	49	6	related	relate	VERB
dpc-2824	49	7	adverse	adverse	ADJ
dpc-2824	49	8	event	event	NOUN
dpc-2824	49	9	in	in	ADP
dpc-2824	49	10	cancer	cancer	NOUN
dpc-2824	49	11	patients	patient	NOUN
dpc-2824	49	12	on	on	ADP
dpc-2824	49	13	ici	ici	PROPN
dpc-2824	49	14	was	be	AUX
dpc-2824	49	15	associated	associate	VERB
dpc-2824	49	16	with	with	ADP
dpc-2824	49	17	a	a	DET
dpc-2824	49	18	longer	long	ADJ
dpc-2824	49	19	progression	progression	NOUN
dpc-2824	49	20	-	-	PUNCT
dpc-2824	49	21	free	free	ADJ
dpc-2824	49	22	-	-	PUNCT
dpc-2824	49	23	survival	survival	NOUN
dpc-2824	49	24	and	and	CCONJ
dpc-2824	49	25	a	a	DET
dpc-2824	49	26	better	well	ADJ
dpc-2824	49	27	objective	objective	ADJ
dpc-2824	49	28	-	-	PUNCT
dpc-2824	49	29	response	response	NOUN
dpc-2824	49	30	-	-	PUNCT
dpc-2824	49	31	rate	rate	NOUN
dpc-2824	49	32	.	.	PUNCT
dpc-2824	50	1	thus	thus	ADV
dpc-2824	50	2	,	,	PUNCT
dpc-2824	50	3	ciraes	ciraes	NOUN
dpc-2824	50	4	may	may	AUX
dpc-2824	50	5	serve	serve	VERB
dpc-2824	50	6	as	as	ADP
dpc-2824	50	7	a	a	DET
dpc-2824	50	8	surrogate	surrogate	ADJ
dpc-2824	50	9	marker	marker	NOUN
dpc-2824	50	10	for	for	ADP
dpc-2824	50	11	better	well	ADJ
dpc-2824	50	12	patient	patient	ADJ
dpc-2824	50	13	outcomes	outcome	NOUN
dpc-2824	50	14	.	.	PUNCT
dpc-2824	51	1	original	original	ADJ
dpc-2824	51	2	article	article	NOUN
dpc-2824	51	3	|	|	ADV
dpc-2824	51	4	dermatol	dermatol	ADJ
dpc-2824	51	5	pract	pract	NOUN
dpc-2824	51	6	concept	concept	NOUN
dpc-2824	51	7	.	.	PUNCT
dpc-2824	52	1	2023;13(3):e2023127	2023;13(3):e2023127	NUM
dpc-2824	52	2	3	3	NUM
dpc-2824	52	3	elapsed	elapse	VERB
dpc-2824	52	4	since	since	SCONJ
dpc-2824	52	5	treatment	treatment	NOUN
dpc-2824	52	6	initiation	initiation	NOUN
dpc-2824	52	7	until	until	ADP
dpc-2824	52	8	disease	disease	NOUN
dpc-2824	52	9	progression	progression	NOUN
dpc-2824	52	10	or	or	CCONJ
dpc-2824	52	11	death	death	NOUN
dpc-2824	52	12	from	from	ADP
dpc-2824	52	13	any	any	DET
dpc-2824	52	14	cause	cause	NOUN
dpc-2824	52	15	,	,	PUNCT
dpc-2824	52	16	whichever	whichever	PRON
dpc-2824	52	17	comes	come	VERB
dpc-2824	52	18	first	first	ADV
dpc-2824	52	19	.	.	PUNCT
dpc-2824	53	1	progression	progression	NOUN
dpc-2824	53	2	was	be	AUX
dpc-2824	53	3	defined	define	VERB
dpc-2824	53	4	as	as	ADP
dpc-2824	53	5	clinical	clinical	ADJ
dpc-2824	53	6	worsening	worsening	NOUN
dpc-2824	53	7	of	of	ADP
dpc-2824	53	8	the	the	DET
dpc-2824	53	9	disease	disease	NOUN
dpc-2824	53	10	or	or	CCONJ
dpc-2824	53	11	radiological	radiological	ADJ
dpc-2824	53	12	progression	progression	NOUN
dpc-2824	53	13	as	as	ADP
dpc-2824	53	14	per	per	ADP
dpc-2824	53	15	recist	recist	NOUN
dpc-2824	53	16	v	v	ADP
dpc-2824	53	17	1.1	1.1	NUM
dpc-2824	53	18	/	/	SYM
dpc-2824	53	19	percist	percist	NOUN
dpc-2824	53	20	v	v	ADP
dpc-2824	53	21	1.0	1.0	NUM
dpc-2824	53	22	or	or	CCONJ
dpc-2824	53	23	death	death	NOUN
dpc-2824	53	24	due	due	ADP
dpc-2824	53	25	to	to	ADP
dpc-2824	53	26	any	any	DET
dpc-2824	53	27	cause	cause	NOUN
dpc-2824	53	28	.	.	PUNCT
dpc-2824	54	1	overall	overall	ADJ
dpc-2824	54	2	survival	survival	NOUN
dpc-2824	54	3	(	(	PUNCT
dpc-2824	54	4	os	os	NOUN
dpc-2824	54	5	)	)	PUNCT
dpc-2824	54	6	is	be	AUX
dpc-2824	54	7	defined	define	VERB
dpc-2824	54	8	as	as	ADP
dpc-2824	54	9	the	the	DET
dpc-2824	54	10	time	time	NOUN
dpc-2824	54	11	as	as	ADP
dpc-2824	54	12	the	the	DET
dpc-2824	54	13	time	time	NOUN
dpc-2824	54	14	elapsed	elapse	VERB
dpc-2824	54	15	since	since	SCONJ
dpc-2824	54	16	treatment	treatment	NOUN
dpc-2824	54	17	initiation	initiation	NOUN
dpc-2824	54	18	until	until	ADP
dpc-2824	54	19	death	death	NOUN
dpc-2824	54	20	from	from	ADP
dpc-2824	54	21	any	any	DET
dpc-2824	54	22	cause	cause	NOUN
dpc-2824	54	23	.	.	PUNCT
dpc-2824	55	1	patients	patient	NOUN
dpc-2824	55	2	were	be	AUX
dpc-2824	55	3	censored	censor	VERB
dpc-2824	55	4	at	at	ADP
dpc-2824	55	5	the	the	DET
dpc-2824	55	6	date	date	NOUN
dpc-2824	55	7	of	of	ADP
dpc-2824	55	8	last	last	ADJ
dpc-2824	55	9	follow	follow	NOUN
dpc-2824	55	10	-	-	PUNCT
dpc-2824	55	11	up	up	NOUN
dpc-2824	55	12	if	if	SCONJ
dpc-2824	55	13	still	still	ADV
dpc-2824	55	14	alive	alive	ADJ
dpc-2824	55	15	at	at	ADP
dpc-2824	55	16	the	the	DET
dpc-2824	55	17	time	time	NOUN
dpc-2824	55	18	of	of	ADP
dpc-2824	55	19	the	the	DET
dpc-2824	55	20	analysis	analysis	NOUN
dpc-2824	55	21	.	.	PUNCT
dpc-2824	56	1	statistical	statistical	ADJ
dpc-2824	56	2	analysis	analysis	NOUN
dpc-2824	56	3	was	be	AUX
dpc-2824	56	4	performed	perform	VERB
dpc-2824	56	5	using	use	VERB
dpc-2824	56	6	ibm	ibm	PROPN
dpc-2824	56	7	spss	spss	PROPN
dpc-2824	56	8	version	version	NOUN
dpc-2824	56	9	20.0	20.0	NUM
dpc-2824	56	10	software	software	NOUN
dpc-2824	56	11	(	(	PUNCT
dpc-2824	56	12	spss	spss	PROPN
dpc-2824	56	13	inc	inc	PROPN
dpc-2824	56	14	,	,	PUNCT
dpc-2824	56	15	chicago	chicago	PROPN
dpc-2824	56	16	,	,	PUNCT
dpc-2824	56	17	usa	usa	PROPN
dpc-2824	56	18	)	)	PUNCT
dpc-2824	56	19	.	.	PUNCT
dpc-2824	57	1	categorical	categorical	ADJ
dpc-2824	57	2	variables	variable	NOUN
dpc-2824	57	3	were	be	AUX
dpc-2824	57	4	expressed	express	VERB
dpc-2824	57	5	using	use	VERB
dpc-2824	57	6	frequency	frequency	NOUN
dpc-2824	57	7	and	and	CCONJ
dpc-2824	57	8	percentage	percentage	NOUN
dpc-2824	57	9	.	.	PUNCT
dpc-2824	58	1	continuous	continuous	ADJ
dpc-2824	58	2	variables	variable	NOUN
dpc-2824	58	3	are	be	AUX
dpc-2824	58	4	expressed	express	VERB
dpc-2824	58	5	as	as	ADP
dpc-2824	58	6	mean	mean	NOUN
dpc-2824	58	7	±	±	NUM
dpc-2824	58	8	sd	sd	NOUN
dpc-2824	58	9	or	or	CCONJ
dpc-2824	58	10	the	the	DET
dpc-2824	58	11	median	median	ADJ
dpc-2824	58	12	and	and	CCONJ
dpc-2824	58	13	interquartile	interquartile	ADJ
dpc-2824	58	14	range	range	NOUN
dpc-2824	58	15	[	[	X
dpc-2824	58	16	iqr	iqr	X
dpc-2824	58	17	]	]	X
dpc-2824	58	18	.	.	PUNCT
dpc-2824	59	1	chi	chi	ADJ
dpc-2824	59	2	-	-	PUNCT
dpc-2824	59	3	square	square	ADJ
dpc-2824	59	4	test	test	NOUN
dpc-2824	59	5	with	with	ADP
dpc-2824	59	6	continuity	continuity	NOUN
dpc-2824	59	7	correction	correction	NOUN
dpc-2824	59	8	was	be	AUX
dpc-2824	59	9	used	use	VERB
dpc-2824	59	10	to	to	PART
dpc-2824	59	11	test	test	VERB
dpc-2824	59	12	the	the	DET
dpc-2824	59	13	statistical	statistical	ADJ
dpc-2824	59	14	significance	significance	NOUN
dpc-2824	59	15	of	of	ADP
dpc-2824	59	16	differences	difference	NOUN
dpc-2824	59	17	in	in	ADP
dpc-2824	59	18	overall	overall	ADJ
dpc-2824	59	19	response	response	NOUN
dpc-2824	59	20	rate	rate	NOUN
dpc-2824	59	21	between	between	ADP
dpc-2824	59	22	patients	patient	NOUN
dpc-2824	59	23	with	with	ADP
dpc-2824	59	24	and	and	CCONJ
dpc-2824	59	25	without	without	ADP
dpc-2824	59	26	adverse	adverse	ADJ
dpc-2824	59	27	events	event	NOUN
dpc-2824	59	28	.	.	PUNCT
dpc-2824	60	1	to	to	PART
dpc-2824	60	2	compute	compute	VERB
dpc-2824	60	3	the	the	DET
dpc-2824	60	4	survival	survival	NOUN
dpc-2824	60	5	probability	probability	NOUN
dpc-2824	60	6	and	and	CCONJ
dpc-2824	60	7	the	the	DET
dpc-2824	60	8	survival	survival	ADJ
dpc-2824	60	9	comparison	comparison	NOUN
dpc-2824	60	10	between	between	ADP
dpc-2824	60	11	patients	patient	NOUN
dpc-2824	60	12	with	with	ADP
dpc-2824	60	13	and	and	CCONJ
dpc-2824	60	14	without	without	ADP
dpc-2824	60	15	adverse	adverse	ADJ
dpc-2824	60	16	events	event	NOUN
dpc-2824	60	17	,	,	PUNCT
dpc-2824	60	18	kaplan	kaplan	PROPN
dpc-2824	60	19	–	–	PUNCT
dpc-2824	60	20	meier	meier	PROPN
dpc-2824	60	21	analysis	analysis	NOUN
dpc-2824	60	22	with	with	ADP
dpc-2824	60	23	logrank	logrank	ADJ
dpc-2824	60	24	test	test	NOUN
dpc-2824	60	25	was	be	AUX
dpc-2824	60	26	used	use	VERB
dpc-2824	60	27	.	.	PUNCT
dpc-2824	61	1	multivariable	multivariable	ADJ
dpc-2824	61	2	analysis	analysis	NOUN
dpc-2824	61	3	of	of	ADP
dpc-2824	61	4	both	both	PRON
dpc-2824	61	5	pfs	pfs	PROPN
dpc-2824	61	6	and	and	CCONJ
dpc-2824	61	7	os	os	NOUN
dpc-2824	61	8	was	be	AUX
dpc-2824	61	9	performed	perform	VERB
dpc-2824	61	10	with	with	ADP
dpc-2824	61	11	cox	cox	PROPN
dpc-2824	61	12	proportional	proportional	PROPN
dpc-2824	61	13	hazard	hazard	NOUN
dpc-2824	61	14	regression	regression	NOUN
dpc-2824	61	15	models	model	NOUN
dpc-2824	61	16	.	.	PUNCT
dpc-2824	62	1	a	a	DET
dpc-2824	62	2	p	p	NOUN
dpc-2824	62	3	value	value	NOUN
dpc-2824	62	4	of	of	ADP
dpc-2824	62	5	<	<	NOUN
dpc-2824	62	6	0.05	0.05	NUM
dpc-2824	62	7	was	be	AUX
dpc-2824	62	8	considered	consider	VERB
dpc-2824	62	9	to	to	PART
dpc-2824	62	10	be	be	AUX
dpc-2824	62	11	statistically	statistically	ADV
dpc-2824	62	12	significant	significant	ADJ
dpc-2824	62	13	.	.	PUNCT
dpc-2824	63	1	results	result	VERB
dpc-2824	63	2	a	a	DET
dpc-2824	63	3	total	total	NOUN
dpc-2824	63	4	of	of	ADP
dpc-2824	63	5	86	86	NUM
dpc-2824	63	6	patients	patient	NOUN
dpc-2824	63	7	(	(	PUNCT
dpc-2824	63	8	m	m	PROPN
dpc-2824	63	9	:	:	PUNCT
dpc-2824	63	10	f	f	PROPN
dpc-2824	63	11	64:22	64:22	NUM
dpc-2824	63	12	)	)	PUNCT
dpc-2824	63	13	of	of	ADP
dpc-2824	63	14	median	median	ADJ
dpc-2824	63	15	age	age	NOUN
dpc-2824	63	16	60.5	60.5	NUM
dpc-2824	63	17	years	year	NOUN
dpc-2824	63	18	(	(	PUNCT
dpc-2824	63	19	iqr:18	iqr:18	NOUN
dpc-2824	63	20	–	–	PUNCT
dpc-2824	63	21	83	83	NUM
dpc-2824	63	22	)	)	PUNCT
dpc-2824	63	23	were	be	AUX
dpc-2824	63	24	included	include	VERB
dpc-2824	63	25	.	.	PUNCT
dpc-2824	64	1	this	this	PRON
dpc-2824	64	2	was	be	AUX
dpc-2824	64	3	an	an	DET
dpc-2824	64	4	umbrella	umbrella	NOUN
dpc-2824	64	5	study	study	NOUN
dpc-2824	64	6	comprising	comprising	NOUN
dpc-2824	64	7	of	of	ADP
dpc-2824	64	8	multiple	multiple	ADJ
dpc-2824	64	9	malignancies	malignancy	NOUN
dpc-2824	64	10	,	,	PUNCT
dpc-2824	64	11	with	with	ADP
dpc-2824	64	12	lung	lung	NOUN
dpc-2824	64	13	cancer	cancer	NOUN
dpc-2824	64	14	being	be	AUX
dpc-2824	64	15	the	the	DET
dpc-2824	64	16	most	most	ADV
dpc-2824	64	17	common	common	ADJ
dpc-2824	64	18	malignancy	malignancy	NOUN
dpc-2824	64	19	(	(	PUNCT
dpc-2824	64	20	26	26	NUM
dpc-2824	64	21	patients	patient	NOUN
dpc-2824	64	22	,	,	PUNCT
dpc-2824	64	23	30.2	30.2	NUM
dpc-2824	64	24	%	%	NOUN
dpc-2824	64	25	)	)	PUNCT
dpc-2824	64	26	.	.	PUNCT
dpc-2824	65	1	other	other	ADJ
dpc-2824	65	2	common	common	ADJ
dpc-2824	65	3	malignancies	malignancy	NOUN
dpc-2824	65	4	included	include	VERB
dpc-2824	65	5	hepatocellular	hepatocellular	ADJ
dpc-2824	65	6	carcinoma	carcinoma	NOUN
dpc-2824	65	7	(	(	PUNCT
dpc-2824	65	8	12	12	NUM
dpc-2824	65	9	patients	patient	NOUN
dpc-2824	65	10	,	,	PUNCT
dpc-2824	65	11	13.9	13.9	NUM
dpc-2824	65	12	%	%	NOUN
dpc-2824	65	13	)	)	PUNCT
dpc-2824	65	14	,	,	PUNCT
dpc-2824	65	15	renal	renal	ADJ
dpc-2824	65	16	cell	cell	NOUN
dpc-2824	65	17	carcinoma	carcinoma	NOUN
dpc-2824	65	18	(	(	PUNCT
dpc-2824	65	19	10	10	NUM
dpc-2824	65	20	patients	patient	NOUN
dpc-2824	65	21	,	,	PUNCT
dpc-2824	65	22	11.6	11.6	NUM
dpc-2824	65	23	%	%	NOUN
dpc-2824	65	24	)	)	PUNCT
dpc-2824	65	25	and	and	CCONJ
dpc-2824	65	26	oropharyngeal	oropharyngeal	ADJ
dpc-2824	65	27	squamous	squamous	ADJ
dpc-2824	65	28	cell	cell	NOUN
dpc-2824	65	29	carcinoma	carcinoma	NOUN
dpc-2824	65	30	(	(	PUNCT
dpc-2824	65	31	10	10	NUM
dpc-2824	65	32	 	 	SPACE
dpc-2824	65	33	patients	patient	NOUN
dpc-2824	65	34	,	,	PUNCT
dpc-2824	65	35	11.6	11.6	NUM
dpc-2824	65	36	%	%	NOUN
dpc-2824	65	37	)	)	PUNCT
dpc-2824	65	38	.	.	PUNCT
dpc-2824	66	1	the	the	DET
dpc-2824	66	2	median	median	ADJ
dpc-2824	66	3	duration	duration	NOUN
dpc-2824	66	4	of	of	ADP
dpc-2824	66	5	ici	ici	PROPN
dpc-2824	66	6	therapy	therapy	NOUN
dpc-2824	66	7	was	be	AUX
dpc-2824	66	8	three	three	NUM
dpc-2824	66	9	months	month	NOUN
dpc-2824	66	10	(	(	PUNCT
dpc-2824	66	11	iqr	iqr	NOUN
dpc-2824	66	12	2	2	NUM
dpc-2824	66	13	-	-	SYM
dpc-2824	66	14	6	6	NUM
dpc-2824	66	15	)	)	PUNCT
dpc-2824	66	16	with	with	ADP
dpc-2824	66	17	a	a	DET
dpc-2824	66	18	median	median	NOUN
dpc-2824	66	19	of	of	ADP
dpc-2824	66	20	five	five	NUM
dpc-2824	66	21	cycles	cycle	NOUN
dpc-2824	66	22	(	(	PUNCT
dpc-2824	66	23	iqr	iqr	NOUN
dpc-2824	66	24	3	3	NUM
dpc-2824	66	25	-	-	SYM
dpc-2824	66	26	8.75	8.75	NUM
dpc-2824	66	27	)	)	PUNCT
dpc-2824	66	28	.	.	PUNCT
dpc-2824	67	1	fifty	fifty	NUM
dpc-2824	67	2	-	-	PUNCT
dpc-2824	67	3	one	one	NUM
dpc-2824	67	4	patients	patient	NOUN
dpc-2824	67	5	(	(	PUNCT
dpc-2824	67	6	59.3	59.3	NUM
dpc-2824	67	7	%	%	NOUN
dpc-2824	67	8	)	)	PUNCT
dpc-2824	67	9	were	be	AUX
dpc-2824	67	10	treated	treat	VERB
dpc-2824	67	11	with	with	ADP
dpc-2824	67	12	nivolumab	nivolumab	NOUN
dpc-2824	67	13	,	,	PUNCT
dpc-2824	67	14	29	29	NUM
dpc-2824	67	15	(	(	PUNCT
dpc-2824	67	16	33.7	33.7	NUM
dpc-2824	67	17	%	%	NOUN
dpc-2824	67	18	)	)	PUNCT
dpc-2824	67	19	with	with	ADP
dpc-2824	67	20	pembrolizumab	pembrolizumab	NOUN
dpc-2824	67	21	,	,	PUNCT
dpc-2824	67	22	five	five	NUM
dpc-2824	67	23	(	(	PUNCT
dpc-2824	67	24	5.8	5.8	NUM
dpc-2824	67	25	%	%	NOUN
dpc-2824	67	26	)	)	PUNCT
dpc-2824	67	27	with	with	ADP
dpc-2824	67	28	atezolizumab	atezolizumab	NOUN
dpc-2824	67	29	and	and	CCONJ
dpc-2824	67	30	one	one	NUM
dpc-2824	67	31	(	(	PUNCT
dpc-2824	67	32	1.2	1.2	NUM
dpc-2824	67	33	%	%	NOUN
dpc-2824	67	34	)	)	PUNCT
dpc-2824	67	35	with	with	ADP
dpc-2824	67	36	combination	combination	NOUN
dpc-2824	67	37	of	of	ADP
dpc-2824	67	38	ipilimumab	ipilimumab	NOUN
dpc-2824	67	39	and	and	CCONJ
dpc-2824	67	40	nivolumab	nivolumab	NOUN
dpc-2824	67	41	.	.	PUNCT
dpc-2824	68	1	patient	patient	ADJ
dpc-2824	68	2	demographics	demographic	NOUN
dpc-2824	68	3	are	be	AUX
dpc-2824	68	4	presented	present	VERB
dpc-2824	68	5	in	in	ADP
dpc-2824	68	6	table	table	NOUN
dpc-2824	68	7	1	1	NUM
dpc-2824	68	8	.	.	PUNCT
dpc-2824	69	1	a	a	DET
dpc-2824	69	2	total	total	NOUN
dpc-2824	69	3	of	of	ADP
dpc-2824	69	4	42	42	NUM
dpc-2824	69	5	iraes	irae	NOUN
dpc-2824	69	6	of	of	ADP
dpc-2824	69	7	any	any	DET
dpc-2824	69	8	grade	grade	NOUN
dpc-2824	69	9	occurred	occur	VERB
dpc-2824	69	10	in	in	ADP
dpc-2824	69	11	28	28	NUM
dpc-2824	69	12	patients	patient	NOUN
dpc-2824	69	13	(	(	PUNCT
dpc-2824	69	14	32.5	32.5	NUM
dpc-2824	69	15	%	%	NOUN
dpc-2824	69	16	)	)	PUNCT
dpc-2824	69	17	with	with	ADP
dpc-2824	69	18	six	six	NUM
dpc-2824	69	19	patients	patient	NOUN
dpc-2824	69	20	(	(	PUNCT
dpc-2824	69	21	6.97	6.97	NUM
dpc-2824	69	22	%	%	NOUN
dpc-2824	69	23	)	)	PUNCT
dpc-2824	69	24	having	have	VERB
dpc-2824	69	25	adverse	adverse	ADJ
dpc-2824	69	26	events	event	NOUN
dpc-2824	69	27	involving	involve	VERB
dpc-2824	69	28	more	more	ADJ
dpc-2824	69	29	than	than	ADP
dpc-2824	69	30	one	one	NUM
dpc-2824	69	31	organ	organ	NOUN
dpc-2824	69	32	system	system	NOUN
dpc-2824	69	33	.	.	PUNCT
dpc-2824	70	1	cutaneous	cutaneous	ADJ
dpc-2824	70	2	(	(	PUNCT
dpc-2824	70	3	18.6	18.6	NUM
dpc-2824	70	4	%	%	NOUN
dpc-2824	70	5	)	)	PUNCT
dpc-2824	70	6	table	table	NOUN
dpc-2824	70	7	1	1	NUM
dpc-2824	70	8	.	.	PUNCT
dpc-2824	71	1	patient	patient	ADJ
dpc-2824	71	2	characteristics	characteristic	NOUN
dpc-2824	71	3	.	.	PUNCT
dpc-2824	72	1	clinical	clinical	ADJ
dpc-2824	72	2	characteristics	characteristic	NOUN
dpc-2824	72	3	n	n	CCONJ
dpc-2824	72	4	(	(	PUNCT
dpc-2824	72	5	%	%	INTJ
dpc-2824	72	6	)	)	PUNCT
dpc-2824	72	7	median	median	ADJ
dpc-2824	72	8	age	age	NOUN
dpc-2824	72	9	at	at	ADP
dpc-2824	72	10	ici	ici	PROPN
dpc-2824	72	11	initiation	initiation	NOUN
dpc-2824	72	12	60.5	60.5	NUM
dpc-2824	72	13	(	(	PUNCT
dpc-2824	72	14	iqr:48	iqr:48	PROPN
dpc-2824	72	15	-	-	PUNCT
dpc-2824	72	16	71	71	NUM
dpc-2824	72	17	)	)	PUNCT
dpc-2824	72	18	gender	gender	NOUN
dpc-2824	72	19	(	(	PUNCT
dpc-2824	72	20	male	male	NOUN
dpc-2824	72	21	)	)	PUNCT
dpc-2824	72	22	64	64	NUM
dpc-2824	72	23	(	(	PUNCT
dpc-2824	72	24	74.4	74.4	NUM
dpc-2824	72	25	%	%	NOUN
dpc-2824	72	26	)	)	PUNCT
dpc-2824	72	27	cancers	cancer	NOUN
dpc-2824	72	28	lung	lung	NOUN
dpc-2824	72	29	cancer	cancer	NOUN
dpc-2824	72	30	26	26	NUM
dpc-2824	72	31	(	(	PUNCT
dpc-2824	72	32	30.2	30.2	NUM
dpc-2824	72	33	%	%	NOUN
dpc-2824	72	34	)	)	PUNCT
dpc-2824	72	35	hepatocellular	hepatocellular	ADJ
dpc-2824	72	36	carcinoma	carcinoma	NOUN
dpc-2824	72	37	12	12	NUM
dpc-2824	72	38	(	(	PUNCT
dpc-2824	72	39	13.9	13.9	NUM
dpc-2824	72	40	%	%	NOUN
dpc-2824	72	41	)	)	PUNCT
dpc-2824	72	42	renal	renal	ADJ
dpc-2824	72	43	cell	cell	NOUN
dpc-2824	72	44	carcinoma	carcinoma	NOUN
dpc-2824	72	45	10	10	NUM
dpc-2824	72	46	(	(	PUNCT
dpc-2824	72	47	11.6	11.6	NUM
dpc-2824	72	48	%	%	NOUN
dpc-2824	72	49	)	)	PUNCT
dpc-2824	72	50	oropharyngeal	oropharyngeal	NOUN
dpc-2824	72	51	scc	scc	NOUN
dpc-2824	72	52	10	10	NUM
dpc-2824	72	53	(	(	PUNCT
dpc-2824	72	54	11.6	11.6	NUM
dpc-2824	72	55	%	%	NOUN
dpc-2824	72	56	)	)	PUNCT
dpc-2824	72	57	melanoma	melanoma	NOUN
dpc-2824	72	58	8	8	NUM
dpc-2824	72	59	(	(	PUNCT
dpc-2824	72	60	9.3	9.3	NUM
dpc-2824	72	61	%	%	NOUN
dpc-2824	72	62	)	)	PUNCT
dpc-2824	72	63	hodgkin	hodgkin	PROPN
dpc-2824	72	64	lymphoma	lymphoma	VERB
dpc-2824	72	65	7	7	NUM
dpc-2824	72	66	(	(	PUNCT
dpc-2824	72	67	8.1	8.1	NUM
dpc-2824	72	68	%	%	NOUN
dpc-2824	72	69	)	)	PUNCT
dpc-2824	72	70	endometrial	endometrial	ADJ
dpc-2824	72	71	cancer	cancer	NOUN
dpc-2824	72	72	3	3	NUM
dpc-2824	72	73	(	(	PUNCT
dpc-2824	72	74	3.5	3.5	NUM
dpc-2824	72	75	%	%	NOUN
dpc-2824	72	76	)	)	PUNCT
dpc-2824	72	77	urothelial	urothelial	ADJ
dpc-2824	72	78	carcinoma	carcinoma	NOUN
dpc-2824	72	79	2	2	NUM
dpc-2824	72	80	(	(	PUNCT
dpc-2824	72	81	2.3	2.3	NUM
dpc-2824	72	82	%	%	NOUN
dpc-2824	72	83	)	)	PUNCT
dpc-2824	72	84	esophageal	esophageal	ADJ
dpc-2824	72	85	adenocarcinoma	adenocarcinoma	NOUN
dpc-2824	72	86	2	2	NUM
dpc-2824	72	87	(	(	PUNCT
dpc-2824	72	88	2.3	2.3	NUM
dpc-2824	72	89	%	%	NOUN
dpc-2824	72	90	)	)	PUNCT
dpc-2824	72	91	othersa	othersa	NOUN
dpc-2824	72	92	6	6	NUM
dpc-2824	72	93	(	(	PUNCT
dpc-2824	72	94	7.2	7.2	NUM
dpc-2824	72	95	%	%	NOUN
dpc-2824	72	96	)	)	PUNCT
dpc-2824	72	97	ici	ici	PROPN
dpc-2824	72	98	nivolumab	nivolumab	ADV
dpc-2824	72	99	51	51	NUM
dpc-2824	72	100	(	(	PUNCT
dpc-2824	72	101	59.3	59.3	NUM
dpc-2824	72	102	%	%	NOUN
dpc-2824	72	103	)	)	PUNCT
dpc-2824	72	104	pembrolizumab	pembrolizumab	NOUN
dpc-2824	72	105	29	29	NUM
dpc-2824	72	106	(	(	PUNCT
dpc-2824	72	107	33.7	33.7	NUM
dpc-2824	72	108	%	%	NOUN
dpc-2824	72	109	)	)	PUNCT
dpc-2824	72	110	atezolizumab	atezolizumab	NOUN
dpc-2824	72	111	5	5	NUM
dpc-2824	72	112	(	(	PUNCT
dpc-2824	72	113	5.8	5.8	NUM
dpc-2824	72	114	%	%	NOUN
dpc-2824	72	115	)	)	PUNCT
dpc-2824	72	116	combination	combination	NOUN
dpc-2824	72	117	(	(	PUNCT
dpc-2824	72	118	nivolumab	nivolumab	NOUN
dpc-2824	72	119	+	+	CCONJ
dpc-2824	72	120	ipilimumab	ipilimumab	ADJ
dpc-2824	72	121	)	)	PUNCT
dpc-2824	72	122	1	1	NUM
dpc-2824	72	123	(	(	PUNCT
dpc-2824	72	124	1.2	1.2	NUM
dpc-2824	72	125	%	%	NOUN
dpc-2824	72	126	)	)	PUNCT
dpc-2824	72	127	grade	grade	NOUN
dpc-2824	72	128	of	of	ADP
dpc-2824	72	129	adverse	adverse	ADJ
dpc-2824	72	130	events	event	NOUN
dpc-2824	72	131	1	1	NUM
dpc-2824	72	132	13	13	NUM
dpc-2824	72	133	(	(	PUNCT
dpc-2824	72	134	15.1	15.1	NUM
dpc-2824	72	135	%	%	NOUN
dpc-2824	72	136	)	)	PUNCT
dpc-2824	72	137	2	2	NUM
dpc-2824	72	138	20	20	NUM
dpc-2824	72	139	(	(	PUNCT
dpc-2824	72	140	23.2	23.2	NUM
dpc-2824	72	141	%	%	NOUN
dpc-2824	72	142	)	)	PUNCT
dpc-2824	72	143	3	3	NUM
dpc-2824	72	144	8	8	NUM
dpc-2824	72	145	(	(	PUNCT
dpc-2824	72	146	9.3	9.3	NUM
dpc-2824	72	147	%	%	NOUN
dpc-2824	72	148	)	)	PUNCT
dpc-2824	72	149	4	4	NUM
dpc-2824	72	150	1	1	NUM
dpc-2824	72	151	(	(	PUNCT
dpc-2824	72	152	1.2	1.2	NUM
dpc-2824	72	153	%	%	NOUN
dpc-2824	72	154	)	)	PUNCT
dpc-2824	72	155	aother	aother	ADJ
dpc-2824	72	156	cancers	cancer	NOUN
dpc-2824	72	157	includes	include	VERB
dpc-2824	72	158	metastatic	metastatic	ADJ
dpc-2824	72	159	breast	breast	NOUN
dpc-2824	72	160	cancer	cancer	NOUN
dpc-2824	72	161	,	,	PUNCT
dpc-2824	72	162	carcinoma	carcinoma	NOUN
dpc-2824	72	163	stomach	stomach	NOUN
dpc-2824	72	164	,	,	PUNCT
dpc-2824	72	165	pineal	pineal	ADJ
dpc-2824	72	166	anaplastic	anaplastic	ADJ
dpc-2824	72	167	astrocytoma	astrocytoma	NOUN
dpc-2824	72	168	,	,	PUNCT
dpc-2824	72	169	head	head	NOUN
dpc-2824	72	170	and	and	CCONJ
dpc-2824	72	171	neck	neck	VERB
dpc-2824	72	172	squamous	squamous	ADJ
dpc-2824	72	173	cell	cell	NOUN
dpc-2824	72	174	carcinoma	carcinoma	NOUN
dpc-2824	72	175	,	,	PUNCT
dpc-2824	72	176	nasal	nasal	ADJ
dpc-2824	72	177	adenoid	adenoid	NOUN
dpc-2824	72	178	cystic	cystic	ADJ
dpc-2824	72	179	carcinoma	carcinoma	NOUN
dpc-2824	72	180	and	and	CCONJ
dpc-2824	72	181	testicular	testicular	ADJ
dpc-2824	72	182	germ	germ	NOUN
dpc-2824	72	183	cell	cell	NOUN
dpc-2824	72	184	tumor	tumor	NOUN
dpc-2824	72	185	accounting	account	VERB
dpc-2824	72	186	for	for	ADP
dpc-2824	72	187	1	1	NUM
dpc-2824	72	188	patient	patient	NOUN
dpc-2824	72	189	(	(	PUNCT
dpc-2824	72	190	1.2	1.2	NUM
dpc-2824	72	191	%	%	NOUN
dpc-2824	72	192	)	)	PUNCT
dpc-2824	72	193	each	each	PRON
dpc-2824	72	194	.	.	PUNCT
dpc-2824	73	1	ici	ici	PROPN
dpc-2824	73	2	=	=	PROPN
dpc-2824	73	3	immune	immune	ADJ
dpc-2824	73	4	checkpoint	checkpoint	NOUN
dpc-2824	73	5	inhibitors	inhibitor	NOUN
dpc-2824	73	6	;	;	PUNCT
dpc-2824	73	7	scc	scc	NOUN
dpc-2824	73	8	=	=	PUNCT
dpc-2824	73	9	squamous	squamous	ADJ
dpc-2824	73	10	cell	cell	NOUN
dpc-2824	73	11	carcinoma	carcinoma	NOUN
dpc-2824	73	12	.	.	PUNCT
dpc-2824	74	1	and	and	CCONJ
dpc-2824	74	2	endocrinological	endocrinological	ADJ
dpc-2824	74	3	adverse	adverse	ADJ
dpc-2824	74	4	events	event	NOUN
dpc-2824	74	5	(	(	PUNCT
dpc-2824	74	6	15.1	15.1	NUM
dpc-2824	74	7	%	%	NOUN
dpc-2824	74	8	)	)	PUNCT
dpc-2824	74	9	were	be	AUX
dpc-2824	74	10	the	the	DET
dpc-2824	74	11	most	most	ADV
dpc-2824	74	12	common	common	ADJ
dpc-2824	74	13	iraes	iraes	NOUN
dpc-2824	74	14	noted	note	VERB
dpc-2824	74	15	.	.	PUNCT
dpc-2824	75	1	median	median	ADJ
dpc-2824	75	2	time	time	NOUN
dpc-2824	75	3	of	of	ADP
dpc-2824	75	4	onset	onset	NOUN
dpc-2824	75	5	of	of	ADP
dpc-2824	75	6	iraes	irae	NOUN
dpc-2824	75	7	of	of	ADP
dpc-2824	75	8	any	any	DET
dpc-2824	75	9	type	type	NOUN
dpc-2824	75	10	was	be	AUX
dpc-2824	75	11	two	two	NUM
dpc-2824	75	12	months	month	NOUN
dpc-2824	75	13	.	.	PUNCT
dpc-2824	76	1	the	the	DET
dpc-2824	76	2	various	various	ADJ
dpc-2824	76	3	iraes	irae	NOUN
dpc-2824	76	4	are	be	AUX
dpc-2824	76	5	represented	represent	VERB
dpc-2824	76	6	in	in	ADP
dpc-2824	76	7	table	table	NOUN
dpc-2824	76	8	2	2	NUM
dpc-2824	76	9	.	.	X
dpc-2824	76	10	twenty	twenty	NUM
dpc-2824	76	11	-	-	PUNCT
dpc-2824	76	12	four	four	NUM
dpc-2824	76	13	ciraes	ciraes	NOUN
dpc-2824	76	14	of	of	ADP
dpc-2824	76	15	any	any	DET
dpc-2824	76	16	grade	grade	NOUN
dpc-2824	76	17	occurred	occur	VERB
dpc-2824	76	18	in	in	ADP
dpc-2824	76	19	16	16	NUM
dpc-2824	76	20	patients	patient	NOUN
dpc-2824	76	21	(	(	PUNCT
dpc-2824	76	22	18.6	18.6	NUM
dpc-2824	76	23	%	%	NOUN
dpc-2824	76	24	)	)	PUNCT
dpc-2824	76	25	pruritus	pruritus	NOUN
dpc-2824	76	26	in	in	ADP
dpc-2824	76	27	11	11	NUM
dpc-2824	76	28	patients	patient	NOUN
dpc-2824	76	29	(	(	PUNCT
dpc-2824	76	30	12.8	12.8	NUM
dpc-2824	76	31	%	%	NOUN
dpc-2824	76	32	,	,	PUNCT
dpc-2824	76	33	4	4	NUM
dpc-2824	76	34	with	with	ADP
dpc-2824	76	35	isolated	isolated	ADJ
dpc-2824	76	36	pruritus	pruritus	NOUN
dpc-2824	76	37	and	and	CCONJ
dpc-2824	76	38	7	7	NUM
dpc-2824	76	39	with	with	ADP
dpc-2824	76	40	pruritis	pruritis	NOUN
dpc-2824	76	41	in	in	ADP
dpc-2824	76	42	addition	addition	NOUN
dpc-2824	76	43	to	to	ADP
dpc-2824	76	44	other	other	ADJ
dpc-2824	76	45	table	table	NOUN
dpc-2824	76	46	2	2	NUM
dpc-2824	76	47	.	.	PUNCT
dpc-2824	76	48	immune	immune	NOUN
dpc-2824	76	49	-	-	PUNCT
dpc-2824	76	50	related	relate	VERB
dpc-2824	76	51	adverse	adverse	ADJ
dpc-2824	76	52	events	event	NOUN
dpc-2824	76	53	(	(	PUNCT
dpc-2824	76	54	iraes	iraes	NOUN
dpc-2824	76	55	)	)	PUNCT
dpc-2824	76	56	and	and	CCONJ
dpc-2824	76	57	their	their	PRON
dpc-2824	76	58	grades	grade	NOUN
dpc-2824	76	59	.	.	PUNCT
dpc-2824	77	1	irae	irae	PROPN
dpc-2824	77	2	grade	grade	NOUN
dpc-2824	77	3	1	1	NUM
dpc-2824	77	4	grade	grade	NOUN
dpc-2824	77	5	2	2	NUM
dpc-2824	77	6	grade	grade	NOUN
dpc-2824	77	7	3	3	NUM
dpc-2824	77	8	grade	grade	NOUN
dpc-2824	77	9	4	4	NUM
dpc-2824	77	10	total	total	NOUN
dpc-2824	77	11	cutaneous	cutaneous	ADJ
dpc-2824	77	12	9	9	NUM
dpc-2824	77	13	9	9	NUM
dpc-2824	77	14	6	6	NUM
dpc-2824	77	15	0	0	NUM
dpc-2824	77	16	24	24	NUM
dpc-2824	77	17	thyroid	thyroid	NOUN
dpc-2824	77	18	disorders	disorder	NOUN
dpc-2824	77	19	1	1	NUM
dpc-2824	77	20	11	11	NUM
dpc-2824	77	21	1	1	NUM
dpc-2824	77	22	0	0	NUM
dpc-2824	77	23	13	13	NUM
dpc-2824	77	24	neurological	neurological	ADJ
dpc-2824	77	25	1	1	NUM
dpc-2824	77	26	0	0	NUM
dpc-2824	77	27	1	1	NUM
dpc-2824	77	28	0	0	NUM
dpc-2824	77	29	2	2	NUM
dpc-2824	77	30	conjunctivitis	conjunctivitis	NOUN
dpc-2824	77	31	1	1	NUM
dpc-2824	77	32	0	0	NUM
dpc-2824	77	33	0	0	NUM
dpc-2824	77	34	0	0	NUM
dpc-2824	77	35	1	1	NUM
dpc-2824	77	36	diarrhea	diarrhea	NOUN
dpc-2824	77	37	1	1	NUM
dpc-2824	77	38	0	0	NUM
dpc-2824	77	39	0	0	NUM
dpc-2824	77	40	0	0	NUM
dpc-2824	77	41	1	1	NUM
dpc-2824	77	42	intracranial	intracranial	ADJ
dpc-2824	77	43	hypertension	hypertension	NOUN
dpc-2824	77	44	0	0	NUM
dpc-2824	77	45	0	0	SYM
dpc-2824	77	46	0	0	NUM
dpc-2824	77	47	1	1	NUM
dpc-2824	77	48	1	1	NUM
dpc-2824	77	49	4	4	NUM
dpc-2824	77	50	original	original	ADJ
dpc-2824	77	51	article	article	NOUN
dpc-2824	77	52	|	|	ADV
dpc-2824	77	53	dermatol	dermatol	ADJ
dpc-2824	77	54	pract	pract	NOUN
dpc-2824	77	55	concept	concept	NOUN
dpc-2824	77	56	.	.	PUNCT
dpc-2824	78	1	2023;13(3):e2023127	2023;13(3):e2023127	NUM
dpc-2824	78	2	of	of	ADP
dpc-2824	78	3	one	one	NUM
dpc-2824	78	4	month	month	NOUN
dpc-2824	78	5	.	.	PUNCT
dpc-2824	79	1	in	in	ADP
dpc-2824	79	2	one	one	NUM
dpc-2824	79	3	patient	patient	NOUN
dpc-2824	79	4	with	with	ADP
dpc-2824	79	5	psoriasiform	psoriasiform	NOUN
dpc-2824	79	6	eruption	eruption	NOUN
dpc-2824	79	7	–	–	PUNCT
dpc-2824	79	8	nivolumab	nivolumab	ADV
dpc-2824	79	9	dosing	dose	VERB
dpc-2824	79	10	was	be	AUX
dpc-2824	79	11	changed	change	VERB
dpc-2824	79	12	from	from	ADP
dpc-2824	79	13	once	once	ADV
dpc-2824	79	14	in	in	ADP
dpc-2824	79	15	two	two	NUM
dpc-2824	79	16	weeks	week	NOUN
dpc-2824	79	17	to	to	PART
dpc-2824	79	18	once	once	ADV
dpc-2824	79	19	in	in	ADP
dpc-2824	79	20	four	four	NUM
dpc-2824	79	21	weeks	week	NOUN
dpc-2824	79	22	.	.	PUNCT
dpc-2824	80	1	of	of	ADP
dpc-2824	80	2	the	the	DET
dpc-2824	80	3	15	15	NUM
dpc-2824	80	4	patients	patient	NOUN
dpc-2824	80	5	treated	treat	VERB
dpc-2824	80	6	for	for	ADP
dpc-2824	80	7	ciraes	ciraes	NOUN
dpc-2824	80	8	,	,	PUNCT
dpc-2824	80	9	12	12	NUM
dpc-2824	80	10	patients	patient	NOUN
dpc-2824	80	11	experienced	experience	VERB
dpc-2824	80	12	significant	significant	ADJ
dpc-2824	80	13	improvement	improvement	NOUN
dpc-2824	80	14	following	follow	VERB
dpc-2824	80	15	treatment	treatment	NOUN
dpc-2824	80	16	,	,	PUNCT
dpc-2824	80	17	one	one	NUM
dpc-2824	80	18	patient	patient	NOUN
dpc-2824	80	19	had	have	VERB
dpc-2824	80	20	partial	partial	ADJ
dpc-2824	80	21	improvement	improvement	NOUN
dpc-2824	80	22	,	,	PUNCT
dpc-2824	80	23	two	two	NUM
dpc-2824	80	24	patients	patient	NOUN
dpc-2824	80	25	had	have	VERB
dpc-2824	80	26	no	no	DET
dpc-2824	80	27	improvement	improvement	NOUN
dpc-2824	80	28	.	.	PUNCT
dpc-2824	81	1	patients	patient	NOUN
dpc-2824	81	2	with	with	ADP
dpc-2824	81	3	iraes	irae	NOUN
dpc-2824	81	4	had	have	VERB
dpc-2824	81	5	a	a	DET
dpc-2824	81	6	longer	long	ADJ
dpc-2824	81	7	median	median	ADJ
dpc-2824	81	8	pfs	pfs	PROPN
dpc-2824	81	9	(	(	PUNCT
dpc-2824	81	10	6	6	NUM
dpc-2824	81	11	 	 	SPACE
dpc-2824	81	12	months	month	NOUN
dpc-2824	81	13	versus	versus	ADP
dpc-2824	81	14	3	3	NUM
dpc-2824	81	15	months	month	NOUN
dpc-2824	81	16	,	,	PUNCT
dpc-2824	81	17	p	p	NOUN
dpc-2824	81	18	=	=	NOUN
dpc-2824	81	19	0.016	0.016	NUM
dpc-2824	81	20	)	)	PUNCT
dpc-2824	81	21	and	and	CCONJ
dpc-2824	81	22	a	a	DET
dpc-2824	81	23	longer	long	ADV
dpc-2824	81	24	median	median	ADJ
dpc-2824	81	25	os	os	NOUN
dpc-2824	81	26	(	(	PUNCT
dpc-2824	81	27	15	15	NUM
dpc-2824	81	28	 	 	SPACE
dpc-2824	81	29	months	month	NOUN
dpc-2824	81	30	versus	versus	ADP
dpc-2824	81	31	8	8	NUM
dpc-2824	81	32	months	month	NOUN
dpc-2824	81	33	,	,	PUNCT
dpc-2824	81	34	p	p	NOUN
dpc-2824	81	35	=	=	NOUN
dpc-2824	81	36	0.03	0.03	NUM
dpc-2824	81	37	)	)	PUNCT
dpc-2824	81	38	compared	compare	VERB
dpc-2824	81	39	to	to	ADP
dpc-2824	81	40	patients	patient	NOUN
dpc-2824	81	41	without	without	ADP
dpc-2824	81	42	any	any	DET
dpc-2824	81	43	adverse	adverse	ADJ
dpc-2824	81	44	events	event	NOUN
dpc-2824	81	45	.	.	PUNCT
dpc-2824	82	1	orr	orr	PROPN
dpc-2824	82	2	was	be	AUX
dpc-2824	82	3	also	also	ADV
dpc-2824	82	4	significantly	significantly	ADV
dpc-2824	82	5	higher	high	ADJ
dpc-2824	82	6	(	(	PUNCT
dpc-2824	82	7	39.2	39.2	NUM
dpc-2824	82	8	%	%	NOUN
dpc-2824	82	9	versus	versus	ADP
dpc-2824	82	10	17.2	17.2	NUM
dpc-2824	82	11	%	%	NOUN
dpc-2824	82	12	,	,	PUNCT
dpc-2824	82	13	p	p	X
dpc-2824	82	14	=	=	NOUN
dpc-2824	82	15	0.02	0.02	NUM
dpc-2824	82	16	)	)	PUNCT
dpc-2824	82	17	.	.	PUNCT
dpc-2824	83	1	kaplan	kaplan	PROPN
dpc-2824	83	2	-	-	PUNCT
dpc-2824	83	3	meier	meier	PROPN
dpc-2824	83	4	curves	curve	NOUN
dpc-2824	83	5	(	(	PUNCT
dpc-2824	83	6	pfs	pfs	PROPN
dpc-2824	83	7	and	and	CCONJ
dpc-2824	83	8	os	os	NOUN
dpc-2824	83	9	)	)	PUNCT
dpc-2824	83	10	comparing	compare	VERB
dpc-2824	83	11	patients	patient	NOUN
dpc-2824	83	12	with	with	ADP
dpc-2824	83	13	and	and	CCONJ
dpc-2824	83	14	without	without	ADP
dpc-2824	83	15	iraes	irae	NOUN
dpc-2824	83	16	are	be	AUX
dpc-2824	83	17	represented	represent	VERB
dpc-2824	83	18	in	in	ADP
dpc-2824	83	19	figure	figure	NOUN
dpc-2824	83	20	1	1	NUM
dpc-2824	83	21	.	.	PUNCT
dpc-2824	84	1	median	median	PROPN
dpc-2824	84	2	pfs	pfs	PROPN
dpc-2824	84	3	(	(	PUNCT
dpc-2824	84	4	8	8	NUM
dpc-2824	84	5	months	month	NOUN
dpc-2824	84	6	versus	versus	ADP
dpc-2824	84	7	3	3	NUM
dpc-2824	84	8	months	month	NOUN
dpc-2824	84	9	,	,	PUNCT
dpc-2824	84	10	p	p	NOUN
dpc-2824	84	11	=	=	NOUN
dpc-2824	84	12	0.023	0.023	NUM
dpc-2824	84	13	)	)	PUNCT
dpc-2824	84	14	and	and	CCONJ
dpc-2824	84	15	orr	orr	PROPN
dpc-2824	84	16	(	(	PUNCT
dpc-2824	84	17	50	50	NUM
dpc-2824	84	18	%	%	NOUN
dpc-2824	84	19	versus	versus	ADP
dpc-2824	84	20	18.5	18.5	NUM
dpc-2824	84	21	%	%	NOUN
dpc-2824	84	22	,	,	PUNCT
dpc-2824	84	23	p	p	X
dpc-2824	84	24	=	=	NOUN
dpc-2824	84	25	0.008	0.008	NUM
dpc-2824	84	26	)	)	PUNCT
dpc-2824	84	27	were	be	AUX
dpc-2824	84	28	significantly	significantly	ADV
dpc-2824	84	29	higher	high	ADJ
dpc-2824	84	30	in	in	ADP
dpc-2824	84	31	patients	patient	NOUN
dpc-2824	84	32	with	with	ADP
dpc-2824	84	33	ciraes	ciraes	NOUN
dpc-2824	84	34	compared	compare	VERB
dpc-2824	84	35	to	to	ADP
dpc-2824	84	36	those	those	PRON
dpc-2824	84	37	without	without	ADP
dpc-2824	84	38	ciraes	ciraes	NOUN
dpc-2824	84	39	(	(	PUNCT
dpc-2824	84	40	inclusive	inclusive	NOUN
dpc-2824	84	41	of	of	ADP
dpc-2824	84	42	patients	patient	NOUN
dpc-2824	84	43	who	who	PRON
dpc-2824	84	44	had	have	VERB
dpc-2824	84	45	aes	aes	NOUN
dpc-2824	84	46	in	in	ADP
dpc-2824	84	47	organs	organ	NOUN
dpc-2824	84	48	other	other	ADJ
dpc-2824	84	49	than	than	ADP
dpc-2824	84	50	skin	skin	NOUN
dpc-2824	84	51	)	)	PUNCT
dpc-2824	84	52	.	.	PUNCT
dpc-2824	85	1	median	median	PROPN
dpc-2824	85	2	os	os	PROPN
dpc-2824	85	3	was	be	AUX
dpc-2824	85	4	also	also	ADV
dpc-2824	85	5	longer	long	ADV
dpc-2824	85	6	(	(	PUNCT
dpc-2824	85	7	15	15	NUM
dpc-2824	85	8	months	month	NOUN
dpc-2824	85	9	versus	versus	ADP
dpc-2824	85	10	10	10	NUM
dpc-2824	85	11	months	month	NOUN
dpc-2824	85	12	)	)	PUNCT
dpc-2824	85	13	.	.	PUNCT
dpc-2824	86	1	however	however	ADV
dpc-2824	86	2	,	,	PUNCT
dpc-2824	86	3	this	this	DET
dpc-2824	86	4	association	association	NOUN
dpc-2824	86	5	was	be	AUX
dpc-2824	86	6	not	not	PART
dpc-2824	86	7	statistically	statistically	ADV
dpc-2824	86	8	significant	significant	ADJ
dpc-2824	86	9	(	(	PUNCT
dpc-2824	86	10	p	p	NOUN
dpc-2824	86	11	=	=	NOUN
dpc-2824	86	12	0.246	0.246	NUM
dpc-2824	86	13	)	)	PUNCT
dpc-2824	86	14	.	.	PUNCT
dpc-2824	87	1	kaplan	kaplan	PROPN
dpc-2824	87	2	-	-	PUNCT
dpc-2824	87	3	meier	meier	PROPN
dpc-2824	87	4	curves	curve	NOUN
dpc-2824	87	5	(	(	PUNCT
dpc-2824	87	6	pfs	pfs	PROPN
dpc-2824	87	7	and	and	CCONJ
dpc-2824	87	8	os	os	NOUN
dpc-2824	87	9	)	)	PUNCT
dpc-2824	87	10	comparing	compare	VERB
dpc-2824	87	11	patients	patient	NOUN
dpc-2824	87	12	with	with	ADP
dpc-2824	87	13	and	and	CCONJ
dpc-2824	87	14	without	without	ADP
dpc-2824	87	15	ciraes	ciraes	NOUN
dpc-2824	87	16	are	be	AUX
dpc-2824	87	17	represented	represent	VERB
dpc-2824	87	18	in	in	ADP
dpc-2824	87	19	figure	figure	NOUN
dpc-2824	87	20	2	2	NUM
dpc-2824	87	21	.	.	PUNCT
dpc-2824	87	22	cutaneous	cutaneous	ADJ
dpc-2824	87	23	lesions	lesion	NOUN
dpc-2824	87	24	)	)	PUNCT
dpc-2824	87	25	,	,	PUNCT
dpc-2824	87	26	maculopapular	maculopapular	ADJ
dpc-2824	87	27	rash	rash	NOUN
dpc-2824	87	28	in	in	ADP
dpc-2824	87	29	7	7	NUM
dpc-2824	87	30	(	(	PUNCT
dpc-2824	87	31	8.1	8.1	NUM
dpc-2824	87	32	%	%	NOUN
dpc-2824	87	33	)	)	PUNCT
dpc-2824	87	34	,	,	PUNCT
dpc-2824	87	35	vitiligo	vitiligo	VERB
dpc-2824	87	36	in	in	ADP
dpc-2824	87	37	2	2	NUM
dpc-2824	87	38	(	(	PUNCT
dpc-2824	87	39	2.3	2.3	NUM
dpc-2824	87	40	%	%	NOUN
dpc-2824	87	41	)	)	PUNCT
dpc-2824	87	42	and	and	CCONJ
dpc-2824	87	43	erythema	erythema	ADJ
dpc-2824	87	44	multiforme	multiforme	NOUN
dpc-2824	87	45	,	,	PUNCT
dpc-2824	87	46	exfoliative	exfoliative	ADJ
dpc-2824	87	47	dermatitis	dermatitis	NOUN
dpc-2824	87	48	,	,	PUNCT
dpc-2824	87	49	psoriasiform	psoriasiform	NOUN
dpc-2824	87	50	eruption	eruption	NOUN
dpc-2824	87	51	,	,	PUNCT
dpc-2824	87	52	mucositis	mucositis	NOUN
dpc-2824	87	53	in	in	ADP
dpc-2824	87	54	one	one	NUM
dpc-2824	87	55	patient	patient	NOUN
dpc-2824	87	56	each	each	PRON
dpc-2824	87	57	(	(	PUNCT
dpc-2824	87	58	1.2	1.2	NUM
dpc-2824	87	59	%	%	NOUN
dpc-2824	87	60	)	)	PUNCT
dpc-2824	87	61	.	.	PUNCT
dpc-2824	88	1	no	no	DET
dpc-2824	88	2	hair	hair	NOUN
dpc-2824	88	3	or	or	CCONJ
dpc-2824	88	4	nail	nail	NOUN
dpc-2824	88	5	changes	change	NOUN
dpc-2824	88	6	were	be	AUX
dpc-2824	88	7	noted	note	VERB
dpc-2824	88	8	.	.	PUNCT
dpc-2824	89	1	there	there	PRON
dpc-2824	89	2	were	be	VERB
dpc-2824	89	3	9	9	NUM
dpc-2824	89	4	grade	grade	NOUN
dpc-2824	89	5	1	1	NUM
dpc-2824	89	6	ciraes	ciraes	NOUN
dpc-2824	89	7	(	(	PUNCT
dpc-2824	89	8	37.5	37.5	NUM
dpc-2824	89	9	%	%	NOUN
dpc-2824	89	10	)	)	PUNCT
dpc-2824	89	11	,	,	PUNCT
dpc-2824	89	12	9	9	NUM
dpc-2824	89	13	grade	grade	NOUN
dpc-2824	89	14	2	2	NUM
dpc-2824	89	15	events	event	NOUN
dpc-2824	89	16	(	(	PUNCT
dpc-2824	89	17	37.5	37.5	NUM
dpc-2824	89	18	%	%	NOUN
dpc-2824	89	19	)	)	PUNCT
dpc-2824	89	20	and	and	CCONJ
dpc-2824	89	21	6	6	NUM
dpc-2824	89	22	grade	grade	NOUN
dpc-2824	89	23	3	3	NUM
dpc-2824	89	24	events	event	NOUN
dpc-2824	89	25	(	(	PUNCT
dpc-2824	89	26	25	25	NUM
dpc-2824	89	27	%	%	NOUN
dpc-2824	89	28	)	)	PUNCT
dpc-2824	89	29	.	.	PUNCT
dpc-2824	90	1	no	no	DET
dpc-2824	90	2	grade	grade	NOUN
dpc-2824	90	3	4	4	NUM
dpc-2824	90	4	ciraes	ciraes	NOUN
dpc-2824	90	5	were	be	AUX
dpc-2824	90	6	noted	note	VERB
dpc-2824	90	7	.	.	PUNCT
dpc-2824	91	1	the	the	DET
dpc-2824	91	2	different	different	ADJ
dpc-2824	91	3	ciraes	ciraes	NOUN
dpc-2824	91	4	and	and	CCONJ
dpc-2824	91	5	their	their	PRON
dpc-2824	91	6	grades	grade	NOUN
dpc-2824	91	7	are	be	AUX
dpc-2824	91	8	represented	represent	VERB
dpc-2824	91	9	in	in	ADP
dpc-2824	91	10	table	table	NOUN
dpc-2824	91	11	3	3	NUM
dpc-2824	91	12	.	.	PUNCT
dpc-2824	91	13	of	of	ADP
dpc-2824	91	14	the	the	DET
dpc-2824	91	15	16	16	NUM
dpc-2824	91	16	patients	patient	NOUN
dpc-2824	91	17	,	,	PUNCT
dpc-2824	91	18	ten	ten	NUM
dpc-2824	91	19	(	(	PUNCT
dpc-2824	91	20	62.5	62.5	NUM
dpc-2824	91	21	%	%	NOUN
dpc-2824	91	22	)	)	PUNCT
dpc-2824	91	23	received	receive	VERB
dpc-2824	91	24	nivolumab	nivolumab	ADV
dpc-2824	91	25	,	,	PUNCT
dpc-2824	91	26	five	five	NUM
dpc-2824	91	27	(	(	PUNCT
dpc-2824	91	28	31.25	31.25	NUM
dpc-2824	91	29	%	%	NOUN
dpc-2824	91	30	)	)	PUNCT
dpc-2824	91	31	pembrolizumab	pembrolizumab	NOUN
dpc-2824	91	32	and	and	CCONJ
dpc-2824	91	33	one	one	NUM
dpc-2824	91	34	(	(	PUNCT
dpc-2824	91	35	6.25	6.25	NUM
dpc-2824	91	36	%	%	NOUN
dpc-2824	91	37	)	)	PUNCT
dpc-2824	91	38	received	receive	VERB
dpc-2824	91	39	a	a	DET
dpc-2824	91	40	combination	combination	NOUN
dpc-2824	91	41	of	of	ADP
dpc-2824	91	42	ipilimumab	ipilimumab	NOUN
dpc-2824	91	43	and	and	CCONJ
dpc-2824	91	44	nivolumab	nivolumab	NOUN
dpc-2824	91	45	.	.	PUNCT
dpc-2824	92	1	ciraes	ciraes	NOUN
dpc-2824	92	2	occurred	occur	VERB
dpc-2824	92	3	after	after	ADP
dpc-2824	92	4	median	median	NOUN
dpc-2824	92	5	of	of	ADP
dpc-2824	92	6	2.75	2.75	NUM
dpc-2824	92	7	months	month	NOUN
dpc-2824	92	8	(	(	PUNCT
dpc-2824	92	9	iqr	iqr	NOUN
dpc-2824	92	10	2	2	NUM
dpc-2824	92	11	-	-	SYM
dpc-2824	92	12	3	3	NUM
dpc-2824	92	13	)	)	PUNCT
dpc-2824	92	14	from	from	ADP
dpc-2824	92	15	the	the	DET
dpc-2824	92	16	initiation	initiation	NOUN
dpc-2824	92	17	of	of	ADP
dpc-2824	92	18	ici	ici	PROPN
dpc-2824	92	19	(	(	PUNCT
dpc-2824	92	20	median	median	ADJ
dpc-2824	92	21	cycles	cycle	NOUN
dpc-2824	92	22	of	of	ADP
dpc-2824	92	23	ici	ici	NOUN
dpc-2824	92	24	:	:	PUNCT
dpc-2824	92	25	4	4	NUM
dpc-2824	92	26	;	;	PUNCT
dpc-2824	92	27	iqr	iqr	NOUN
dpc-2824	92	28	:	:	PUNCT
dpc-2824	92	29	3	3	NUM
dpc-2824	92	30	-	-	SYM
dpc-2824	92	31	6	6	NUM
dpc-2824	92	32	)	)	PUNCT
dpc-2824	92	33	.	.	PUNCT
dpc-2824	93	1	of	of	ADP
dpc-2824	93	2	the	the	DET
dpc-2824	93	3	16	16	NUM
dpc-2824	93	4	patients	patient	NOUN
dpc-2824	93	5	with	with	ADP
dpc-2824	93	6	ciraes	ciraes	NOUN
dpc-2824	93	7	,	,	PUNCT
dpc-2824	93	8	11	11	NUM
dpc-2824	93	9	(	(	PUNCT
dpc-2824	93	10	68.75	68.75	NUM
dpc-2824	93	11	%	%	NOUN
dpc-2824	93	12	)	)	PUNCT
dpc-2824	93	13	were	be	AUX
dpc-2824	93	14	managed	manage	VERB
dpc-2824	93	15	with	with	ADP
dpc-2824	93	16	topicals	topical	NOUN
dpc-2824	93	17	,	,	PUNCT
dpc-2824	93	18	antihistamines	antihistamine	NOUN
dpc-2824	93	19	or	or	CCONJ
dpc-2824	93	20	a	a	DET
dpc-2824	93	21	combination	combination	NOUN
dpc-2824	93	22	of	of	ADP
dpc-2824	93	23	both	both	PRON
dpc-2824	93	24	.	.	PUNCT
dpc-2824	94	1	four	four	NUM
dpc-2824	94	2	patients	patient	NOUN
dpc-2824	94	3	required	require	VERB
dpc-2824	94	4	systemic	systemic	ADJ
dpc-2824	94	5	immunosuppression	immunosuppression	NOUN
dpc-2824	94	6	.	.	PUNCT
dpc-2824	95	1	in	in	ADP
dpc-2824	95	2	addition	addition	NOUN
dpc-2824	95	3	to	to	ADP
dpc-2824	95	4	medical	medical	ADJ
dpc-2824	95	5	management	management	NOUN
dpc-2824	95	6	,	,	PUNCT
dpc-2824	95	7	four	four	NUM
dpc-2824	95	8	patients	patient	NOUN
dpc-2824	95	9	(	(	PUNCT
dpc-2824	95	10	25	25	NUM
dpc-2824	95	11	%	%	NOUN
dpc-2824	95	12	)	)	PUNCT
dpc-2824	95	13	with	with	ADP
dpc-2824	95	14	grade	grade	NOUN
dpc-2824	95	15	3	3	NUM
dpc-2824	95	16	maculopapular	maculopapular	ADJ
dpc-2824	95	17	rash	rash	NOUN
dpc-2824	95	18	(	(	PUNCT
dpc-2824	95	19	2	2	NUM
dpc-2824	95	20	)	)	PUNCT
dpc-2824	95	21	,	,	PUNCT
dpc-2824	95	22	exfoliative	exfoliative	ADJ
dpc-2824	95	23	dermatitis	dermatitis	NOUN
dpc-2824	95	24	 	 	SPACE
dpc-2824	95	25	(	(	PUNCT
dpc-2824	95	26	1	1	NUM
dpc-2824	95	27	)	)	PUNCT
dpc-2824	95	28	and	and	CCONJ
dpc-2824	95	29	erythema	erythema	ADJ
dpc-2824	95	30	multiforme	multiforme	NOUN
dpc-2824	95	31	with	with	ADP
dpc-2824	95	32	mucositis	mucositis	PROPN
dpc-2824	95	33	(	(	PUNCT
dpc-2824	95	34	1	1	X
dpc-2824	95	35	)	)	PUNCT
dpc-2824	95	36	required	require	VERB
dpc-2824	95	37	an	an	DET
dpc-2824	95	38	interruption	interruption	NOUN
dpc-2824	95	39	in	in	ADP
dpc-2824	95	40	ici	ici	NOUN
dpc-2824	95	41	therapy	therapy	NOUN
dpc-2824	95	42	until	until	ADP
dpc-2824	95	43	the	the	DET
dpc-2824	95	44	resolution	resolution	NOUN
dpc-2824	95	45	of	of	ADP
dpc-2824	95	46	lesions	lesion	NOUN
dpc-2824	95	47	.	.	PUNCT
dpc-2824	96	1	the	the	DET
dpc-2824	96	2	patient	patient	NOUN
dpc-2824	96	3	with	with	ADP
dpc-2824	96	4	erythema	erythema	ADJ
dpc-2824	96	5	multiforme	multiforme	NOUN
dpc-2824	96	6	developed	develop	VERB
dpc-2824	96	7	further	further	ADJ
dpc-2824	96	8	grade	grade	NOUN
dpc-2824	96	9	4	4	NUM
dpc-2824	96	10	complications	complication	NOUN
dpc-2824	96	11	(	(	PUNCT
dpc-2824	96	12	intracranial	intracranial	ADJ
dpc-2824	96	13	hypertension	hypertension	NOUN
dpc-2824	96	14	)	)	PUNCT
dpc-2824	96	15	and	and	CCONJ
dpc-2824	96	16	icis	icis	NOUN
dpc-2824	96	17	were	be	AUX
dpc-2824	96	18	stopped	stop	VERB
dpc-2824	96	19	.	.	PUNCT
dpc-2824	97	1	the	the	DET
dpc-2824	97	2	other	other	ADJ
dpc-2824	97	3	patients	patient	NOUN
dpc-2824	97	4	were	be	AUX
dpc-2824	97	5	restarted	restart	VERB
dpc-2824	97	6	on	on	ADP
dpc-2824	97	7	ici	ici	NOUN
dpc-2824	97	8	therapy	therapy	NOUN
dpc-2824	97	9	under	under	ADP
dpc-2824	97	10	careful	careful	ADJ
dpc-2824	97	11	observation	observation	NOUN
dpc-2824	97	12	after	after	ADP
dpc-2824	97	13	a	a	DET
dpc-2824	97	14	drug	drug	NOUN
dpc-2824	97	15	-	-	PUNCT
dpc-2824	97	16	free	free	ADJ
dpc-2824	97	17	period	period	NOUN
dpc-2824	97	18	table	table	NOUN
dpc-2824	97	19	3	3	NUM
dpc-2824	97	20	.	.	X
dpc-2824	97	21	nature	nature	NOUN
dpc-2824	97	22	and	and	CCONJ
dpc-2824	97	23	grades	grade	NOUN
dpc-2824	97	24	of	of	ADP
dpc-2824	97	25	cutaneous	cutaneous	ADJ
dpc-2824	97	26	immune	immune	NOUN
dpc-2824	97	27	-	-	PUNCT
dpc-2824	97	28	related	relate	VERB
dpc-2824	97	29	adverse	adverse	ADJ
dpc-2824	97	30	events	event	NOUN
dpc-2824	97	31	(	(	PUNCT
dpc-2824	97	32	ciraes	ciraes	NOUN
dpc-2824	97	33	)	)	PUNCT
dpc-2824	97	34	.	.	PUNCT
dpc-2824	98	1	cutaneous	cutaneous	ADJ
dpc-2824	98	2	iraes	iraes	VERB
dpc-2824	98	3	no	no	INTJ
dpc-2824	98	4	.	.	PUNCT
dpc-2824	99	1	of	of	ADP
dpc-2824	99	2	patients	patient	NOUN
dpc-2824	99	3	(	(	PUNCT
dpc-2824	99	4	%	%	INTJ
dpc-2824	99	5	)	)	PUNCT
dpc-2824	99	6	total	total	ADJ
dpc-2824	99	7	ciraes	ciraes	NOUN
dpc-2824	99	8	nature	nature	NOUN
dpc-2824	99	9	grade	grade	NOUN
dpc-2824	99	10	1	1	NUM
dpc-2824	99	11	grade	grade	NOUN
dpc-2824	99	12	2	2	NUM
dpc-2824	99	13	grade	grade	NOUN
dpc-2824	99	14	3	3	NUM
dpc-2824	99	15	grade	grade	NOUN
dpc-2824	99	16	4	4	NUM
dpc-2824	99	17	16	16	NUM
dpc-2824	99	18	(	(	PUNCT
dpc-2824	99	19	18.6	18.6	NUM
dpc-2824	99	20	%	%	NOUN
dpc-2824	99	21	)	)	PUNCT
dpc-2824	99	22	24	24	NUM
dpc-2824	99	23	pruritus	pruritus	NOUN
dpc-2824	99	24	5	5	NUM
dpc-2824	99	25	5	5	NUM
dpc-2824	99	26	1	1	NUM
dpc-2824	99	27	0	0	NUM
dpc-2824	99	28	maculopapular	maculopapular	ADJ
dpc-2824	99	29	rash	rash	NOUN
dpc-2824	99	30	3	3	NUM
dpc-2824	99	31	2	2	NUM
dpc-2824	99	32	2	2	NUM
dpc-2824	99	33	0	0	NUM
dpc-2824	99	34	vitiligo	vitiligo	VERB
dpc-2824	99	35	like	like	ADP
dpc-2824	99	36	depigmentation	depigmentation	NOUN
dpc-2824	99	37	1	1	NUM
dpc-2824	99	38	1	1	NUM
dpc-2824	99	39	0	0	NUM
dpc-2824	99	40	0	0	NUM
dpc-2824	99	41	psoriasiform	psoriasiform	NOUN
dpc-2824	99	42	eruption	eruption	NOUN
dpc-2824	99	43	0	0	NUM
dpc-2824	99	44	1	1	NUM
dpc-2824	99	45	0	0	NUM
dpc-2824	99	46	0	0	NUM
dpc-2824	99	47	erythroderma	erythroderma	NOUN
dpc-2824	99	48	0	0	NUM
dpc-2824	99	49	0	0	NUM
dpc-2824	99	50	1	1	NUM
dpc-2824	99	51	0	0	NUM
dpc-2824	99	52	erythema	erythema	ADJ
dpc-2824	99	53	multiforme	multiforme	NOUN
dpc-2824	99	54	0	0	NUM
dpc-2824	99	55	0	0	NUM
dpc-2824	99	56	1	1	NUM
dpc-2824	99	57	0	0	NUM
dpc-2824	99	58	mucositis	mucositis	NOUN
dpc-2824	99	59	0	0	NUM
dpc-2824	99	60	0	0	NUM
dpc-2824	99	61	1	1	NUM
dpc-2824	99	62	0	0	NUM
dpc-2824	99	63	figure	figure	NOUN
dpc-2824	99	64	1	1	NUM
dpc-2824	99	65	.	.	PUNCT
dpc-2824	100	1	kaplan	kaplan	PROPN
dpc-2824	100	2	meier	meier	PROPN
dpc-2824	100	3	survival	survival	PROPN
dpc-2824	100	4	curves	curve	NOUN
dpc-2824	100	5	comparing	compare	VERB
dpc-2824	100	6	(	(	PUNCT
dpc-2824	100	7	a	a	PRON
dpc-2824	100	8	)	)	PUNCT
dpc-2824	100	9	progression	progression	NOUN
dpc-2824	100	10	free	free	ADJ
dpc-2824	100	11	survival	survival	NOUN
dpc-2824	100	12	and	and	CCONJ
dpc-2824	100	13	(	(	PUNCT
dpc-2824	100	14	b	b	NOUN
dpc-2824	100	15	)	)	PUNCT
dpc-2824	100	16	overall	overall	ADJ
dpc-2824	100	17	survival	survival	NOUN
dpc-2824	100	18	between	between	ADP
dpc-2824	100	19	patients	patient	NOUN
dpc-2824	100	20	with	with	ADP
dpc-2824	100	21	and	and	CCONJ
dpc-2824	100	22	without	without	ADP
dpc-2824	100	23	immune	immune	NOUN
dpc-2824	100	24	-	-	PUNCT
dpc-2824	100	25	related	relate	VERB
dpc-2824	100	26	adverse	adverse	ADJ
dpc-2824	100	27	events	event	NOUN
dpc-2824	100	28	(	(	PUNCT
dpc-2824	100	29	iraes	iraes	NOUN
dpc-2824	100	30	)	)	PUNCT
dpc-2824	100	31	.	.	PUNCT
dpc-2824	101	1	original	original	ADJ
dpc-2824	101	2	article	article	NOUN
dpc-2824	101	3	|	|	ADV
dpc-2824	101	4	dermatol	dermatol	ADJ
dpc-2824	101	5	pract	pract	NOUN
dpc-2824	101	6	concept	concept	NOUN
dpc-2824	101	7	.	.	PUNCT
dpc-2824	102	1	2023;13(3):e2023127	2023;13(3):e2023127	NUM
dpc-2824	102	2	5	5	NUM
dpc-2824	102	3	malignant	malignant	ADJ
dpc-2824	102	4	melanoma	melanoma	NOUN
dpc-2824	102	5	.	.	PUNCT
dpc-2824	103	1	though	though	SCONJ
dpc-2824	103	2	other	other	ADJ
dpc-2824	103	3	studies	study	NOUN
dpc-2824	103	4	have	have	AUX
dpc-2824	103	5	reported	report	VERB
dpc-2824	103	6	adverse	adverse	ADJ
dpc-2824	103	7	events	event	NOUN
dpc-2824	103	8	like	like	ADP
dpc-2824	103	9	bullous	bullous	ADJ
dpc-2824	103	10	pemphigoid	pemphigoid	NOUN
dpc-2824	103	11	,	,	PUNCT
dpc-2824	103	12	lichenoid	lichenoid	PROPN
dpc-2824	103	13	eruption	eruption	NOUN
dpc-2824	103	14	,	,	PUNCT
dpc-2824	103	15	acneiform	acneiform	ADJ
dpc-2824	103	16	eruptions	eruption	NOUN
dpc-2824	103	17	,	,	PUNCT
dpc-2824	103	18	neutrophilic	neutrophilic	ADJ
dpc-2824	103	19	disorders	disorder	NOUN
dpc-2824	103	20	and	and	CCONJ
dpc-2824	103	21	sarcoid	sarcoid	ADJ
dpc-2824	103	22	like	like	ADP
dpc-2824	103	23	lesions	lesion	NOUN
dpc-2824	103	24	,	,	PUNCT
dpc-2824	103	25	we	we	PRON
dpc-2824	103	26	did	do	AUX
dpc-2824	103	27	not	not	PART
dpc-2824	103	28	see	see	VERB
dpc-2824	103	29	any	any	DET
dpc-2824	103	30	such	such	ADJ
dpc-2824	103	31	reactions	reaction	NOUN
dpc-2824	103	32	.	.	PUNCT
dpc-2824	104	1	we	we	PRON
dpc-2824	104	2	also	also	ADV
dpc-2824	104	3	did	do	AUX
dpc-2824	104	4	not	not	PART
dpc-2824	104	5	encounter	encounter	VERB
dpc-2824	104	6	any	any	DET
dpc-2824	104	7	scars	scar	NOUN
dpc-2824	104	8	like	like	ADP
dpc-2824	104	9	sjs	sjs	PROPN
dpc-2824	104	10	/	/	SYM
dpc-2824	104	11	ten	ten	NUM
dpc-2824	104	12	,	,	PUNCT
dpc-2824	104	13	dress	dress	NOUN
dpc-2824	104	14	and	and	CCONJ
dpc-2824	104	15	agep	agep	NOUN
dpc-2824	104	16	that	that	PRON
dpc-2824	104	17	have	have	AUX
dpc-2824	104	18	been	be	AUX
dpc-2824	104	19	reported	report	VERB
dpc-2824	104	20	in	in	ADP
dpc-2824	104	21	other	other	ADJ
dpc-2824	104	22	studies	study	NOUN
dpc-2824	104	23	[	[	X
dpc-2824	104	24	17	17	NUM
dpc-2824	104	25	]	]	PUNCT
dpc-2824	104	26	.	.	PUNCT
dpc-2824	105	1	ciraes	ciraes	NOUN
dpc-2824	105	2	occurred	occur	VERB
dpc-2824	105	3	at	at	ADP
dpc-2824	105	4	a	a	DET
dpc-2824	105	5	median	median	ADJ
dpc-2824	105	6	duration	duration	NOUN
dpc-2824	105	7	of	of	ADP
dpc-2824	105	8	2.75	2.75	NUM
dpc-2824	105	9	months	month	NOUN
dpc-2824	105	10	after	after	ADP
dpc-2824	105	11	initiation	initiation	NOUN
dpc-2824	105	12	of	of	ADP
dpc-2824	105	13	ici	ici	NOUN
dpc-2824	105	14	therapy	therapy	NOUN
dpc-2824	105	15	whereas	whereas	SCONJ
dpc-2824	105	16	other	other	ADJ
dpc-2824	105	17	iraes	iraes	NOUN
dpc-2824	105	18	(	(	PUNCT
dpc-2824	105	19	other	other	ADJ
dpc-2824	105	20	than	than	ADP
dpc-2824	105	21	skin	skin	NOUN
dpc-2824	105	22	)	)	PUNCT
dpc-2824	105	23	occurred	occur	VERB
dpc-2824	105	24	earlier	early	ADV
dpc-2824	105	25	(	(	PUNCT
dpc-2824	105	26	median	median	ADJ
dpc-2824	105	27	duration	duration	NOUN
dpc-2824	105	28	:	:	PUNCT
dpc-2824	105	29	2	2	NUM
dpc-2824	105	30	months	month	NOUN
dpc-2824	105	31	)	)	PUNCT
dpc-2824	105	32	.	.	PUNCT
dpc-2824	106	1	in	in	ADP
dpc-2824	106	2	a	a	DET
dpc-2824	106	3	previous	previous	ADJ
dpc-2824	106	4	study	study	NOUN
dpc-2824	106	5	on	on	ADP
dpc-2824	106	6	the	the	DET
dpc-2824	106	7	characteristics	characteristic	NOUN
dpc-2824	106	8	of	of	ADP
dpc-2824	106	9	ciraes	ciraes	NOUN
dpc-2824	106	10	and	and	CCONJ
dpc-2824	106	11	non	non	ADJ
dpc-2824	106	12	-	-	ADJ
dpc-2824	106	13	cutaneous	cutaneous	ADJ
dpc-2824	106	14	iraes	irae	NOUN
dpc-2824	106	15	,	,	PUNCT
dpc-2824	106	16	ciraes	cirae	NOUN
dpc-2824	106	17	were	be	AUX
dpc-2824	106	18	found	find	VERB
dpc-2824	106	19	to	to	PART
dpc-2824	106	20	precede	precede	VERB
dpc-2824	106	21	and	and	CCONJ
dpc-2824	106	22	increase	increase	VERB
dpc-2824	106	23	the	the	DET
dpc-2824	106	24	risk	risk	NOUN
dpc-2824	106	25	of	of	ADP
dpc-2824	106	26	other	other	ADJ
dpc-2824	106	27	organ	organ	NOUN
dpc-2824	106	28	involvement	involvement	NOUN
dpc-2824	106	29	in	in	ADP
dpc-2824	106	30	the	the	DET
dpc-2824	106	31	same	same	ADJ
dpc-2824	106	32	patient	patient	NOUN
dpc-2824	106	33	on	on	ADP
dpc-2824	106	34	ici	ici	NOUN
dpc-2824	106	35	therapy	therapy	NOUN
dpc-2824	106	36	[	[	X
dpc-2824	106	37	18	18	NUM
dpc-2824	106	38	]	]	PUNCT
dpc-2824	106	39	.	.	PUNCT
dpc-2824	107	1	in	in	ADP
dpc-2824	107	2	our	our	PRON
dpc-2824	107	3	study	study	NOUN
dpc-2824	107	4	,	,	PUNCT
dpc-2824	107	5	of	of	ADP
dpc-2824	107	6	the	the	DET
dpc-2824	107	7	six	six	NUM
dpc-2824	107	8	patients	patient	NOUN
dpc-2824	107	9	who	who	PRON
dpc-2824	107	10	developed	develop	VERB
dpc-2824	107	11	both	both	CCONJ
dpc-2824	107	12	cutaneous	cutaneous	ADJ
dpc-2824	107	13	and	and	CCONJ
dpc-2824	107	14	non	non	ADJ
dpc-2824	107	15	-	-	ADJ
dpc-2824	107	16	cutaneous	cutaneous	ADJ
dpc-2824	107	17	iraes	irae	NOUN
dpc-2824	107	18	,	,	PUNCT
dpc-2824	107	19	only	only	ADV
dpc-2824	107	20	two	two	NUM
dpc-2824	107	21	patients	patient	NOUN
dpc-2824	107	22	had	have	VERB
dpc-2824	107	23	cutaneous	cutaneous	ADJ
dpc-2824	107	24	involvement	involvement	NOUN
dpc-2824	107	25	prior	prior	ADV
dpc-2824	107	26	to	to	ADP
dpc-2824	107	27	the	the	DET
dpc-2824	107	28	extracutaneous	extracutaneous	ADJ
dpc-2824	107	29	adverse	adverse	ADJ
dpc-2824	107	30	events	event	NOUN
dpc-2824	107	31	,	,	PUNCT
dpc-2824	107	32	whereas	whereas	SCONJ
dpc-2824	107	33	it	it	PRON
dpc-2824	107	34	was	be	AUX
dpc-2824	107	35	the	the	DET
dpc-2824	107	36	reverse	reverse	NOUN
dpc-2824	107	37	in	in	ADP
dpc-2824	107	38	the	the	DET
dpc-2824	107	39	other	other	ADJ
dpc-2824	107	40	four	four	NUM
dpc-2824	107	41	.	.	PUNCT
dpc-2824	108	1	ciraes	cirae	NOUN
dpc-2824	108	2	were	be	AUX
dpc-2824	108	3	well	well	ADV
dpc-2824	108	4	tolerated	tolerate	VERB
dpc-2824	108	5	.	.	PUNCT
dpc-2824	109	1	the	the	DET
dpc-2824	109	2	majority	majority	NOUN
dpc-2824	109	3	of	of	ADP
dpc-2824	109	4	the	the	DET
dpc-2824	109	5	cutaneous	cutaneous	ADJ
dpc-2824	109	6	toxicities	toxicity	NOUN
dpc-2824	109	7	were	be	AUX
dpc-2824	109	8	mild	mild	ADJ
dpc-2824	109	9	and	and	CCONJ
dpc-2824	109	10	were	be	AUX
dpc-2824	109	11	managed	manage	VERB
dpc-2824	109	12	with	with	ADP
dpc-2824	109	13	topicals	topical	NOUN
dpc-2824	109	14	and	and	CCONJ
dpc-2824	109	15	antihistamines	antihistamine	NOUN
dpc-2824	109	16	.	.	PUNCT
dpc-2824	110	1	grade	grade	NOUN
dpc-2824	110	2	1	1	NUM
dpc-2824	110	3	and	and	CCONJ
dpc-2824	110	4	2	2	NUM
dpc-2824	110	5	ciraes	ciraes	NOUN
dpc-2824	110	6	formed	form	VERB
dpc-2824	110	7	75	75	NUM
dpc-2824	110	8	%	%	NOUN
dpc-2824	110	9	of	of	ADP
dpc-2824	110	10	the	the	DET
dpc-2824	110	11	total	total	NOUN
dpc-2824	110	12	.	.	PUNCT
dpc-2824	111	1	grade	grade	NOUN
dpc-2824	111	2	4	4	NUM
dpc-2824	111	3	dermatological	dermatological	ADJ
dpc-2824	111	4	iraes	irae	NOUN
dpc-2824	111	5	–	–	PUNCT
dpc-2824	111	6	were	be	AUX
dpc-2824	111	7	not	not	PART
dpc-2824	111	8	seen	see	VERB
dpc-2824	111	9	in	in	ADP
dpc-2824	111	10	our	our	PRON
dpc-2824	111	11	cohort	cohort	NOUN
dpc-2824	111	12	.	.	PUNCT
dpc-2824	112	1	of	of	ADP
dpc-2824	112	2	the	the	DET
dpc-2824	112	3	15	15	NUM
dpc-2824	112	4	,	,	PUNCT
dpc-2824	112	5	14	14	NUM
dpc-2824	112	6	had	have	VERB
dpc-2824	112	7	improvement	improvement	NOUN
dpc-2824	112	8	in	in	ADP
dpc-2824	112	9	their	their	PRON
dpc-2824	112	10	symptoms	symptom	NOUN
dpc-2824	112	11	with	with	ADP
dpc-2824	112	12	13	13	NUM
dpc-2824	112	13	having	have	VERB
dpc-2824	112	14	significant	significant	ADJ
dpc-2824	112	15	improvement	improvement	NOUN
dpc-2824	112	16	(	(	PUNCT
dpc-2824	112	17	fall	fall	NOUN
dpc-2824	112	18	of	of	ADP
dpc-2824	112	19	two	two	NUM
dpc-2824	112	20	grades	grade	NOUN
dpc-2824	112	21	or	or	CCONJ
dpc-2824	112	22	fall	fall	VERB
dpc-2824	112	23	to	to	ADP
dpc-2824	112	24	grade	grade	NOUN
dpc-2824	112	25	0	0	NUM
dpc-2824	112	26	)	)	PUNCT
dpc-2824	112	27	.	.	PUNCT
dpc-2824	113	1	one	one	NUM
dpc-2824	113	2	patient	patient	NOUN
dpc-2824	113	3	with	with	ADP
dpc-2824	113	4	psoriasiform	psoriasiform	NOUN
dpc-2824	113	5	eruption	eruption	NOUN
dpc-2824	113	6	had	have	VERB
dpc-2824	113	7	only	only	ADV
dpc-2824	113	8	moderate	moderate	ADJ
dpc-2824	113	9	improvement	improvement	NOUN
dpc-2824	113	10	–	–	PUNCT
dpc-2824	113	11	however	however	ADV
dpc-2824	113	12	,	,	PUNCT
dpc-2824	113	13	this	this	DET
dpc-2824	113	14	patient	patient	NOUN
dpc-2824	113	15	was	be	AUX
dpc-2824	113	16	not	not	PART
dpc-2824	113	17	treated	treat	VERB
dpc-2824	113	18	with	with	ADP
dpc-2824	113	19	any	any	DET
dpc-2824	113	20	immunomodulatory	immunomodulatory	ADJ
dpc-2824	113	21	agents	agent	NOUN
dpc-2824	113	22	.	.	PUNCT
dpc-2824	114	1	two	two	NUM
dpc-2824	114	2	patients	patient	NOUN
dpc-2824	114	3	with	with	ADP
dpc-2824	114	4	vitiligo	vitiligo	NOUN
dpc-2824	114	5	like	like	ADP
dpc-2824	114	6	depigmentation	depigmentation	NOUN
dpc-2824	114	7	did	do	AUX
dpc-2824	114	8	not	not	PART
dpc-2824	114	9	request	request	VERB
dpc-2824	114	10	any	any	DET
dpc-2824	114	11	treatment	treatment	NOUN
dpc-2824	114	12	.	.	PUNCT
dpc-2824	115	1	however	however	ADV
dpc-2824	115	2	,	,	PUNCT
dpc-2824	115	3	these	these	DET
dpc-2824	115	4	patients	patient	NOUN
dpc-2824	115	5	had	have	VERB
dpc-2824	115	6	only	only	ADV
dpc-2824	115	7	grade	grade	NOUN
dpc-2824	115	8	1	1	NUM
dpc-2824	115	9	and	and	CCONJ
dpc-2824	115	10	grade	grade	NOUN
dpc-2824	115	11	 	 	SPACE
dpc-2824	115	12	2	2	NUM
dpc-2824	115	13	vitiligo	vitiligo	NOUN
dpc-2824	115	14	like	like	ADP
dpc-2824	115	15	depigmentation	depigmentation	NOUN
dpc-2824	115	16	with	with	ADP
dpc-2824	115	17	limited	limited	ADJ
dpc-2824	115	18	area	area	NOUN
dpc-2824	115	19	of	of	ADP
dpc-2824	115	20	involvement	involvement	NOUN
dpc-2824	115	21	.	.	PUNCT
dpc-2824	116	1	one	one	NUM
dpc-2824	116	2	of	of	ADP
dpc-2824	116	3	these	these	DET
dpc-2824	116	4	patients	patient	NOUN
dpc-2824	116	5	had	have	AUX
dpc-2824	116	6	associated	associate	VERB
dpc-2824	116	7	pruritus	pruritus	NOUN
dpc-2824	116	8	which	which	PRON
dpc-2824	116	9	was	be	AUX
dpc-2824	116	10	treated	treat	VERB
dpc-2824	116	11	with	with	ADP
dpc-2824	116	12	antihistamines	antihistamine	NOUN
dpc-2824	116	13	.	.	PUNCT
dpc-2824	117	1	the	the	DET
dpc-2824	117	2	occurrence	occurrence	NOUN
dpc-2824	117	3	of	of	ADP
dpc-2824	117	4	any	any	DET
dpc-2824	117	5	irae	irae	NOUN
dpc-2824	117	6	was	be	AUX
dpc-2824	117	7	associated	associate	VERB
dpc-2824	117	8	with	with	ADP
dpc-2824	117	9	a	a	DET
dpc-2824	117	10	higher	high	ADJ
dpc-2824	117	11	orr	orr	NOUN
dpc-2824	117	12	and	and	CCONJ
dpc-2824	117	13	a	a	DET
dpc-2824	117	14	longer	long	ADV
dpc-2824	117	15	pfs	pfs	PROPN
dpc-2824	117	16	and	and	CCONJ
dpc-2824	117	17	os	os	NOUN
dpc-2824	117	18	.	.	PUNCT
dpc-2824	118	1	thus	thus	ADV
dpc-2824	118	2	,	,	PUNCT
dpc-2824	118	3	the	the	DET
dpc-2824	118	4	appearance	appearance	NOUN
dpc-2824	118	5	of	of	ADP
dpc-2824	118	6	any	any	DET
dpc-2824	118	7	irae	irae	NOUN
dpc-2824	118	8	in	in	ADP
dpc-2824	118	9	itself	itself	PRON
dpc-2824	118	10	may	may	AUX
dpc-2824	118	11	be	be	AUX
dpc-2824	118	12	an	an	DET
dpc-2824	118	13	indicator	indicator	NOUN
dpc-2824	118	14	of	of	ADP
dpc-2824	118	15	better	well	ADJ
dpc-2824	118	16	patient	patient	ADJ
dpc-2824	118	17	survival	survival	NOUN
dpc-2824	118	18	,	,	PUNCT
dpc-2824	118	19	similar	similar	ADJ
dpc-2824	118	20	to	to	ADP
dpc-2824	118	21	findings	finding	NOUN
dpc-2824	118	22	reported	report	VERB
dpc-2824	118	23	in	in	ADP
dpc-2824	118	24	other	other	ADJ
dpc-2824	118	25	studies	study	NOUN
dpc-2824	118	26	[	[	X
dpc-2824	118	27	3,19	3,19	X
dpc-2824	118	28	]	]	PUNCT
dpc-2824	118	29	.	.	PUNCT
dpc-2824	119	1	patients	patient	NOUN
dpc-2824	119	2	cox	cox	PROPN
dpc-2824	119	3	proportional	proportional	PROPN
dpc-2824	119	4	hazard	hazard	NOUN
dpc-2824	119	5	regression	regression	NOUN
dpc-2824	119	6	showed	show	VERB
dpc-2824	119	7	any	any	DET
dpc-2824	119	8	irae	irae	NOUN
dpc-2824	119	9	(	(	PUNCT
dpc-2824	119	10	hazard	hazard	NOUN
dpc-2824	119	11	ratio	ratio	NOUN
dpc-2824	119	12	:	:	PUNCT
dpc-2824	119	13	0.558	0.558	NUM
dpc-2824	119	14	,	,	PUNCT
dpc-2824	119	15	p	p	X
dpc-2824	119	16	=	=	NOUN
dpc-2824	119	17	0.033	0.033	NUM
dpc-2824	119	18	)	)	PUNCT
dpc-2824	119	19	and	and	CCONJ
dpc-2824	119	20	ciraes	ciraes	NOUN
dpc-2824	119	21	(	(	PUNCT
dpc-2824	119	22	hazard	hazard	NOUN
dpc-2824	119	23	ratio	ratio	NOUN
dpc-2824	119	24	:	:	PUNCT
dpc-2824	119	25	0.698	0.698	NUM
dpc-2824	119	26	,	,	PUNCT
dpc-2824	119	27	p	p	X
dpc-2824	119	28	=	=	PROPN
dpc-2824	119	29	0.046	0.046	NUM
dpc-2824	119	30	)	)	PUNCT
dpc-2824	119	31	to	to	PART
dpc-2824	119	32	have	have	AUX
dpc-2824	119	33	a	a	DET
dpc-2824	119	34	significant	significant	ADJ
dpc-2824	119	35	association	association	NOUN
dpc-2824	119	36	with	with	ADP
dpc-2824	119	37	increased	increase	VERB
dpc-2824	119	38	pfs	pfs	PROPN
dpc-2824	119	39	.	.	PUNCT
dpc-2824	120	1	development	development	NOUN
dpc-2824	120	2	of	of	ADP
dpc-2824	120	3	any	any	DET
dpc-2824	120	4	irae	irae	NOUN
dpc-2824	120	5	was	be	AUX
dpc-2824	120	6	also	also	ADV
dpc-2824	120	7	associated	associate	VERB
dpc-2824	120	8	with	with	ADP
dpc-2824	120	9	significantly	significantly	ADV
dpc-2824	120	10	increased	increase	VERB
dpc-2824	120	11	os	os	NOUN
dpc-2824	120	12	(	(	PUNCT
dpc-2824	120	13	hazard	hazard	NOUN
dpc-2824	120	14	ratio	ratio	NOUN
dpc-2824	120	15	:	:	PUNCT
dpc-2824	120	16	0.453	0.453	NUM
dpc-2824	120	17	,	,	PUNCT
dpc-2824	120	18	p	p	X
dpc-2824	120	19	 	 	SPACE
dpc-2824	120	20	=	=	NOUN
dpc-2824	120	21	 	 	SPACE
dpc-2824	120	22	0.028	0.028	NUM
dpc-2824	120	23	)	)	PUNCT
dpc-2824	120	24	,	,	PUNCT
dpc-2824	120	25	whereas	whereas	SCONJ
dpc-2824	120	26	ciraes	cirae	NOUN
dpc-2824	120	27	were	be	AUX
dpc-2824	120	28	not	not	PART
dpc-2824	120	29	.	.	PUNCT
dpc-2824	121	1	conclusions	conclusion	NOUN
dpc-2824	121	2	icis	icis	PROPN
dpc-2824	121	3	are	be	AUX
dpc-2824	121	4	effective	effective	ADJ
dpc-2824	121	5	in	in	ADP
dpc-2824	121	6	treating	treat	VERB
dpc-2824	121	7	various	various	ADJ
dpc-2824	121	8	cancers	cancer	NOUN
dpc-2824	121	9	and	and	CCONJ
dpc-2824	121	10	have	have	AUX
dpc-2824	121	11	revolutionized	revolutionize	VERB
dpc-2824	121	12	cancer	cancer	NOUN
dpc-2824	121	13	treatment	treatment	NOUN
dpc-2824	121	14	,	,	PUNCT
dpc-2824	121	15	however	however	ADV
dpc-2824	121	16	,	,	PUNCT
dpc-2824	121	17	studies	study	NOUN
dpc-2824	121	18	and	and	CCONJ
dpc-2824	121	19	trials	trial	NOUN
dpc-2824	121	20	on	on	ADP
dpc-2824	121	21	ici	ici	PROPN
dpc-2824	121	22	safety	safety	NOUN
dpc-2824	121	23	and	and	CCONJ
dpc-2824	121	24	efficacy	efficacy	NOUN
dpc-2824	121	25	have	have	VERB
dpc-2824	121	26	inadequate	inadequate	ADJ
dpc-2824	121	27	representation	representation	NOUN
dpc-2824	121	28	of	of	ADP
dpc-2824	121	29	indian	indian	ADJ
dpc-2824	121	30	population	population	NOUN
dpc-2824	121	31	.	.	PUNCT
dpc-2824	122	1	we	we	PRON
dpc-2824	122	2	have	have	AUX
dpc-2824	122	3	conducted	conduct	VERB
dpc-2824	122	4	a	a	DET
dpc-2824	122	5	real	real	ADJ
dpc-2824	122	6	-	-	PUNCT
dpc-2824	122	7	world	world	NOUN
dpc-2824	122	8	study	study	NOUN
dpc-2824	122	9	characterizing	characterize	VERB
dpc-2824	122	10	the	the	DET
dpc-2824	122	11	ciraes	ciraes	NOUN
dpc-2824	122	12	seen	see	VERB
dpc-2824	122	13	in	in	ADP
dpc-2824	122	14	an	an	DET
dpc-2824	122	15	indian	indian	ADJ
dpc-2824	122	16	cohort	cohort	NOUN
dpc-2824	122	17	on	on	ADP
dpc-2824	122	18	ici	ici	NOUN
dpc-2824	122	19	therapy	therapy	NOUN
dpc-2824	122	20	.	.	PUNCT
dpc-2824	123	1	ici	ici	PROPN
dpc-2824	123	2	response	response	NOUN
dpc-2824	123	3	rates	rate	NOUN
dpc-2824	123	4	can	can	AUX
dpc-2824	123	5	be	be	AUX
dpc-2824	123	6	variable	variable	ADJ
dpc-2824	123	7	and	and	CCONJ
dpc-2824	123	8	reports	report	NOUN
dpc-2824	123	9	have	have	AUX
dpc-2824	123	10	indicated	indicate	VERB
dpc-2824	123	11	that	that	SCONJ
dpc-2824	123	12	the	the	DET
dpc-2824	123	13	presence	presence	NOUN
dpc-2824	123	14	of	of	ADP
dpc-2824	123	15	iraes	iraes	NOUN
dpc-2824	123	16	maybe	maybe	ADV
dpc-2824	123	17	associated	associate	VERB
dpc-2824	123	18	with	with	ADP
dpc-2824	123	19	a	a	DET
dpc-2824	123	20	better	well	ADV
dpc-2824	123	21	therapeutic	therapeutic	ADJ
dpc-2824	123	22	effect	effect	NOUN
dpc-2824	123	23	especially	especially	ADV
dpc-2824	123	24	in	in	ADP
dpc-2824	123	25	lung	lung	NOUN
dpc-2824	123	26	cancer	cancer	NOUN
dpc-2824	123	27	and	and	CCONJ
dpc-2824	123	28	malignant	malignant	ADJ
dpc-2824	123	29	melanoma	melanoma	NOUN
dpc-2824	123	30	.	.	PUNCT
dpc-2824	124	1	identification	identification	NOUN
dpc-2824	124	2	of	of	ADP
dpc-2824	124	3	predictors	predictor	NOUN
dpc-2824	124	4	of	of	ADP
dpc-2824	124	5	ici	ici	NOUN
dpc-2824	124	6	response	response	NOUN
dpc-2824	124	7	are	be	AUX
dpc-2824	124	8	important	important	ADJ
dpc-2824	124	9	especially	especially	ADV
dpc-2824	124	10	in	in	ADP
dpc-2824	124	11	lowand	lowand	ADJ
dpc-2824	124	12	mid	mid	ADJ
dpc-2824	124	13	-	-	ADJ
dpc-2824	124	14	income	income	ADJ
dpc-2824	124	15	countries	country	NOUN
dpc-2824	124	16	where	where	SCONJ
dpc-2824	124	17	financial	financial	ADJ
dpc-2824	124	18	constraints	constraint	NOUN
dpc-2824	124	19	and	and	CCONJ
dpc-2824	124	20	accessibility	accessibility	NOUN
dpc-2824	124	21	to	to	ADP
dpc-2824	124	22	advanced	advanced	ADJ
dpc-2824	124	23	diagnostic	diagnostic	ADJ
dpc-2824	124	24	procedures	procedure	NOUN
dpc-2824	124	25	can	can	AUX
dpc-2824	124	26	be	be	AUX
dpc-2824	124	27	hurdles	hurdle	NOUN
dpc-2824	124	28	.	.	PUNCT
dpc-2824	125	1	we	we	PRON
dpc-2824	125	2	have	have	AUX
dpc-2824	125	3	studied	study	VERB
dpc-2824	125	4	the	the	DET
dpc-2824	125	5	association	association	NOUN
dpc-2824	125	6	between	between	ADP
dpc-2824	125	7	the	the	DET
dpc-2824	125	8	presence	presence	NOUN
dpc-2824	125	9	of	of	ADP
dpc-2824	125	10	iraes	irae	NOUN
dpc-2824	125	11	and	and	CCONJ
dpc-2824	125	12	ciraes	ciraes	NOUN
dpc-2824	125	13	and	and	CCONJ
dpc-2824	125	14	treatment	treatment	NOUN
dpc-2824	125	15	efficacy	efficacy	NOUN
dpc-2824	125	16	in	in	ADP
dpc-2824	125	17	terms	term	NOUN
dpc-2824	125	18	of	of	ADP
dpc-2824	125	19	tumor	tumor	NOUN
dpc-2824	125	20	response	response	NOUN
dpc-2824	125	21	and	and	CCONJ
dpc-2824	125	22	survival	survival	NOUN
dpc-2824	125	23	outcomes	outcome	NOUN
dpc-2824	125	24	.	.	PUNCT
dpc-2824	126	1	the	the	DET
dpc-2824	126	2	incidence	incidence	NOUN
dpc-2824	126	3	rates	rate	NOUN
dpc-2824	126	4	of	of	ADP
dpc-2824	126	5	ciraes	ciraes	NOUN
dpc-2824	126	6	can	can	AUX
dpc-2824	126	7	be	be	AUX
dpc-2824	126	8	variable	variable	ADJ
dpc-2824	126	9	with	with	ADP
dpc-2824	126	10	high	high	ADJ
dpc-2824	126	11	incidences	incidence	NOUN
dpc-2824	126	12	of	of	ADP
dpc-2824	126	13	up	up	ADP
dpc-2824	126	14	-	-	PUNCT
dpc-2824	126	15	to	to	PART
dpc-2824	126	16	70	70	NUM
dpc-2824	126	17	%	%	NOUN
dpc-2824	126	18	being	be	AUX
dpc-2824	126	19	reported	report	VERB
dpc-2824	126	20	in	in	ADP
dpc-2824	126	21	patients	patient	NOUN
dpc-2824	126	22	[	[	X
dpc-2824	126	23	11	11	NUM
dpc-2824	126	24	]	]	PUNCT
dpc-2824	126	25	.	.	PUNCT
dpc-2824	127	1	a	a	DET
dpc-2824	127	2	recent	recent	ADJ
dpc-2824	127	3	population	population	NOUN
dpc-2824	127	4	level	level	NOUN
dpc-2824	127	5	analysis	analysis	NOUN
dpc-2824	127	6	of	of	ADP
dpc-2824	127	7	ciraes	ciraes	NOUN
dpc-2824	127	8	in	in	ADP
dpc-2824	127	9	patients	patient	NOUN
dpc-2824	127	10	receiving	receive	VERB
dpc-2824	127	11	icis	icis	NOUN
dpc-2824	127	12	in	in	ADP
dpc-2824	127	13	the	the	DET
dpc-2824	127	14	united	united	PROPN
dpc-2824	127	15	states	states	PROPN
dpc-2824	127	16	has	have	AUX
dpc-2824	127	17	observed	observe	VERB
dpc-2824	127	18	an	an	DET
dpc-2824	127	19	incidence	incidence	NOUN
dpc-2824	127	20	of	of	ADP
dpc-2824	127	21	25.1	25.1	NUM
dpc-2824	127	22	%	%	NOUN
dpc-2824	127	23	[	[	X
dpc-2824	127	24	12	12	NUM
dpc-2824	127	25	]	]	PUNCT
dpc-2824	127	26	.	.	PUNCT
dpc-2824	128	1	similar	similar	ADJ
dpc-2824	128	2	incidence	incidence	NOUN
dpc-2824	128	3	has	have	AUX
dpc-2824	128	4	been	be	AUX
dpc-2824	128	5	observed	observe	VERB
dpc-2824	128	6	in	in	ADP
dpc-2824	128	7	a	a	DET
dpc-2824	128	8	large	large	ADJ
dpc-2824	128	9	taiwanese	taiwanese	ADJ
dpc-2824	128	10	cohort	cohort	NOUN
dpc-2824	128	11	(	(	PUNCT
dpc-2824	128	12	27.4	27.4	NUM
dpc-2824	128	13	%	%	NOUN
dpc-2824	128	14	)	)	PUNCT
dpc-2824	129	1	[	[	X
dpc-2824	129	2	13	13	NUM
dpc-2824	129	3	]	]	PUNCT
dpc-2824	129	4	.	.	PUNCT
dpc-2824	130	1	compared	compare	VERB
dpc-2824	130	2	to	to	ADP
dpc-2824	130	3	this	this	PRON
dpc-2824	130	4	,	,	PUNCT
dpc-2824	130	5	we	we	PRON
dpc-2824	130	6	observed	observe	VERB
dpc-2824	130	7	a	a	DET
dpc-2824	130	8	relatively	relatively	ADV
dpc-2824	130	9	lower	low	ADJ
dpc-2824	130	10	incidence	incidence	NOUN
dpc-2824	130	11	of	of	ADP
dpc-2824	130	12	ciraes	ciraes	NOUN
dpc-2824	130	13	(	(	PUNCT
dpc-2824	130	14	18.6	18.6	NUM
dpc-2824	130	15	%	%	NOUN
dpc-2824	130	16	)	)	PUNCT
dpc-2824	130	17	.	.	PUNCT
dpc-2824	131	1	with	with	ADP
dpc-2824	131	2	regard	regard	NOUN
dpc-2824	131	3	to	to	ADP
dpc-2824	131	4	the	the	DET
dpc-2824	131	5	individual	individual	ADJ
dpc-2824	131	6	types	type	NOUN
dpc-2824	131	7	of	of	ADP
dpc-2824	131	8	ciraes	ciraes	NOUN
dpc-2824	131	9	,	,	PUNCT
dpc-2824	131	10	the	the	DET
dpc-2824	131	11	majority	majority	NOUN
dpc-2824	131	12	noted	note	VERB
dpc-2824	131	13	in	in	ADP
dpc-2824	131	14	our	our	PRON
dpc-2824	131	15	study	study	NOUN
dpc-2824	131	16	were	be	AUX
dpc-2824	131	17	pruritus	pruritus	NOUN
dpc-2824	131	18	and	and	CCONJ
dpc-2824	131	19	maculopapular	maculopapular	ADJ
dpc-2824	131	20	rash	rash	NOUN
dpc-2824	131	21	similar	similar	ADJ
dpc-2824	131	22	to	to	ADP
dpc-2824	131	23	prior	prior	ADJ
dpc-2824	131	24	literature	literature	NOUN
dpc-2824	131	25	focusing	focus	VERB
dpc-2824	131	26	on	on	ADP
dpc-2824	131	27	ici	ici	PROPN
dpc-2824	131	28	associated	associate	VERB
dpc-2824	131	29	cutaneous	cutaneous	ADJ
dpc-2824	131	30	reactions	reaction	NOUN
dpc-2824	131	31	[	[	X
dpc-2824	131	32	13–15	13–15	NUM
dpc-2824	131	33	]	]	PUNCT
dpc-2824	131	34	.	.	PUNCT
dpc-2824	132	1	vitiligo	vitiligo	VERB
dpc-2824	132	2	like	like	ADP
dpc-2824	132	3	depigmentation	depigmentation	NOUN
dpc-2824	132	4	has	have	AUX
dpc-2824	132	5	been	be	AUX
dpc-2824	132	6	commonly	commonly	ADV
dpc-2824	132	7	reported	report	VERB
dpc-2824	132	8	in	in	ADP
dpc-2824	132	9	melanoma	melanoma	NOUN
dpc-2824	132	10	patients	patient	NOUN
dpc-2824	132	11	treated	treat	VERB
dpc-2824	132	12	with	with	ADP
dpc-2824	132	13	ici	ici	PROPN
dpc-2824	132	14	[	[	X
dpc-2824	132	15	16	16	NUM
dpc-2824	132	16	]	]	PUNCT
dpc-2824	132	17	.	.	PUNCT
dpc-2824	133	1	this	this	PRON
dpc-2824	133	2	was	be	AUX
dpc-2824	133	3	also	also	ADV
dpc-2824	133	4	seen	see	VERB
dpc-2824	133	5	in	in	ADP
dpc-2824	133	6	our	our	PRON
dpc-2824	133	7	study	study	NOUN
dpc-2824	133	8	,	,	PUNCT
dpc-2824	133	9	in	in	ADP
dpc-2824	133	10	two	two	NUM
dpc-2824	133	11	patients	patient	NOUN
dpc-2824	133	12	with	with	ADP
dpc-2824	133	13	figure	figure	NOUN
dpc-2824	133	14	2	2	NUM
dpc-2824	133	15	.	.	PUNCT
dpc-2824	134	1	kaplan	kaplan	PROPN
dpc-2824	134	2	meier	meier	PROPN
dpc-2824	134	3	survival	survival	PROPN
dpc-2824	134	4	curves	curve	NOUN
dpc-2824	134	5	comparing	compare	VERB
dpc-2824	134	6	(	(	PUNCT
dpc-2824	134	7	a	a	PRON
dpc-2824	134	8	)	)	PUNCT
dpc-2824	134	9	progression	progression	NOUN
dpc-2824	134	10	free	free	ADJ
dpc-2824	134	11	survival	survival	NOUN
dpc-2824	134	12	and	and	CCONJ
dpc-2824	134	13	(	(	PUNCT
dpc-2824	134	14	b	b	NOUN
dpc-2824	134	15	)	)	PUNCT
dpc-2824	134	16	overall	overall	ADJ
dpc-2824	134	17	survival	survival	NOUN
dpc-2824	134	18	between	between	ADP
dpc-2824	134	19	patients	patient	NOUN
dpc-2824	134	20	with	with	ADP
dpc-2824	134	21	and	and	CCONJ
dpc-2824	134	22	without	without	ADP
dpc-2824	134	23	cutaneous	cutaneous	ADJ
dpc-2824	134	24	immune	immune	NOUN
dpc-2824	134	25	-	-	PUNCT
dpc-2824	134	26	related	relate	VERB
dpc-2824	134	27	adverse	adverse	ADJ
dpc-2824	134	28	events	event	NOUN
dpc-2824	134	29	(	(	PUNCT
dpc-2824	134	30	ciraes	ciraes	NOUN
dpc-2824	134	31	)	)	PUNCT
dpc-2824	134	32	.	.	PUNCT
dpc-2824	135	1	6	6	NUM
dpc-2824	135	2	original	original	ADJ
dpc-2824	135	3	article	article	NOUN
dpc-2824	135	4	|	|	ADV
dpc-2824	135	5	dermatol	dermatol	ADJ
dpc-2824	135	6	pract	pract	NOUN
dpc-2824	135	7	concept	concept	NOUN
dpc-2824	135	8	.	.	PUNCT
dpc-2824	136	1	2023;13(3):e2023127	2023;13(3):e2023127	NUM
dpc-2824	136	2	2020;12(7):3796–803	2020;12(7):3796–803	NUM
dpc-2824	136	3	.	.	PUNCT
dpc-2824	137	1	doi:10.21037	doi:10.21037	PROPN
dpc-2824	137	2	/	/	SYM
dpc-2824	137	3	jtd.2019.08.29	jtd.2019.08.29	PROPN
dpc-2824	137	4	.	.	PUNCT
dpc-2824	138	1	pmid	pmid	PROPN
dpc-2824	138	2	:	:	PUNCT
dpc-2824	138	3	32802459	32802459	NUM
dpc-2824	138	4	.	.	PUNCT
dpc-2824	139	1	pmcid	pmcid	NOUN
dpc-2824	139	2	:	:	PUNCT
dpc-2824	139	3	pmc7399433	pmc7399433	NOUN
dpc-2824	139	4	.	.	PUNCT
dpc-2824	140	1	8	8	NUM
dpc-2824	140	2	.	.	PUNCT
dpc-2824	141	1	florez	florez	PROPN
dpc-2824	141	2	ma	ma	PROPN
dpc-2824	141	3	,	,	PUNCT
dpc-2824	141	4	kemnade	kemnade	PROPN
dpc-2824	141	5	jo	jo	PROPN
dpc-2824	141	6	,	,	PUNCT
dpc-2824	141	7	chen	chen	PROPN
dpc-2824	141	8	n	n	CCONJ
dpc-2824	141	9	,	,	PUNCT
dpc-2824	141	10	et	et	PROPN
dpc-2824	141	11	al	al	PROPN
dpc-2824	141	12	.	.	PUNCT
dpc-2824	141	13	persistent	persistent	ADJ
dpc-2824	141	14	ethnicity	ethnicity	NOUN
dpc-2824	141	15	associated	associate	VERB
dpc-2824	141	16	disparity	disparity	NOUN
dpc-2824	141	17	in	in	ADP
dpc-2824	141	18	anti	anti	ADJ
dpc-2824	141	19	-	-	ADJ
dpc-2824	141	20	tumor	tumor	ADJ
dpc-2824	141	21	effectiveness	effectiveness	NOUN
dpc-2824	141	22	of	of	ADP
dpc-2824	141	23	immune	immune	ADJ
dpc-2824	141	24	checkpoint	checkpoint	NOUN
dpc-2824	141	25	inhibitors	inhibitor	NOUN
dpc-2824	141	26	despite	despite	SCONJ
dpc-2824	141	27	equal	equal	ADJ
dpc-2824	141	28	access	access	NOUN
dpc-2824	141	29	.	.	PUNCT
dpc-2824	142	1	cancer	cancer	NOUN
dpc-2824	142	2	res	re	NOUN
dpc-2824	142	3	commun	commun	PROPN
dpc-2824	142	4	.	.	PUNCT
dpc-2824	143	1	2022;2022(8):806–813	2022;2022(8):806–813	X
dpc-2824	143	2	.	.	PUNCT
dpc-2824	144	1	doi	doi	NOUN
dpc-2824	144	2	:	:	PUNCT
dpc-2824	144	3	10.1158/2767	10.1158/2767	NUM
dpc-2824	144	4	-	-	SYM
dpc-2824	144	5	9764.crc-21	9764.crc-21	NUM
dpc-2824	144	6	-	-	PUNCT
dpc-2824	144	7	0143	0143	NUM
dpc-2824	144	8	.	.	PUNCT
dpc-2824	145	1	pmid	pmid	NOUN
dpc-2824	145	2	:	:	PUNCT
dpc-2824	145	3	35966167	35966167	NUM
dpc-2824	145	4	.	.	PUNCT
dpc-2824	146	1	pmcid	pmcid	NOUN
dpc-2824	146	2	:	:	PUNCT
dpc-2824	146	3	pmc9367161	pmc9367161	ADJ
dpc-2824	146	4	.	.	PUNCT
dpc-2824	147	1	9	9	X
dpc-2824	147	2	.	.	X
dpc-2824	147	3	resnick	resnick	PROPN
dpc-2824	147	4	k	k	PROPN
dpc-2824	147	5	,	,	PUNCT
dpc-2824	147	6	zang	zang	PROPN
dpc-2824	147	7	p	p	PROPN
dpc-2824	147	8	,	,	PUNCT
dpc-2824	147	9	travis	travis	PROPN
dpc-2824	147	10	larsen	larsen	PROPN
dpc-2824	147	11	t	t	PROPN
dpc-2824	147	12	,	,	PUNCT
dpc-2824	147	13	et	et	PROPN
dpc-2824	147	14	al	al	PROPN
dpc-2824	147	15	.	.	PROPN
dpc-2824	147	16	impact	impact	NOUN
dpc-2824	147	17	of	of	ADP
dpc-2824	147	18	ethnicity	ethnicity	NOUN
dpc-2824	147	19	and	and	CCONJ
dpc-2824	147	20	immune	immune	NOUN
dpc-2824	147	21	-	-	PUNCT
dpc-2824	147	22	related	relate	VERB
dpc-2824	147	23	adverse	adverse	ADJ
dpc-2824	147	24	events	event	NOUN
dpc-2824	147	25	(	(	PUNCT
dpc-2824	147	26	irae	irae	NOUN
dpc-2824	147	27	)	)	PUNCT
dpc-2824	147	28	on	on	ADP
dpc-2824	147	29	outcomes	outcome	NOUN
dpc-2824	147	30	for	for	ADP
dpc-2824	147	31	non	non	ADJ
dpc-2824	147	32	-	-	ADJ
dpc-2824	147	33	small	small	ADJ
dpc-2824	147	34	cell	cell	NOUN
dpc-2824	147	35	lung	lung	NOUN
dpc-2824	147	36	cancer	cancer	NOUN
dpc-2824	147	37	(	(	PUNCT
dpc-2824	147	38	nsclc	nsclc	NOUN
dpc-2824	147	39	)	)	PUNCT
dpc-2824	147	40	patients	patient	NOUN
dpc-2824	147	41	treated	treat	VERB
dpc-2824	147	42	with	with	ADP
dpc-2824	147	43	immune	immune	ADJ
dpc-2824	147	44	checkpoint	checkpoint	NOUN
dpc-2824	147	45	inhibitors	inhibitor	NOUN
dpc-2824	147	46	.	.	PUNCT
dpc-2824	148	1	j	j	PROPN
dpc-2824	148	2	clin	clin	PROPN
dpc-2824	148	3	oncol	oncol	PROPN
dpc-2824	148	4	.	.	PUNCT
dpc-2824	148	5	  	  	SPACE
dpc-2824	149	1	2022;40:16	2022;40:16	NUM
dpc-2824	149	2	:	:	PUNCT
dpc-2824	149	3	suppl	suppl	ADJ
dpc-2824	149	4	,	,	PUNCT
dpc-2824	149	5	  	  	SPACE
dpc-2824	149	6	e21115	e21115	NOUN
dpc-2824	149	7	-	-	PUNCT
dpc-2824	149	8	e21115	e21115	NOUN
dpc-2824	149	9	.	.	PUNCT
dpc-2824	150	1	doi	doi	NOUN
dpc-2824	150	2	:	:	PUNCT
dpc-2824	150	3	10.1200	10.1200	NUM
dpc-2824	150	4	/	/	SYM
dpc-2824	150	5	jco.2022.40.16_suppl.e21115	jco.2022.40.16_suppl.e21115	NOUN
dpc-2824	150	6	.	.	PUNCT
dpc-2824	151	1	10	10	NUM
dpc-2824	151	2	.	.	PUNCT
dpc-2824	151	3	peravali	peravali	PROPN
dpc-2824	151	4	m	m	PROPN
dpc-2824	151	5	,	,	PUNCT
dpc-2824	151	6	gomes	gomes	PROPN
dpc-2824	151	7	-	-	PUNCT
dpc-2824	151	8	lima	lima	PROPN
dpc-2824	151	9	c	c	PROPN
dpc-2824	151	10	,	,	PUNCT
dpc-2824	151	11	tefera	tefera	NOUN
dpc-2824	151	12	e	e	NOUN
dpc-2824	151	13	,	,	PUNCT
dpc-2824	151	14	et	et	PROPN
dpc-2824	151	15	al	al	PROPN
dpc-2824	151	16	.	.	PUNCT
dpc-2824	152	1	racial	racial	ADJ
dpc-2824	152	2	disparities	disparity	NOUN
dpc-2824	152	3	in	in	ADP
dpc-2824	152	4	immune	immune	NOUN
dpc-2824	152	5	-	-	PUNCT
dpc-2824	152	6	related	relate	VERB
dpc-2824	152	7	adverse	adverse	ADJ
dpc-2824	152	8	events	event	NOUN
dpc-2824	152	9	of	of	ADP
dpc-2824	152	10	immune	immune	ADJ
dpc-2824	152	11	checkpoint	checkpoint	NOUN
dpc-2824	152	12	inhibitors	inhibitor	NOUN
dpc-2824	152	13	and	and	CCONJ
dpc-2824	152	14	association	association	NOUN
dpc-2824	152	15	with	with	ADP
dpc-2824	152	16	survival	survival	NOUN
dpc-2824	152	17	based	base	VERB
dpc-2824	152	18	on	on	ADP
dpc-2824	152	19	clinical	clinical	ADJ
dpc-2824	152	20	and	and	CCONJ
dpc-2824	152	21	biochemical	biochemical	ADJ
dpc-2824	152	22	responses	response	NOUN
dpc-2824	152	23	.	.	PUNCT
dpc-2824	153	1	world	world	PROPN
dpc-2824	153	2	j	j	PROPN
dpc-2824	153	3	clin	clin	PROPN
dpc-2824	153	4	oncol	oncol	PROPN
dpc-2824	153	5	.	.	PUNCT
dpc-2824	154	1	2021;12(2):103114	2021;12(2):103114	X
dpc-2824	154	2	.	.	PUNCT
dpc-2824	155	1	doi:10.5306	doi:10.5306	NOUN
dpc-2824	155	2	/	/	SYM
dpc-2824	155	3	wjco.v12.i2.103	wjco.v12.i2.103	ADJ
dpc-2824	155	4	.	.	PUNCT
dpc-2824	156	1	pmid	pmid	NOUN
dpc-2824	156	2	:	:	PUNCT
dpc-2824	156	3	33680877	33680877	NUM
dpc-2824	156	4	.	.	PUNCT
dpc-2824	157	1	pmcid	pmcid	NOUN
dpc-2824	157	2	:	:	PUNCT
dpc-2824	157	3	pmc7918525	pmc7918525	NOUN
dpc-2824	157	4	.	.	PUNCT
dpc-2824	158	1	11	11	NUM
dpc-2824	158	2	.	.	PUNCT
dpc-2824	159	1	schneider	schneider	PROPN
dpc-2824	159	2	bj	bj	PROPN
dpc-2824	159	3	,	,	PUNCT
dpc-2824	159	4	naidoo	naidoo	PROPN
dpc-2824	159	5	j	j	PROPN
dpc-2824	159	6	,	,	PUNCT
dpc-2824	159	7	santomasso	santomasso	ADJ
dpc-2824	159	8	bd	bd	PROPN
dpc-2824	159	9	,	,	PUNCT
dpc-2824	159	10	et	et	PROPN
dpc-2824	159	11	al	al	PROPN
dpc-2824	159	12	.	.	PUNCT
dpc-2824	159	13	management	management	NOUN
dpc-2824	159	14	of	of	ADP
dpc-2824	159	15	immune	immune	NOUN
dpc-2824	159	16	-	-	PUNCT
dpc-2824	159	17	related	relate	VERB
dpc-2824	159	18	adverse	adverse	ADJ
dpc-2824	159	19	events	event	NOUN
dpc-2824	159	20	in	in	ADP
dpc-2824	159	21	patients	patient	NOUN
dpc-2824	159	22	treated	treat	VERB
dpc-2824	159	23	with	with	ADP
dpc-2824	159	24	immune	immune	ADJ
dpc-2824	159	25	checkpoint	checkpoint	NOUN
dpc-2824	159	26	inhibitor	inhibitor	NOUN
dpc-2824	159	27	therapy	therapy	NOUN
dpc-2824	159	28	:	:	PUNCT
dpc-2824	159	29	asco	asco	PROPN
dpc-2824	159	30	guideline	guideline	NOUN
dpc-2824	159	31	update	update	NOUN
dpc-2824	159	32	.	.	PUNCT
dpc-2824	160	1	j	j	PROPN
dpc-2824	160	2	clin	clin	PROPN
dpc-2824	160	3	oncol	oncol	PROPN
dpc-2824	160	4	.	.	PUNCT
dpc-2824	161	1	2021;39(36):4073	2021;39(36):4073	NOUN
dpc-2824	161	2	-	-	SYM
dpc-2824	161	3	4126	4126	NUM
dpc-2824	161	4	.	.	PUNCT
dpc-2824	162	1	doi:10.1200	doi:10.1200	PROPN
dpc-2824	162	2	/	/	SYM
dpc-2824	162	3	jco.21	jco.21	PROPN
dpc-2824	162	4	.01440	.01440	PROPN
dpc-2824	162	5	.	.	PUNCT
dpc-2824	163	1	pmid	pmid	NOUN
dpc-2824	163	2	:	:	PUNCT
dpc-2824	163	3	34724392	34724392	NUM
dpc-2824	163	4	.	.	PUNCT
dpc-2824	164	1	12	12	NUM
dpc-2824	164	2	.	.	PUNCT
dpc-2824	165	1	wongvibulsin	wongvibulsin	PROPN
dpc-2824	165	2	s	s	PART
dpc-2824	165	3	,	,	PUNCT
dpc-2824	165	4	pahalyants	pahalyant	VERB
dpc-2824	165	5	v	v	ADP
dpc-2824	165	6	,	,	PUNCT
dpc-2824	165	7	kalinich	kalinich	PROPN
dpc-2824	165	8	m	m	PROPN
dpc-2824	165	9	,	,	PUNCT
dpc-2824	165	10	et	et	PROPN
dpc-2824	165	11	al	al	PROPN
dpc-2824	165	12	.	.	PUNCT
dpc-2824	166	1	epidemiology	epidemiology	NOUN
dpc-2824	166	2	and	and	CCONJ
dpc-2824	166	3	risk	risk	NOUN
dpc-2824	166	4	factors	factor	NOUN
dpc-2824	166	5	for	for	ADP
dpc-2824	166	6	the	the	DET
dpc-2824	166	7	development	development	NOUN
dpc-2824	166	8	of	of	ADP
dpc-2824	166	9	cutaneous	cutaneous	ADJ
dpc-2824	166	10	toxicities	toxicity	NOUN
dpc-2824	166	11	in	in	ADP
dpc-2824	166	12	patients	patient	NOUN
dpc-2824	166	13	treated	treat	VERB
dpc-2824	166	14	with	with	ADP
dpc-2824	166	15	immune	immune	NOUN
dpc-2824	166	16	-	-	PUNCT
dpc-2824	166	17	checkpoint	checkpoint	NOUN
dpc-2824	166	18	inhibitors	inhibitor	NOUN
dpc-2824	166	19	:	:	PUNCT
dpc-2824	166	20	a	a	DET
dpc-2824	166	21	united	united	PROPN
dpc-2824	166	22	states	states	PROPN
dpc-2824	166	23	population	population	NOUN
dpc-2824	166	24	-	-	PUNCT
dpc-2824	166	25	level	level	NOUN
dpc-2824	166	26	analysis	analysis	NOUN
dpc-2824	166	27	.	.	PUNCT
dpc-2824	166	28	  	  	SPACE
dpc-2824	167	1	j	j	PROPN
dpc-2824	167	2	am	be	AUX
dpc-2824	167	3	acad	acad	ADJ
dpc-2824	167	4	dermatol	dermatol	NOUN
dpc-2824	167	5	.	.	PUNCT
dpc-2824	168	1	2022;86(3):563	2022;86(3):563	NUM
dpc-2824	168	2	-	-	SYM
dpc-2824	168	3	572	572	NUM
dpc-2824	168	4	.	.	PUNCT
dpc-2824	168	5	doi:10.1016	doi:10.1016	PROPN
dpc-2824	168	6	/	/	SYM
dpc-2824	168	7	j.jaad.2021.03.094	j.jaad.2021.03.094	PROPN
dpc-2824	168	8	.	.	PUNCT
dpc-2824	169	1	pmid	pmid	NOUN
dpc-2824	169	2	:	:	PUNCT
dpc-2824	169	3	33819538	33819538	NUM
dpc-2824	169	4	.	.	PUNCT
dpc-2824	170	1	13	13	NUM
dpc-2824	170	2	.	.	PUNCT
dpc-2824	171	1	cho	cho	PROPN
dpc-2824	171	2	yt	yt	PROPN
dpc-2824	171	3	,	,	PUNCT
dpc-2824	171	4	lin	lin	PROPN
dpc-2824	171	5	yt	yt	PROPN
dpc-2824	171	6	,	,	PUNCT
dpc-2824	171	7	yang	yang	PROPN
dpc-2824	171	8	cw	cw	PROPN
dpc-2824	171	9	,	,	PUNCT
dpc-2824	171	10	chu	chu	PROPN
dpc-2824	171	11	cy	cy	AUX
dpc-2824	171	12	.	.	PROPN
dpc-2824	171	13	cutaneous	cutaneous	ADJ
dpc-2824	171	14	immune	immune	NOUN
dpc-2824	171	15	-	-	PUNCT
dpc-2824	171	16	related	relate	VERB
dpc-2824	171	17	adverse	adverse	ADJ
dpc-2824	171	18	events	event	NOUN
dpc-2824	171	19	among	among	ADP
dpc-2824	171	20	taiwanese	taiwanese	ADJ
dpc-2824	171	21	cancer	cancer	NOUN
dpc-2824	171	22	patients	patient	NOUN
dpc-2824	171	23	receiving	receive	VERB
dpc-2824	171	24	immune	immune	ADJ
dpc-2824	171	25	checkpoint	checkpoint	NOUN
dpc-2824	171	26	inhibitors	inhibitor	NOUN
dpc-2824	171	27	link	link	VERB
dpc-2824	171	28	to	to	ADP
dpc-2824	171	29	a	a	DET
dpc-2824	171	30	survival	survival	NOUN
dpc-2824	171	31	benefit	benefit	NOUN
dpc-2824	171	32	.	.	PUNCT
dpc-2824	172	1	sci	sci	PROPN
dpc-2824	172	2	rep	rep	PROPN
dpc-2824	172	3	.	.	PROPN
dpc-2824	172	4	2022;12(1):7021	2022;12(1):7021	PROPN
dpc-2824	172	5	.	.	PUNCT
dpc-2824	173	1	doi	doi	NOUN
dpc-2824	173	2	:	:	PUNCT
dpc-2824	173	3	10.1038	10.1038	NUM
dpc-2824	173	4	/	/	SYM
dpc-2824	173	5	s41598	s41598	NOUN
dpc-2824	173	6	-	-	PUNCT
dpc-2824	173	7	022	022	NUM
dpc-2824	173	8	-	-	PUNCT
dpc-2824	173	9	11128	11128	NUM
dpc-2824	173	10	-	-	SYM
dpc-2824	173	11	5	5	NUM
dpc-2824	173	12	.	.	PUNCT
dpc-2824	174	1	pmid	pmid	NOUN
dpc-2824	174	2	:	:	PUNCT
dpc-2824	174	3	35487955	35487955	NUM
dpc-2824	174	4	.	.	PUNCT
dpc-2824	175	1	pmcid	pmcid	NOUN
dpc-2824	175	2	:	:	PUNCT
dpc-2824	175	3	pmc9055047	pmc9055047	ADV
dpc-2824	175	4	.	.	PUNCT
dpc-2824	176	1	14	14	NUM
dpc-2824	176	2	.	.	PUNCT
dpc-2824	177	1	geisler	geisler	PROPN
dpc-2824	177	2	an	an	PROPN
dpc-2824	177	3	,	,	PUNCT
dpc-2824	177	4	phillips	phillips	PROPN
dpc-2824	177	5	gs	gs	PROPN
dpc-2824	177	6	,	,	PUNCT
dpc-2824	177	7	barrios	barrios	PROPN
dpc-2824	177	8	dm	dm	NUM
dpc-2824	177	9	,	,	PUNCT
dpc-2824	177	10	et	et	PROPN
dpc-2824	177	11	al	al	PROPN
dpc-2824	177	12	.	.	PROPN
dpc-2824	177	13	immune	immune	ADJ
dpc-2824	177	14	checkpoint	checkpoint	NOUN
dpc-2824	177	15	inhibitor	inhibitor	NOUN
dpc-2824	177	16	—	—	PUNCT
dpc-2824	177	17	related	relate	VERB
dpc-2824	177	18	dermatologic	dermatologic	ADJ
dpc-2824	177	19	adverse	adverse	ADJ
dpc-2824	177	20	events	event	NOUN
dpc-2824	177	21	.	.	PUNCT
dpc-2824	178	1	j	j	PROPN
dpc-2824	178	2	am	be	AUX
dpc-2824	178	3	acad	acad	ADJ
dpc-2824	178	4	dermatol	dermatol	NOUN
dpc-2824	178	5	.	.	PUNCT
dpc-2824	179	1	2020;83(5):1255–1268	2020;83(5):1255–1268	NOUN
dpc-2824	179	2	.	.	PUNCT
dpc-2824	179	3	doi:10.1016	doi:10.1016	PROPN
dpc-2824	179	4	/	/	SYM
dpc-2824	179	5	j.	j.	PROPN
dpc-2824	179	6	jaad.2020.03.132	jaad.2020.03.132	PROPN
dpc-2824	179	7	.	.	PUNCT
dpc-2824	180	1	pmid	pmid	NOUN
dpc-2824	180	2	:	:	PUNCT
dpc-2824	180	3	32454097	32454097	NUM
dpc-2824	180	4	.	.	PUNCT
dpc-2824	181	1	pmcid	pmcid	ADJ
dpc-2824	181	2	:	:	PUNCT
dpc-2824	181	3	pmc7572894	pmc7572894	ADJ
dpc-2824	181	4	.	.	PUNCT
dpc-2824	182	1	15	15	NUM
dpc-2824	182	2	.	.	PUNCT
dpc-2824	183	1	wang	wang	PROPN
dpc-2824	183	2	e	e	PROPN
dpc-2824	183	3	,	,	PUNCT
dpc-2824	183	4	kraehenbuehl	kraehenbuehl	PROPN
dpc-2824	183	5	l	l	PROPN
dpc-2824	183	6	,	,	PUNCT
dpc-2824	183	7	ketosugbo	ketosugbo	PROPN
dpc-2824	183	8	k	k	PROPN
dpc-2824	183	9	,	,	PUNCT
dpc-2824	183	10	kern	kern	PROPN
dpc-2824	183	11	ja	ja	PROPN
dpc-2824	183	12	,	,	PUNCT
dpc-2824	183	13	lacouture	lacouture	VERB
dpc-2824	183	14	me	i	PRON
dpc-2824	183	15	,	,	PUNCT
dpc-2824	183	16	leung	leung	PROPN
dpc-2824	183	17	dym	dym	PROPN
dpc-2824	183	18	.	.	PUNCT
dpc-2824	184	1	immune	immune	NOUN
dpc-2824	184	2	-	-	PUNCT
dpc-2824	184	3	related	relate	VERB
dpc-2824	184	4	cutaneous	cutaneous	ADJ
dpc-2824	184	5	adverse	adverse	ADJ
dpc-2824	184	6	events	event	NOUN
dpc-2824	184	7	due	due	ADP
dpc-2824	184	8	to	to	ADP
dpc-2824	184	9	checkpoint	checkpoint	NOUN
dpc-2824	184	10	inhibitors	inhibitor	NOUN
dpc-2824	184	11	.	.	PUNCT
dpc-2824	185	1	ann	ann	PROPN
dpc-2824	185	2	allergy	allergy	PROPN
dpc-2824	185	3	asthma	asthma	PROPN
dpc-2824	185	4	immunol	immunol	NOUN
dpc-2824	185	5	.	.	PUNCT
dpc-2824	186	1	2021;126(6):613–622	2021;126(6):613–622	NUM
dpc-2824	186	2	.	.	PUNCT
dpc-2824	186	3	doi:10.1016	doi:10.1016	PROPN
dpc-2824	186	4	/	/	SYM
dpc-2824	186	5	j.anai.2021.02.009	j.anai.2021.02.009	PROPN
dpc-2824	186	6	.	.	PUNCT
dpc-2824	187	1	pmid	pmid	NOUN
dpc-2824	187	2	:	:	PUNCT
dpc-2824	187	3	33609771	33609771	NUM
dpc-2824	187	4	.	.	PUNCT
dpc-2824	188	1	pmcid	pmcid	NOUN
dpc-2824	188	2	:	:	PUNCT
dpc-2824	188	3	pmc8165024	pmc8165024	NOUN
dpc-2824	188	4	.	.	PUNCT
dpc-2824	189	1	16	16	NUM
dpc-2824	189	2	.	.	PUNCT
dpc-2824	189	3	larsabal	larsabal	PROPN
dpc-2824	189	4	m	m	PROPN
dpc-2824	189	5	,	,	PUNCT
dpc-2824	189	6	marti	marti	PROPN
dpc-2824	189	7	a	a	PROPN
dpc-2824	189	8	,	,	PUNCT
dpc-2824	189	9	jacquemin	jacquemin	PROPN
dpc-2824	189	10	c	c	NOUN
dpc-2824	189	11	,	,	PUNCT
dpc-2824	189	12	et	et	PROPN
dpc-2824	189	13	al	al	PROPN
dpc-2824	189	14	.	.	PROPN
dpc-2824	189	15	vitiligo	vitiligo	NOUN
dpc-2824	189	16	-	-	PUNCT
dpc-2824	189	17	like	like	ADJ
dpc-2824	189	18	lesions	lesion	NOUN
dpc-2824	189	19	occurring	occur	VERB
dpc-2824	189	20	in	in	ADP
dpc-2824	189	21	patients	patient	NOUN
dpc-2824	189	22	receiving	receive	VERB
dpc-2824	189	23	anti	anti	ADJ
dpc-2824	189	24	-	-	ADJ
dpc-2824	189	25	programmed	program	VERB
dpc-2824	189	26	cell	cell	NOUN
dpc-2824	189	27	death–1	death–1	NOUN
dpc-2824	189	28	therapies	therapy	NOUN
dpc-2824	189	29	are	be	AUX
dpc-2824	189	30	clinically	clinically	ADV
dpc-2824	189	31	and	and	CCONJ
dpc-2824	189	32	biologically	biologically	ADV
dpc-2824	189	33	distinct	distinct	ADJ
dpc-2824	189	34	from	from	ADP
dpc-2824	189	35	vitiligo	vitiligo	PROPN
dpc-2824	189	36	.	.	PUNCT
dpc-2824	190	1	j	j	PROPN
dpc-2824	190	2	am	be	AUX
dpc-2824	190	3	acad	acad	ADJ
dpc-2824	190	4	dermatol	dermatol	NOUN
dpc-2824	190	5	.	.	PUNCT
dpc-2824	191	1	2017;76(5):863	2017;76(5):863	NUM
dpc-2824	191	2	-	-	PUNCT
dpc-2824	191	3	870	870	NUM
dpc-2824	191	4	.	.	PUNCT
dpc-2824	192	1	doi:10.1016	doi:10.1016	PROPN
dpc-2824	192	2	/	/	SYM
dpc-2824	192	3	j.	j.	PROPN
dpc-2824	192	4	jaad.2016.10.044	jaad.2016.10.044	PROPN
dpc-2824	192	5	.	.	PUNCT
dpc-2824	193	1	pmid	pmid	PROPN
dpc-2824	193	2	:	:	PUNCT
dpc-2824	193	3	28094061	28094061	NUM
dpc-2824	193	4	.	.	PUNCT
dpc-2824	194	1	17	17	NUM
dpc-2824	194	2	.	.	X
dpc-2824	195	1	malviya	malviya	PROPN
dpc-2824	195	2	n	n	CCONJ
dpc-2824	195	3	,	,	PUNCT
dpc-2824	195	4	tattersall	tattersall	NOUN
dpc-2824	195	5	iw	iw	PROPN
dpc-2824	195	6	,	,	PUNCT
dpc-2824	195	7	leventhal	leventhal	PROPN
dpc-2824	195	8	j	j	PROPN
dpc-2824	195	9	,	,	PUNCT
dpc-2824	195	10	alloo	alloo	ADJ
dpc-2824	195	11	a.	a.	NOUN
dpc-2824	195	12	cutaneous	cutaneous	ADJ
dpc-2824	195	13	immune	immune	NOUN
dpc-2824	195	14	-	-	PUNCT
dpc-2824	195	15	related	relate	VERB
dpc-2824	195	16	adverse	adverse	ADJ
dpc-2824	195	17	events	event	NOUN
dpc-2824	195	18	to	to	PART
dpc-2824	195	19	checkpoint	checkpoint	VERB
dpc-2824	195	20	inhibitors	inhibitor	NOUN
dpc-2824	195	21	.	.	PUNCT
dpc-2824	196	1	clin	clin	PROPN
dpc-2824	196	2	dermatol	dermatol	NOUN
dpc-2824	196	3	.	.	PUNCT
dpc-2824	197	1	2020;38(6):660–678	2020;38(6):660–678	NUM
dpc-2824	197	2	.	.	PUNCT
dpc-2824	197	3	doi:10.1016	doi:10.1016	PROPN
dpc-2824	197	4	/	/	SYM
dpc-2824	197	5	j.clindermatol.2020	j.clindermatol.2020	PROPN
dpc-2824	197	6	.	.	PUNCT
dpc-2824	198	1	06.011	06.011	NUM
dpc-2824	198	2	.	.	PUNCT
dpc-2824	199	1	pmid	pmid	NOUN
dpc-2824	199	2	:	:	PUNCT
dpc-2824	199	3	33341200	33341200	NUM
dpc-2824	199	4	.	.	PUNCT
dpc-2824	200	1	18	18	NUM
dpc-2824	200	2	.	.	X
dpc-2824	201	1	thompson	thompson	PROPN
dpc-2824	201	2	ll	ll	PROPN
dpc-2824	201	3	,	,	PUNCT
dpc-2824	201	4	krasnow	krasnow	PROPN
dpc-2824	201	5	na	na	PROPN
dpc-2824	201	6	,	,	PUNCT
dpc-2824	201	7	chang	chang	PROPN
dpc-2824	201	8	ms	ms	PROPN
dpc-2824	201	9	,	,	PUNCT
dpc-2824	201	10	et	et	PROPN
dpc-2824	201	11	al	al	PROPN
dpc-2824	201	12	.	.	PUNCT
dpc-2824	201	13	patterns	pattern	NOUN
dpc-2824	201	14	of	of	ADP
dpc-2824	201	15	cutaneous	cutaneous	ADJ
dpc-2824	201	16	and	and	CCONJ
dpc-2824	201	17	noncutaneous	noncutaneous	ADJ
dpc-2824	201	18	immune	immune	NOUN
dpc-2824	201	19	-	-	PUNCT
dpc-2824	201	20	related	relate	VERB
dpc-2824	201	21	adverse	adverse	ADJ
dpc-2824	201	22	events	event	NOUN
dpc-2824	201	23	among	among	ADP
dpc-2824	201	24	patients	patient	NOUN
dpc-2824	201	25	with	with	ADP
dpc-2824	201	26	advanced	advanced	ADJ
dpc-2824	201	27	cancer	cancer	NOUN
dpc-2824	201	28	.	.	PUNCT
dpc-2824	202	1	jama	jama	PROPN
dpc-2824	202	2	dermatol	dermatol	NOUN
dpc-2824	202	3	.	.	PUNCT
dpc-2824	203	1	2021;157(5):577–582	2021;157(5):577–582	NUM
dpc-2824	203	2	.	.	PUNCT
dpc-2824	203	3	doi:10.1001	doi:10.1001	PROPN
dpc-2824	203	4	/	/	SYM
dpc-2824	203	5	jamadermatol.2021.0326	jamadermatol.2021.0326	NOUN
dpc-2824	203	6	.	.	PUNCT
dpc-2824	204	1	pmid	pmid	NOUN
dpc-2824	204	2	:	:	PUNCT
dpc-2824	204	3	33760001	33760001	NUM
dpc-2824	204	4	.	.	PUNCT
dpc-2824	205	1	pmcid	pmcid	NOUN
dpc-2824	205	2	:	:	PUNCT
dpc-2824	205	3	pmc7992016	pmc7992016	PROPN
dpc-2824	205	4	.	.	PUNCT
dpc-2824	206	1	19	19	NUM
dpc-2824	206	2	.	.	X
dpc-2824	206	3	fujii	fujii	PROPN
dpc-2824	206	4	t	t	PROPN
dpc-2824	206	5	,	,	PUNCT
dpc-2824	206	6	colen	colen	PROPN
dpc-2824	206	7	rr	rr	PROPN
dpc-2824	206	8	,	,	PUNCT
dpc-2824	206	9	bilen	bilen	PROPN
dpc-2824	206	10	ma	ma	PROPN
dpc-2824	206	11	,	,	PUNCT
dpc-2824	206	12	et	et	PROPN
dpc-2824	206	13	al	al	PROPN
dpc-2824	206	14	.	.	PROPN
dpc-2824	206	15	incidence	incidence	NOUN
dpc-2824	206	16	of	of	ADP
dpc-2824	206	17	immune	immune	NOUN
dpc-2824	206	18	-	-	PUNCT
dpc-2824	206	19	related	relate	VERB
dpc-2824	206	20	adverse	adverse	ADJ
dpc-2824	206	21	events	event	NOUN
dpc-2824	206	22	and	and	CCONJ
dpc-2824	206	23	its	its	PRON
dpc-2824	206	24	association	association	NOUN
dpc-2824	206	25	with	with	ADP
dpc-2824	206	26	treatment	treatment	NOUN
dpc-2824	206	27	outcomes	outcome	NOUN
dpc-2824	206	28	:	:	PUNCT
dpc-2824	206	29	the	the	DET
dpc-2824	206	30	md	md	PROPN
dpc-2824	206	31	anderson	anderson	PROPN
dpc-2824	206	32	cancer	cancer	PROPN
dpc-2824	206	33	center	center	PROPN
dpc-2824	206	34	experience	experience	NOUN
dpc-2824	206	35	.	.	PUNCT
dpc-2824	207	1	invest	invest	VERB
dpc-2824	207	2	new	new	ADJ
dpc-2824	207	3	drugs	drug	NOUN
dpc-2824	207	4	.	.	PUNCT
dpc-2824	208	1	with	with	SCONJ
dpc-2824	208	2	any	any	DET
dpc-2824	208	3	ciraes	ciraes	NOUN
dpc-2824	208	4	had	have	VERB
dpc-2824	208	5	a	a	DET
dpc-2824	208	6	significantly	significantly	ADV
dpc-2824	208	7	longer	long	ADJ
dpc-2824	208	8	median	median	ADJ
dpc-2824	208	9	pfs	pfs	PROPN
dpc-2824	208	10	and	and	CCONJ
dpc-2824	208	11	a	a	DET
dpc-2824	208	12	higher	high	ADJ
dpc-2824	208	13	orr	orr	PROPN
dpc-2824	208	14	.	.	PROPN
dpc-2824	208	15	multivariable	multivariable	ADJ
dpc-2824	208	16	analysis	analysis	NOUN
dpc-2824	208	17	also	also	ADV
dpc-2824	208	18	showed	show	VERB
dpc-2824	208	19	ciraes	ciraes	NOUN
dpc-2824	208	20	to	to	PART
dpc-2824	208	21	be	be	AUX
dpc-2824	208	22	associated	associate	VERB
dpc-2824	208	23	with	with	ADP
dpc-2824	208	24	a	a	DET
dpc-2824	208	25	longer	long	ADV
dpc-2824	208	26	pfs	pf	VERB
dpc-2824	208	27	.	.	PUNCT
dpc-2824	209	1	they	they	PRON
dpc-2824	209	2	were	be	AUX
dpc-2824	209	3	also	also	ADV
dpc-2824	209	4	associated	associate	VERB
dpc-2824	209	5	with	with	ADP
dpc-2824	209	6	a	a	DET
dpc-2824	209	7	longer	long	ADJ
dpc-2824	209	8	os	os	NOUN
dpc-2824	209	9	;	;	PUNCT
dpc-2824	209	10	however	however	ADV
dpc-2824	209	11	,	,	PUNCT
dpc-2824	209	12	it	it	PRON
dpc-2824	209	13	was	be	AUX
dpc-2824	209	14	not	not	PART
dpc-2824	209	15	statistically	statistically	ADV
dpc-2824	209	16	significant	significant	ADJ
dpc-2824	209	17	.	.	PUNCT
dpc-2824	210	1	this	this	PRON
dpc-2824	210	2	is	be	AUX
dpc-2824	210	3	in	in	ADP
dpc-2824	210	4	contrast	contrast	NOUN
dpc-2824	210	5	with	with	ADP
dpc-2824	210	6	other	other	ADJ
dpc-2824	210	7	studies	study	NOUN
dpc-2824	210	8	where	where	SCONJ
dpc-2824	210	9	in	in	ADP
dpc-2824	210	10	ciraes	ciraes	NOUN
dpc-2824	210	11	were	be	AUX
dpc-2824	210	12	associated	associate	VERB
dpc-2824	210	13	with	with	ADP
dpc-2824	210	14	better	well	ADJ
dpc-2824	210	15	survival	survival	NOUN
dpc-2824	210	16	outcomes	outcome	NOUN
dpc-2824	210	17	with	with	ADP
dpc-2824	210	18	regard	regard	NOUN
dpc-2824	210	19	to	to	ADP
dpc-2824	210	20	both	both	DET
dpc-2824	210	21	pfs	pfs	PROPN
dpc-2824	210	22	and	and	CCONJ
dpc-2824	210	23	os	os	NOUN
dpc-2824	210	24	[	[	X
dpc-2824	210	25	4,20–22	4,20–22	NOUN
dpc-2824	210	26	]	]	PUNCT
dpc-2824	210	27	.	.	PUNCT
dpc-2824	211	1	limitations	limitation	NOUN
dpc-2824	211	2	of	of	ADP
dpc-2824	211	3	the	the	DET
dpc-2824	211	4	study	study	NOUN
dpc-2824	211	5	are	be	AUX
dpc-2824	211	6	its	its	PRON
dpc-2824	211	7	retrospective	retrospective	ADJ
dpc-2824	211	8	design	design	NOUN
dpc-2824	211	9	and	and	CCONJ
dpc-2824	211	10	small	small	ADJ
dpc-2824	211	11	sample	sample	NOUN
dpc-2824	211	12	size	size	NOUN
dpc-2824	211	13	.	.	PUNCT
dpc-2824	212	1	six	six	NUM
dpc-2824	212	2	out	out	ADP
dpc-2824	212	3	of	of	ADP
dpc-2824	212	4	the	the	DET
dpc-2824	212	5	16	16	NUM
dpc-2824	212	6	patients	patient	NOUN
dpc-2824	212	7	with	with	ADP
dpc-2824	212	8	cutaneous	cutaneous	ADJ
dpc-2824	212	9	iraes	irae	NOUN
dpc-2824	212	10	also	also	ADV
dpc-2824	212	11	had	have	VERB
dpc-2824	212	12	other	other	ADJ
dpc-2824	212	13	organ	organ	NOUN
dpc-2824	212	14	iraes	irae	NOUN
dpc-2824	212	15	which	which	PRON
dpc-2824	212	16	may	may	AUX
dpc-2824	212	17	be	be	AUX
dpc-2824	212	18	a	a	DET
dpc-2824	212	19	confounding	confound	VERB
dpc-2824	212	20	factor	factor	NOUN
dpc-2824	212	21	.	.	PUNCT
dpc-2824	213	1	in	in	ADP
dpc-2824	213	2	conclusion	conclusion	NOUN
dpc-2824	213	3	,	,	PUNCT
dpc-2824	213	4	pruritus	pruritus	NOUN
dpc-2824	213	5	and	and	CCONJ
dpc-2824	213	6	maculopapular	maculopapular	ADJ
dpc-2824	213	7	rash	rash	NOUN
dpc-2824	213	8	were	be	AUX
dpc-2824	213	9	the	the	DET
dpc-2824	213	10	most	most	ADV
dpc-2824	213	11	common	common	ADJ
dpc-2824	213	12	ciraes	ciraes	NOUN
dpc-2824	213	13	seen	see	VERB
dpc-2824	213	14	in	in	ADP
dpc-2824	213	15	our	our	PRON
dpc-2824	213	16	study	study	NOUN
dpc-2824	213	17	of	of	ADP
dpc-2824	213	18	indian	indian	ADJ
dpc-2824	213	19	patients	patient	NOUN
dpc-2824	213	20	on	on	ADP
dpc-2824	213	21	ici	ici	NOUN
dpc-2824	213	22	therapy	therapy	NOUN
dpc-2824	213	23	which	which	PRON
dpc-2824	213	24	is	be	AUX
dpc-2824	213	25	similar	similar	ADJ
dpc-2824	213	26	to	to	ADP
dpc-2824	213	27	the	the	DET
dpc-2824	213	28	profile	profile	NOUN
dpc-2824	213	29	of	of	ADP
dpc-2824	213	30	ciraes	ciraes	NOUN
dpc-2824	213	31	seen	see	VERB
dpc-2824	213	32	in	in	ADP
dpc-2824	213	33	other	other	ADJ
dpc-2824	213	34	populations	population	NOUN
dpc-2824	213	35	.	.	PUNCT
dpc-2824	214	1	however	however	ADV
dpc-2824	214	2	,	,	PUNCT
dpc-2824	214	3	the	the	DET
dpc-2824	214	4	incidence	incidence	NOUN
dpc-2824	214	5	of	of	ADP
dpc-2824	214	6	ciraes	ciraes	NOUN
dpc-2824	214	7	was	be	AUX
dpc-2824	214	8	lower	low	ADJ
dpc-2824	214	9	.	.	PUNCT
dpc-2824	215	1	ciraes	cirae	NOUN
dpc-2824	215	2	were	be	AUX
dpc-2824	215	3	found	find	VERB
dpc-2824	215	4	to	to	PART
dpc-2824	215	5	be	be	AUX
dpc-2824	215	6	associated	associate	VERB
dpc-2824	215	7	with	with	ADP
dpc-2824	215	8	a	a	DET
dpc-2824	215	9	superior	superior	ADJ
dpc-2824	215	10	orr	orr	PROPN
dpc-2824	215	11	and	and	CCONJ
dpc-2824	215	12	pfs	pfs	PROPN
dpc-2824	215	13	.	.	PUNCT
dpc-2824	216	1	compared	compare	VERB
dpc-2824	216	2	to	to	ADP
dpc-2824	216	3	adverse	adverse	ADJ
dpc-2824	216	4	events	event	NOUN
dpc-2824	216	5	in	in	ADP
dpc-2824	216	6	other	other	ADJ
dpc-2824	216	7	organ	organ	NOUN
dpc-2824	216	8	systems	system	NOUN
dpc-2824	216	9	,	,	PUNCT
dpc-2824	216	10	cutaneous	cutaneous	ADJ
dpc-2824	216	11	adverse	adverse	ADJ
dpc-2824	216	12	events	event	NOUN
dpc-2824	216	13	are	be	AUX
dpc-2824	216	14	readily	readily	ADV
dpc-2824	216	15	evident	evident	ADJ
dpc-2824	216	16	on	on	ADP
dpc-2824	216	17	a	a	DET
dpc-2824	216	18	simple	simple	ADJ
dpc-2824	216	19	physical	physical	ADJ
dpc-2824	216	20	examination	examination	NOUN
dpc-2824	216	21	and	and	CCONJ
dpc-2824	216	22	do	do	AUX
dpc-2824	216	23	not	not	PART
dpc-2824	216	24	usually	usually	ADV
dpc-2824	216	25	require	require	VERB
dpc-2824	216	26	any	any	DET
dpc-2824	216	27	investigations	investigation	NOUN
dpc-2824	216	28	.	.	PUNCT
dpc-2824	217	1	thus	thus	ADV
dpc-2824	217	2	,	,	PUNCT
dpc-2824	217	3	ciraes	ciraes	NOUN
dpc-2824	217	4	may	may	AUX
dpc-2824	217	5	serve	serve	VERB
dpc-2824	217	6	as	as	ADP
dpc-2824	217	7	an	an	DET
dpc-2824	217	8	easily	easily	ADV
dpc-2824	217	9	accessible	accessible	ADJ
dpc-2824	217	10	and	and	CCONJ
dpc-2824	217	11	actional	actional	ADJ
dpc-2824	217	12	clinical	clinical	ADJ
dpc-2824	217	13	surrogate	surrogate	ADJ
dpc-2824	217	14	marker	marker	NOUN
dpc-2824	217	15	for	for	ADP
dpc-2824	217	16	predicting	predict	VERB
dpc-2824	217	17	the	the	DET
dpc-2824	217	18	tumor	tumor	NOUN
dpc-2824	217	19	response	response	NOUN
dpc-2824	217	20	.	.	PUNCT
dpc-2824	218	1	this	this	PRON
dpc-2824	218	2	can	can	AUX
dpc-2824	218	3	especially	especially	ADV
dpc-2824	218	4	be	be	AUX
dpc-2824	218	5	important	important	ADJ
dpc-2824	218	6	in	in	ADP
dpc-2824	218	7	resource	resource	NOUN
dpc-2824	218	8	poor	poor	ADJ
dpc-2824	218	9	settings	setting	NOUN
dpc-2824	218	10	.	.	PUNCT
dpc-2824	219	1	references	reference	NOUN
dpc-2824	219	2	1	1	NUM
dpc-2824	219	3	.	.	PUNCT
dpc-2824	219	4	lee	lee	PROPN
dpc-2824	219	5	l	l	PROPN
dpc-2824	219	6	,	,	PUNCT
dpc-2824	219	7	gupta	gupta	PROPN
dpc-2824	219	8	m	m	PROPN
dpc-2824	219	9	,	,	PUNCT
dpc-2824	219	10	sahasranaman	sahasranaman	NOUN
dpc-2824	219	11	s.	s.	PROPN
dpc-2824	219	12	immune	immune	ADJ
dpc-2824	219	13	checkpoint	checkpoint	NOUN
dpc-2824	219	14	inhibitors	inhibitor	NOUN
dpc-2824	219	15	:	:	PUNCT
dpc-2824	219	16	an	an	DET
dpc-2824	219	17	introduction	introduction	NOUN
dpc-2824	219	18	to	to	ADP
dpc-2824	219	19	the	the	DET
dpc-2824	219	20	next	next	ADJ
dpc-2824	219	21	-	-	PUNCT
dpc-2824	219	22	generation	generation	NOUN
dpc-2824	219	23	cancer	cancer	NOUN
dpc-2824	219	24	immunotherapy	immunotherapy	NOUN
dpc-2824	219	25	.	.	PUNCT
dpc-2824	220	1	j	j	PROPN
dpc-2824	220	2	clin	clin	PROPN
dpc-2824	220	3	pharmacol	pharmacol	PROPN
dpc-2824	220	4	.	.	PUNCT
dpc-2824	221	1	2016;56(2):157–169	2016;56(2):157–169	PROPN
dpc-2824	221	2	.	.	PUNCT
dpc-2824	222	1	doi:10.1002	doi:10.1002	NOUN
dpc-2824	222	2	/jcph.591	/jcph.591	NOUN
dpc-2824	222	3	.	.	PUNCT
dpc-2824	223	1	pmid	pmid	NOUN
dpc-2824	223	2	:	:	PUNCT
dpc-2824	223	3	26183909	26183909	NUM
dpc-2824	223	4	.	.	PUNCT
dpc-2824	224	1	2	2	X
dpc-2824	224	2	.	.	X
dpc-2824	224	3	ramos	ramo	NOUN
dpc-2824	224	4	-	-	PUNCT
dpc-2824	224	5	casals	casal	NOUN
dpc-2824	224	6	m	m	PROPN
dpc-2824	224	7	,	,	PUNCT
dpc-2824	224	8	brahmer	brahmer	PROPN
dpc-2824	224	9	jr	jr	PROPN
dpc-2824	224	10	,	,	PUNCT
dpc-2824	224	11	callahan	callahan	PROPN
dpc-2824	224	12	mk	mk	PROPN
dpc-2824	224	13	,	,	PUNCT
dpc-2824	224	14	et	et	PROPN
dpc-2824	224	15	al	al	PROPN
dpc-2824	224	16	.	.	PROPN
dpc-2824	224	17	immune	immune	NOUN
dpc-2824	224	18	-	-	PUNCT
dpc-2824	224	19	related	relate	VERB
dpc-2824	224	20	adverse	adverse	ADJ
dpc-2824	224	21	events	event	NOUN
dpc-2824	224	22	of	of	ADP
dpc-2824	224	23	checkpoint	checkpoint	NOUN
dpc-2824	224	24	inhibitors	inhibitor	NOUN
dpc-2824	224	25	.	.	PUNCT
dpc-2824	225	1	nat	nat	PROPN
dpc-2824	225	2	rev	rev	VERB
dpc-2824	225	3	dis	dis	PROPN
dpc-2824	225	4	primers	primer	NOUN
dpc-2824	225	5	.	.	PUNCT
dpc-2824	226	1	2020;6(1):38	2020;6(1):38	NUM
dpc-2824	226	2	.	.	PUNCT
dpc-2824	226	3	doi:10.1038	doi:10.1038	PROPN
dpc-2824	226	4	/	/	SYM
dpc-2824	226	5	s41572	s41572	NOUN
dpc-2824	226	6	-	-	PUNCT
dpc-2824	226	7	020	020	NUM
dpc-2824	226	8	-	-	PUNCT
dpc-2824	226	9	0160	0160	NUM
dpc-2824	226	10	-	-	PUNCT
dpc-2824	226	11	6	6	NUM
dpc-2824	226	12	.	.	PUNCT
dpc-2824	227	1	pmid	pmid	NOUN
dpc-2824	227	2	:	:	PUNCT
dpc-2824	227	3	32382051	32382051	NUM
dpc-2824	227	4	.	.	PUNCT
dpc-2824	228	1	pmcid	pmcid	NOUN
dpc-2824	228	2	:	:	PUNCT
dpc-2824	228	3	pmc9728094	pmc9728094	PROPN
dpc-2824	228	4	.	.	PUNCT
dpc-2824	229	1	3	3	X
dpc-2824	229	2	.	.	X
dpc-2824	229	3	rogado	rogado	PROPN
dpc-2824	229	4	j	j	PROPN
dpc-2824	229	5	,	,	PUNCT
dpc-2824	229	6	sánchez	sánchez	PROPN
dpc-2824	229	7	-	-	PUNCT
dpc-2824	229	8	torres	torres	PROPN
dpc-2824	229	9	jm	jm	PROPN
dpc-2824	229	10	,	,	PUNCT
dpc-2824	229	11	romero	romero	PROPN
dpc-2824	229	12	-	-	PUNCT
dpc-2824	229	13	laorden	laorden	PROPN
dpc-2824	229	14	n	n	CCONJ
dpc-2824	229	15	,	,	PUNCT
dpc-2824	229	16	et	et	PROPN
dpc-2824	229	17	al	al	PROPN
dpc-2824	229	18	.	.	PROPN
dpc-2824	229	19	immune	immune	PROPN
dpc-2824	229	20	related	relate	VERB
dpc-2824	229	21	adverse	adverse	ADJ
dpc-2824	229	22	events	event	NOUN
dpc-2824	229	23	predict	predict	VERB
dpc-2824	229	24	the	the	DET
dpc-2824	229	25	therapeutic	therapeutic	ADJ
dpc-2824	229	26	efficacy	efficacy	NOUN
dpc-2824	229	27	of	of	ADP
dpc-2824	229	28	anti	anti	ADJ
dpc-2824	229	29	-	-	ADJ
dpc-2824	229	30	pd-1	pd-1	ADJ
dpc-2824	229	31	antibodies	antibody	NOUN
dpc-2824	229	32	in	in	ADP
dpc-2824	229	33	cancer	cancer	NOUN
dpc-2824	229	34	patients	patient	NOUN
dpc-2824	229	35	.	.	PUNCT
dpc-2824	230	1	eur	eur	PROPN
dpc-2824	230	2	j	j	PROPN
dpc-2824	230	3	cancer	cancer	NOUN
dpc-2824	230	4	.	.	PUNCT
dpc-2824	231	1	2019;109:21	2019;109:21	NUM
dpc-2824	231	2	-	-	SYM
dpc-2824	231	3	27	27	NUM
dpc-2824	231	4	.	.	PUNCT
dpc-2824	232	1	doi:10.1016	doi:10.1016	PROPN
dpc-2824	232	2	/	/	SYM
dpc-2824	232	3	j.ejca.2018.10.014	j.ejca.2018.10.014	PROPN
dpc-2824	232	4	.	.	PUNCT
dpc-2824	233	1	pmid	pmid	NOUN
dpc-2824	233	2	:	:	PUNCT
dpc-2824	233	3	30682533	30682533	NUM
dpc-2824	233	4	.	.	PUNCT
dpc-2824	234	1	4	4	X
dpc-2824	234	2	.	.	X
dpc-2824	234	3	thompson	thompson	PROPN
dpc-2824	234	4	ll	ll	PROPN
dpc-2824	234	5	,	,	PUNCT
dpc-2824	234	6	chang	chang	PROPN
dpc-2824	234	7	ms	ms	PROPN
dpc-2824	234	8	,	,	PUNCT
dpc-2824	234	9	polyakov	polyakov	PROPN
dpc-2824	234	10	nj	nj	PROPN
dpc-2824	234	11	,	,	PUNCT
dpc-2824	234	12	et	et	PROPN
dpc-2824	234	13	al	al	PROPN
dpc-2824	234	14	.	.	PROPN
dpc-2824	235	1	prognostic	prognostic	ADJ
dpc-2824	235	2	significance	significance	NOUN
dpc-2824	235	3	of	of	ADP
dpc-2824	235	4	cutaneous	cutaneous	ADJ
dpc-2824	235	5	immune	immune	NOUN
dpc-2824	235	6	-	-	PUNCT
dpc-2824	235	7	related	relate	VERB
dpc-2824	235	8	adverse	adverse	ADJ
dpc-2824	235	9	events	event	NOUN
dpc-2824	235	10	in	in	ADP
dpc-2824	235	11	patients	patient	NOUN
dpc-2824	235	12	with	with	ADP
dpc-2824	235	13	melanoma	melanoma	NOUN
dpc-2824	235	14	and	and	CCONJ
dpc-2824	235	15	other	other	ADJ
dpc-2824	235	16	cancers	cancer	NOUN
dpc-2824	235	17	on	on	ADP
dpc-2824	235	18	immune	immune	ADJ
dpc-2824	235	19	checkpoint	checkpoint	NOUN
dpc-2824	235	20	inhibitors	inhibitor	NOUN
dpc-2824	235	21	.	.	PUNCT
dpc-2824	235	22	  	  	SPACE
dpc-2824	236	1	j	j	PROPN
dpc-2824	236	2	am	be	AUX
dpc-2824	236	3	acad	acad	ADJ
dpc-2824	236	4	dermatol	dermatol	NOUN
dpc-2824	236	5	.	.	PUNCT
dpc-2824	237	1	2022;86(4):886	2022;86(4):886	NUM
dpc-2824	237	2	-	-	PUNCT
dpc-2824	237	3	889	889	NUM
dpc-2824	237	4	.	.	PUNCT
dpc-2824	238	1	doi:10.1016	doi:10.1016	PROPN
dpc-2824	238	2	/	/	SYM
dpc-2824	238	3	j.jaad.2021.03.024	j.jaad.2021.03.024	PROPN
dpc-2824	238	4	.	.	PUNCT
dpc-2824	239	1	pmid	pmid	NOUN
dpc-2824	239	2	:	:	PUNCT
dpc-2824	239	3	33722547	33722547	NUM
dpc-2824	239	4	.	.	PUNCT
dpc-2824	240	1	5	5	NUM
dpc-2824	240	2	.	.	X
dpc-2824	240	3	haratani	haratani	PROPN
dpc-2824	240	4	k	k	PROPN
dpc-2824	240	5	,	,	PUNCT
dpc-2824	240	6	hayashi	hayashi	PROPN
dpc-2824	240	7	h	h	PROPN
dpc-2824	240	8	,	,	PUNCT
dpc-2824	240	9	chiba	chiba	PROPN
dpc-2824	240	10	y	y	PROPN
dpc-2824	240	11	,	,	PUNCT
dpc-2824	240	12	et	et	PROPN
dpc-2824	240	13	al	al	PROPN
dpc-2824	240	14	.	.	PROPN
dpc-2824	240	15	association	association	PROPN
dpc-2824	240	16	of	of	ADP
dpc-2824	240	17	immune	immune	ADJ
dpc-2824	240	18	related	relate	VERB
dpc-2824	240	19	adverse	adverse	ADJ
dpc-2824	240	20	events	event	NOUN
dpc-2824	240	21	with	with	ADP
dpc-2824	240	22	nivolumab	nivolumab	NOUN
dpc-2824	240	23	efficacy	efficacy	NOUN
dpc-2824	240	24	in	in	ADP
dpc-2824	240	25	nonsmall	nonsmall	ADJ
dpc-2824	240	26	-	-	PUNCT
dpc-2824	240	27	cell	cell	NOUN
dpc-2824	240	28	lung	lung	NOUN
dpc-2824	240	29	cancer	cancer	NOUN
dpc-2824	240	30	.	.	PUNCT
dpc-2824	240	31	  	  	SPACE
dpc-2824	240	32	jama	jama	PROPN
dpc-2824	240	33	oncol	oncol	ADJ
dpc-2824	240	34	.	.	PUNCT
dpc-2824	241	1	2018;4(3):374	2018;4(3):374	NUM
dpc-2824	241	2	-	-	SYM
dpc-2824	241	3	378	378	NUM
dpc-2824	241	4	.	.	PUNCT
dpc-2824	242	1	doi:10.1001	doi:10.1001	PROPN
dpc-2824	242	2	/	/	SYM
dpc-2824	242	3	jamaoncol.2017.2925	jamaoncol.2017.2925	PROPN
dpc-2824	242	4	.	.	PUNCT
dpc-2824	243	1	pmid	pmid	PROPN
dpc-2824	243	2	:	:	PUNCT
dpc-2824	243	3	28975219	28975219	NUM
dpc-2824	243	4	.	.	PUNCT
dpc-2824	244	1	pmcid	pmcid	NOUN
dpc-2824	244	2	:	:	PUNCT
dpc-2824	244	3	pmc6583041	pmc6583041	NOUN
dpc-2824	244	4	.	.	PUNCT
dpc-2824	245	1	6	6	NUM
dpc-2824	245	2	.	.	X
dpc-2824	245	3	sanlorenzo	sanlorenzo	NOUN
dpc-2824	245	4	m	m	PROPN
dpc-2824	245	5	,	,	PUNCT
dpc-2824	245	6	vujic	vujic	PROPN
dpc-2824	245	7	i	i	PROPN
dpc-2824	245	8	,	,	PUNCT
dpc-2824	245	9	daud	daud	PROPN
dpc-2824	245	10	a	a	X
dpc-2824	245	11	,	,	PUNCT
dpc-2824	245	12	et	et	PROPN
dpc-2824	245	13	al	al	PROPN
dpc-2824	245	14	.	.	PROPN
dpc-2824	245	15	pembrolizumab	pembrolizumab	NOUN
dpc-2824	245	16	cutaneous	cutaneous	ADJ
dpc-2824	245	17	adverse	adverse	ADJ
dpc-2824	245	18	events	event	NOUN
dpc-2824	245	19	and	and	CCONJ
dpc-2824	245	20	their	their	PRON
dpc-2824	245	21	association	association	NOUN
dpc-2824	245	22	with	with	ADP
dpc-2824	245	23	disease	disease	NOUN
dpc-2824	245	24	progression	progression	NOUN
dpc-2824	245	25	.	.	PUNCT
dpc-2824	245	26	  	  	SPACE
dpc-2824	246	1	jama	jama	NOUN
dpc-2824	246	2	dermatol	dermatol	NOUN
dpc-2824	246	3	.	.	PUNCT
dpc-2824	247	1	2015;151(11):1206	2015;151(11):1206	NUM
dpc-2824	247	2	-	-	SYM
dpc-2824	247	3	1212	1212	NUM
dpc-2824	247	4	.	.	PUNCT
dpc-2824	248	1	doi:10	doi:10	PROPN
dpc-2824	248	2	.1001	.1001	PROPN
dpc-2824	248	3	/	/	SYM
dpc-2824	248	4	jamadermatol.2015.1916	jamadermatol.2015.1916	PROPN
dpc-2824	248	5	.	.	PUNCT
dpc-2824	249	1	pmid	pmid	NOUN
dpc-2824	249	2	:	:	PUNCT
dpc-2824	249	3	26222619	26222619	NUM
dpc-2824	249	4	.	.	PUNCT
dpc-2824	250	1	pmcid	pmcid	ADJ
dpc-2824	250	2	:	:	PUNCT
dpc-2824	250	3	pmc5061067	pmc5061067	NOUN
dpc-2824	250	4	.	.	PUNCT
dpc-2824	251	1	7	7	X
dpc-2824	251	2	.	.	X
dpc-2824	251	3	lee	lee	PROPN
dpc-2824	251	4	j	j	PROPN
dpc-2824	251	5	,	,	PUNCT
dpc-2824	251	6	sun	sun	PROPN
dpc-2824	251	7	jm	jm	PROPN
dpc-2824	251	8	,	,	PUNCT
dpc-2824	251	9	lee	lee	PROPN
dpc-2824	251	10	sh	sh	PROPN
dpc-2824	251	11	,	,	PUNCT
dpc-2824	251	12	ahn	ahn	PROPN
dpc-2824	251	13	js	js	PROPN
dpc-2824	251	14	,	,	PUNCT
dpc-2824	251	15	park	park	PROPN
dpc-2824	251	16	k	k	PROPN
dpc-2824	251	17	,	,	PUNCT
dpc-2824	251	18	ahn	ahn	PROPN
dpc-2824	251	19	mj	mj	PROPN
dpc-2824	251	20	.	.	PROPN
dpc-2824	251	21	are	be	AUX
dpc-2824	251	22	there	there	PRON
dpc-2824	251	23	any	any	DET
dpc-2824	251	24	ethnic	ethnic	ADJ
dpc-2824	251	25	differences	difference	NOUN
dpc-2824	251	26	in	in	ADP
dpc-2824	251	27	the	the	DET
dpc-2824	251	28	efficacy	efficacy	NOUN
dpc-2824	251	29	and	and	CCONJ
dpc-2824	251	30	safety	safety	NOUN
dpc-2824	251	31	of	of	ADP
dpc-2824	251	32	immune	immune	ADJ
dpc-2824	251	33	checkpoint	checkpoint	NOUN
dpc-2824	251	34	inhibitors	inhibitor	NOUN
dpc-2824	251	35	for	for	ADP
dpc-2824	251	36	treatment	treatment	NOUN
dpc-2824	251	37	of	of	ADP
dpc-2824	251	38	lung	lung	NOUN
dpc-2824	251	39	cancer	cancer	NOUN
dpc-2824	251	40	?	?	PUNCT
dpc-2824	252	1	j	j	PROPN
dpc-2824	252	2	thorac	thorac	PROPN
dpc-2824	252	3	dis	dis	PROPN
dpc-2824	252	4	.	.	PUNCT
dpc-2824	253	1	original	original	ADJ
dpc-2824	253	2	article	article	NOUN
dpc-2824	253	3	|	|	ADV
dpc-2824	253	4	dermatol	dermatol	ADJ
dpc-2824	253	5	pract	pract	NOUN
dpc-2824	253	6	concept	concept	NOUN
dpc-2824	253	7	.	.	PUNCT
dpc-2824	254	1	2023;13(3):e2023127	2023;13(3):e2023127	NUM
dpc-2824	254	2	7	7	NUM
dpc-2824	254	3	21	21	NUM
dpc-2824	254	4	.	.	PUNCT
dpc-2824	255	1	phillips	phillips	PROPN
dpc-2824	255	2	gs	gs	PROPN
dpc-2824	255	3	,	,	PUNCT
dpc-2824	255	4	wu	wu	PROPN
dpc-2824	255	5	j	j	PROPN
dpc-2824	255	6	,	,	PUNCT
dpc-2824	255	7	hellmann	hellmann	PROPN
dpc-2824	255	8	md	md	PROPN
dpc-2824	255	9	,	,	PUNCT
dpc-2824	255	10	et	et	PROPN
dpc-2824	255	11	al	al	PROPN
dpc-2824	255	12	.	.	PUNCT
dpc-2824	256	1	treatment	treatment	NOUN
dpc-2824	256	2	outcomes	outcome	NOUN
dpc-2824	256	3	of	of	ADP
dpc-2824	256	4	immune	immune	NOUN
dpc-2824	256	5	-	-	PUNCT
dpc-2824	256	6	related	relate	VERB
dpc-2824	256	7	cutaneous	cutaneous	ADJ
dpc-2824	256	8	adverse	adverse	ADJ
dpc-2824	256	9	events	event	NOUN
dpc-2824	256	10	.	.	PUNCT
dpc-2824	257	1	j	j	PROPN
dpc-2824	257	2	clin	clin	PROPN
dpc-2824	257	3	oncol	oncol	PROPN
dpc-2824	257	4	.	.	PUNCT
dpc-2824	258	1	2019;37(30):2746–2758	2019;37(30):2746–2758	X
dpc-2824	258	2	.	.	PUNCT
dpc-2824	259	1	doi:10.1200	doi:10.1200	PROPN
dpc-2824	259	2	/	/	SYM
dpc-2824	259	3	jco.18.02141	jco.18.02141	PROPN
dpc-2824	259	4	.	.	PUNCT
dpc-2824	260	1	pmid	pmid	NOUN
dpc-2824	260	2	:	:	PUNCT
dpc-2824	260	3	31216228	31216228	NUM
dpc-2824	260	4	.	.	PUNCT
dpc-2824	261	1	pmcid	pmcid	NOUN
dpc-2824	261	2	:	:	PUNCT
dpc-2824	261	3	pmc7001790	pmc7001790	NOUN
dpc-2824	261	4	.	.	PUNCT
dpc-2824	262	1	22	22	NUM
dpc-2824	262	2	.	.	PUNCT
dpc-2824	263	1	gault	gault	PROPN
dpc-2824	263	2	a	a	PROPN
dpc-2824	263	3	,	,	PUNCT
dpc-2824	263	4	anderson	anderson	PROPN
dpc-2824	263	5	ae	ae	PROPN
dpc-2824	263	6	,	,	PUNCT
dpc-2824	263	7	plummer	plummer	PROPN
dpc-2824	263	8	r	r	PROPN
dpc-2824	263	9	,	,	PUNCT
dpc-2824	263	10	et	et	PROPN
dpc-2824	263	11	al	al	PROPN
dpc-2824	263	12	.	.	PUNCT
dpc-2824	264	1	cutaneous	cutaneous	ADJ
dpc-2824	264	2	immune	immune	ADJ
dpc-2824	264	3	related	relate	VERB
dpc-2824	264	4	adverse	adverse	ADJ
dpc-2824	264	5	events	event	NOUN
dpc-2824	264	6	in	in	ADP
dpc-2824	264	7	patients	patient	NOUN
dpc-2824	264	8	with	with	ADP
dpc-2824	264	9	melanoma	melanoma	NOUN
dpc-2824	264	10	treated	treat	VERB
dpc-2824	264	11	with	with	ADP
dpc-2824	264	12	checkpoint	checkpoint	NOUN
dpc-2824	264	13	inhibitors	inhibitor	NOUN
dpc-2824	264	14	.	.	PUNCT
dpc-2824	265	1	br	br	PROPN
dpc-2824	265	2	j	j	PROPN
dpc-2824	265	3	dermatol	dermatol	NOUN
dpc-2824	265	4	.	.	PUNCT
dpc-2824	266	1	2021;185(2):263–271	2021;185(2):263–271	NOUN
dpc-2824	266	2	.	.	PUNCT
dpc-2824	267	1	doi:10.1111	doi:10.1111	PROPN
dpc-2824	267	2	/	/	SYM
dpc-2824	267	3	bjd.19750	bjd.19750	PROPN
dpc-2824	267	4	.	.	PUNCT
dpc-2824	268	1	pmid	pmid	NOUN
dpc-2824	268	2	:	:	PUNCT
dpc-2824	268	3	33393076.original	33393076.original	ADJ
dpc-2824	268	4	article	article	NOUN
dpc-2824	268	5	2018;36(4):638–646	2018;36(4):638–646	PROPN
dpc-2824	268	6	.	.	PUNCT
dpc-2824	268	7	doi	doi	NOUN
dpc-2824	268	8	:	:	PUNCT
dpc-2824	268	9	10.1007	10.1007	NUM
dpc-2824	268	10	/	/	SYM
dpc-2824	268	11	s10637	s10637	NOUN
dpc-2824	268	12	-	-	PUNCT
dpc-2824	268	13	017	017	NUM
dpc-2824	268	14	-	-	PUNCT
dpc-2824	268	15	0534	0534	NUM
dpc-2824	268	16	-	-	SYM
dpc-2824	268	17	0	0	NUM
dpc-2824	268	18	.	.	PUNCT
dpc-2824	269	1	pmid	pmid	NOUN
dpc-2824	269	2	:	:	PUNCT
dpc-2824	269	3	29159766	29159766	NUM
dpc-2824	269	4	.	.	PUNCT
dpc-2824	270	1	pmcid	pmcid	NOUN
dpc-2824	270	2	:	:	PUNCT
dpc-2824	270	3	pmc5962379	pmc5962379	PROPN
dpc-2824	270	4	.	.	PUNCT
dpc-2824	271	1	20	20	NUM
dpc-2824	271	2	.	.	PUNCT
dpc-2824	271	3	rose	rise	VERB
dpc-2824	271	4	lm	lm	INTJ
dpc-2824	271	5	,	,	PUNCT
dpc-2824	271	6	deberg	deberg	PROPN
dpc-2824	271	7	ha	ha	INTJ
dpc-2824	271	8	,	,	PUNCT
dpc-2824	271	9	vishnu	vishnu	ADJ
dpc-2824	271	10	p	p	NOUN
dpc-2824	271	11	,	,	PUNCT
dpc-2824	271	12	et	et	PROPN
dpc-2824	271	13	al	al	PROPN
dpc-2824	271	14	.	.	PROPN
dpc-2824	271	15	incidence	incidence	NOUN
dpc-2824	271	16	of	of	ADP
dpc-2824	271	17	skin	skin	NOUN
dpc-2824	271	18	and	and	CCONJ
dpc-2824	271	19	respiratory	respiratory	ADJ
dpc-2824	271	20	immune	immune	NOUN
dpc-2824	271	21	-	-	PUNCT
dpc-2824	271	22	related	relate	VERB
dpc-2824	271	23	adverse	adverse	ADJ
dpc-2824	271	24	events	event	NOUN
dpc-2824	271	25	correlates	correlate	VERB
dpc-2824	271	26	with	with	ADP
dpc-2824	271	27	specific	specific	ADJ
dpc-2824	271	28	tumor	tumor	NOUN
dpc-2824	271	29	types	type	NOUN
dpc-2824	271	30	in	in	ADP
dpc-2824	271	31	patients	patient	NOUN
dpc-2824	271	32	treated	treat	VERB
dpc-2824	271	33	with	with	ADP
dpc-2824	271	34	checkpoint	checkpoint	NOUN
dpc-2824	271	35	inhibitors	inhibitor	NOUN
dpc-2824	271	36	.	.	PUNCT
dpc-2824	272	1	front	front	ADJ
dpc-2824	272	2	oncol	oncol	ADJ
dpc-2824	272	3	.	.	PUNCT
dpc-2824	273	1	2021;10:570752	2021;10:570752	X
dpc-2824	273	2	.	.	PUNCT
dpc-2824	273	3	doi	doi	NOUN
dpc-2824	273	4	:	:	PUNCT
dpc-2824	273	5	10.3389	10.3389	NUM
dpc-2824	273	6	/	/	SYM
dpc-2824	273	7	fonc.2020.570752	fonc.2020.570752	NOUN
dpc-2824	273	8	.	.	PUNCT
dpc-2824	274	1	pmid	pmid	NOUN
dpc-2824	274	2	:	:	PUNCT
dpc-2824	274	3	33520695	33520695	NUM
dpc-2824	274	4	.	.	PUNCT
dpc-2824	275	1	pmcid	pmcid	ADJ
dpc-2824	275	2	:	:	PUNCT
dpc-2824	275	3	pmc7844139	pmc7844139	NOUN
dpc-2824	275	4	.	.	PUNCT